









Background Calcific aortic stenosis is the commonest valvular heart condition seen
in the western world and appears to be the result of an active inflammatory process
closely resembling atherosclerosis. 1 hypothesised that (a) risk factors for
atherosclerosis would predict, and (b) lipid-lowering therapy would retard, disease
progression and clinical outcome in patients with calcific aortic stenosis.
Objectives (i) To compare the magnitude and reproducibility of measures of
valvular stenosis and calcification, (ii) to determine the effect of intensive lipid-
lowering therapy on disease progression and clinical outcome, and (iii) to describe
predictors of disease progression and clinical outcome in patients with aortic
stenosis.
Methods These issues were addressed in the context of a randomised controlled trial
of which I was study co-ordinator. In the Scottish Aortic stenosis and Lipid-lowering
Therapy, Impact on REgression (SALTIRE) trial, 155 patients aged 68 ± 11 years
(range 34-85) with aortic valve stenosis were randomised, and underwent helical
computed tomography (CT) and Doppler echocardiography. Seventy-seven patients
were assigned to atorvastatin 80 mg daily and 78 to matched placebo over a median
period of 25 months. Of the 155 patients, 102 had detectable coronary artery
calcification on CT with 48 of these patients being randomised to atorvastatin and 54
to placebo.
Results (i) Stenosis severity: Doppler echocardiography demonstrated a mean aortic
jet velocity of 3.45 ± 0.66 metres per second (m/s) and a peak gradient of 49 ± 11
millimetres of mercury (mmHg). Computed tomography and Doppler
echocardiography showed good reproducibility. The median aortic valve calcium
(AVC) score was 5858 Hounsfield units (HU) (interquartile range, 1555-14596) and
this positively correlated with aortic jet velocity and peak gradient (r=0.54, p<0.0001
for both), (ii) Disease progression: Aortic jet velocity increased by 0.199 ± 0.210
m/s per year in the atorvastatin group and 0.203 ± 0.208 m/s per year in the placebo
group (p=0.95; adjusted mean difference, 0.002; 95% confidence interval (CI)),
(-0.066 to +0.070 m/s/yr). Progression in valvular calcification was 22 ± 21% per
year in the atorvastatin group, and 22 ± 20% per year in the placebo group (p=0.93;
ratio of post-treatment AVC score, 0.998; 95% CI, 0.947 to 1.050). The rate of
change in coronary artery calcification was 26% per year (0.234 ± 0.037 log arbitrary
units/yr (LogAU/yr); n=39) in the atorvastatin group and 18% per year (0.167 ±
0.034 LogAU/yr; n=49) in the placebo group: geometric mean difference of +7% per
year (95% CI, -3% to +18%; p=0.18). (iii) Lipid-lowering'. Atorvastatin reduced
serum low-density lipoprotein (LDL) cholesterol (-53%; p<0.001) and C-reactive
protein (CRP) (-49%; p<0.001) concentrations whilst there was no change with
placebo (-7% and +17%; p>0.95 for both). There was no correlation between serum
LDL concentrations and the progression of aortic stenosis or coronary calcification,
(vi) Predictors ofdisease progression and outcome'. Aortic valve disease progression
was predicted by age, sex, height, hypertension, serum brain natriuretic peptide
(BNP) concentration, and baseline valve disease severity. Clinical outcome was
predicted by baseline and rate of progression of aortic stenosis severity and serum
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BNP concentrations.
Conclusions Calcification of the aortic valve is closely associated with the severity
of aortic stenosis with heavy calcification suggesting the presence of severe aortic
stenosis that requires urgent cardiological assessment. In contrast to observational
studies, intensive lipid-lowering therapy does not halt the progression or induce
regression of aortic stenosis or coronary artery calcification. However, our studies
cannot exclude a small reduction in disease progression or a significant reduction in
major clinical end-points. Long-term, large scale, randomised, controlled trials are
needed to establish the role of statin therapy in patients with calcific aortic stenosis.
The major predictors of disease progression and clinical outcome remain baseline
measures of disease severity; namely aortic jet velocity, aortic valve calcification and
serum BNP concentration. With the exception of hypertension, the presence of
atherosclerotic risk factors and vascular disease are not predictive. Our findings
suggest that atherogenesis does not provide a major contribution to the progression
of aortic stenosis.
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ABBREVIATIONS
ACE Angiotensin-converting enzyme
ANOVA Analysis of variance
AS Aortic stenosis
AU Arbitrary units
AVA Aortic valve area
AVC Aortic valve calcium
AVR Aortic valve replacement






HMG CoA Hydroxymethylglutaryl coenzyme A
HsCRP Highly sensitive C-reactive protein
HU Hounsfield units
ICAM-1 Intercellular adhesion molecule-1
ITT Intention-to-treat
LAD Left anterior descending
LDL Low-density lipoprotein
Lp (a) Lipoprotein a
LVOTD Left ventricular outflow tract diameter
MR Magnetic resonance
NYHA New York Heart Association
PLSD Protected least squares difference
PWA Pulse wave analysis
SALTIRE The Scottish Aortic stenosis and Lipid lowering
Therapy Impact on REgression trial
SD Standard deviation
SE Standard error
VCAM-1 Vascular cell adhesion molecule-1
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1.1 INTRODUCTION
Aortic stenosis is the commonest adult heart valve condition seen in the western
world. It may be the result of a congenital lesion, or it can arise following rheumatic
fever. More commonly it occurs as a result of calcification of a congenitally bicuspid
or a trileaflet aortic valve (calcific aortic stenosis). Over the last 30-50 years, its
diagnosis and management has been revolutionised by the development of invasive
(cardiac catheterisation) and non-invasive (echocardiography) haemodynamic
assessments as well as potentially curative cardiac surgery. Recent insights have
been made into the pathogenesis of calcific aortic stenosis, resulting in speculation
that the disease mimics atherosclerosis and progression could be delayed or
prevented by the use of lipid-lowering therapy. If confirmed, such pharmacological
therapy may have the potential to reduce the need for aortic valve surgery.
1.2 EPIDEMIOLOGY
Calcific aortic stenosis was first documented in 1904 [Monckeburg 1904] and at that
time was regarded as uncommon. In the 19th century, calcific aortic stenosis was not
recognised as a clinical entity since pathological studies revealed only cusp
thickening and sclerosis [Osier 1886], As a result, aortic valve sclerosis (thickening
without stenosis) and aortic valve stenosis were regarded as different pathological
conditions for many decades. Recent evidence, however, suggests that they represent
different stages of the same disease process [Stewart et al 1997; Cosmi et al 2002;
Faggiano et al 2003]: sclerosis arising from the development of valvular calcific
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lesions that progress slowly over several decades before ultimately causing aortic
stenosis [Mensah and Friesinger 1996], The current prominence of calcific aortic
valve disease is likely to represent increased human longevity together with the
decline in rheumatic valvular heart disease.
Aortic valve sclerosis is present in 20-30% of individuals over 65 years and 48%
over 85 years [Otto et al 1999], and aortic stenosis in 2% and 4% respectively
[Lindroos et al 1993; Stewart et al 1997; Otto et al 1999]. Calcific sclerosis and
valvular stenosis occur in patients with both a normal tricuspid aortic valve as well as
in those with a bicuspid valve. The prevalence of bicuspid aortic valves is difficult to
determine but is estimated to affect 1-2% of the general population [Ward 2000]. Up
to 70% of patients with a bicuspid aortic valve develop valvular stenosis [Ward
2000] and will typically require aortic valve replacement (AVR) one to two decades
earlier in life (fifth to sixth decade) than in those with a tricuspid aortic valve.
1.3 NATURAL HISTORY
Prior to the introduction of haemodynamic assessment and cardiac surgery, the
natural history of aortic stenosis was described by its clinical presentation. Calcific
aortic stenosis is a gradually progressive disease, characterised by a long
asymptomatic phase lasting several decades, followed by a shorter symptomatic
phase usually associated with severe narrowing of the aortic valve orifice.
The outlook for patients with asymptomatic aortic stenosis is generally good and
closely matches that of life table estimates for age and sex matched controls
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[Pellikka et al 1990], A striking feature of aortic stenosis is that the prognosis
changes dramatically with the onset of symptoms in association with severe outflow
obstruction: a 2-year survival rate of 50%. Although few studies specifically assessed
the influence of age, patients over the age of seventy have a worse prognosis with 2-
and 3-year survival rates of 37% and 25% respectively [O'Keefe et al 1987], The
prognosis also depends upon the clinical presentation with a mean survival of 3 years
for those presenting with angina and syncope, 2 years with the onset of
breathlessness, and as little as 1 year in those who develop overt left ventricular
failure [Ross and Braunwald 1968; Aronow et al 1993].
1.3.1 OTHER CARDIOVASCULAR EVENTS
Despite the favourable outlook in those patients with mild asymptomatic disease,
there is an increased risk of cardiovascular events unrelated to the aortic valve
disease. Otto and colleagues demonstrated that, in patients with aortic sclerosis, there
is a 50% increased risk ofmyocardial infarction and cardiovascular death even in the
absence of significant outflow tract obstruction [Otto et al 1999]. The Helsinki
Ageing Study also suggested that patients with moderate to severe aortic stenosis had
higher all cause and cardiovascular mortality irrespective of associated symptoms. In
particular, a higher rate of stroke related death was noted although the majority of
these patients had atrial fibrillation [Iivanainen et al 1996],
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1.4 PATHOLOGY OF CALCIFIC AORTIC STENOSIS
For many decades, calcific aortic stenosis has been attributed to prolonged "wear and
tear" and age-associated valvular degeneration. Contrary to this supposition,
however, is the absence of aortic valve calcification or stenosis on echocardiography
in a third of individuals over the age of 80 [Lindroos et al 1993], Recent evidence
suggests that calcific aortic stenosis may result from an active inflammatory process
involving biochemical, humoral and genetic factors.
1.4.1 Histology
Normal aortic valve leaflets are macroscopically smooth, thin and opalescent, with
clearly defined tissue layers at a microscopic level and very few cells [Olssson et al
1994], Increasing age gives rise to non-specific thickening of the tips of the valve
leaflets, with an increase in the number of adipose cells and thinning of tissue layers
[Otto et al 1994]. In calcific aortic stenosis, there is characteristic leaflet thickening,
with irregular nodular masses on the aortic aspect of the valve. Microscopic
assessment of both mild and severely affected valves reveals endothelial and
basement membrane disruption, with underlying subendothelial thickening. The
lesion itself contains disorganised collagen fibres, chronic inflammatory cells,
lipoproteins, lipid, extracellular bone matrix proteins and bone mineral [Olsson et al
1994; Otto et al 1994],
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1.4.2 Pathogenesis
The histological features described closely resemble those seen in atherosclerosis and
are strongly suggestive of chronic inflammation. In calcific aortic stenosis, the
factors initiating the inflammatory process have not been identified but mechanical
injury to the endothelium is thought to pave the way for subsequent inflammation.
This concept is supported by the pattern of aortic valve cusp involvement that
corresponds to areas of low shear and high tensile stress: namely the aortic surface of
the leaflets and predilection for the non-coronary cusp [Thubrikar et al 1986; Cujec
and Pollick 1988; Yearwood et al 1989; Otto 2002]. Congenitally bicuspid aortic
valves are less efficient than tricuspid valves at distributing mechanical stress and
this may account for their predilection to develop rapidly progressive stenosis
[Beppu et al 1993],
1.4.2.1 Role of lipids
Endothelial injury or disruption may allow circulating lipids to enter the valvular
interstitial tissue [O'Brien et al 1996] and accumulate in areas of calcification and
inflammation [O'Brien et al 1996; Olsson et al 1999], The lipoproteins implicated in
atherogenesis, including low-density lipoprotein (LDL) and lipoprotein (a) (Lp (a)),
are present in early aortic valve lesions [O'Brien et al 1996] and undergo oxidative
modification [Olsson et al 1999]. These oxidised lipoproteins are highly cytotoxic
[Chisholm 1991] and capable of stimulating inflammatory activity [Berliner et al
1990; Rajavashisth et al 1990] and mineralisation [Hirsch et al 1993; Sarig et al
1994; Parhami et al 1997],
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1.4.2.2 Inflammation
Both macrophages and activated T lymphocytes are present in the early and
advanced lesions of congenitally bicuspid [Wallby et al 2002] and tricuspid aortic
valves [Olsson et al 1994; Otto et al 1994], Migration of these effector inflammatory
cells appears to be mediated through increased endothelial expression of cellular
adhesion molecules such as E-selectin, intercellular adhesion molecule-1 (ICAM-1
and vascular cell adhesion molecule-1 (VCAM-1) [Ghaisas et al 2000; Miiller et al
2000]. Once recruited into the subendothelium, the inflammatory cells release
enzymes, such as matrix metalloproteinases, that cause degradation of collagen,
elastin and proteoglycans within the aortic valve cusps [Edep et al 2000],
1.4.2.3 Calcification
Mineralisation is a characteristic of both atherosclerotic and aortic valve lesions, and
arises in close proximity to areas of inflammation. It is a prominent feature in calcific
aortic stenosis and has been demonstrated in early [Otto et al 1994] as well as
advanced lesions [Mohler et al 2001], Surgically excised valves have even revealed
areas of mature lamellar bone, haemopoietic marrow and bone remodelling [Mohler
et al 2001]. Several features suggest the presence of an active highly regulated
process closely resembling developmental bone formation [Bostrom et al 1995;
Demer 1995].
The initiation of mineralisation (nucleation) may be stimulated by the presence of
cellular degradation products following apoptosis [Kockx and Elerman 1998] or by
the presence of oxidised lipids [Olsson et al 1999; Mohler et al 2001]. In vitro
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studies of cultured explants of stenotic valves have identified cells with osteoblastic
characteristics capable of phenotypic differentiation and spontaneous calcification
[Mohler et al 1999], Their origin is unknown but they may be derived from a pool of
circulating immature pluripotent mesenchymal cells [Prockop 1997], These
osteogenic cells or "calcifying valvular cells" express and produce a variety of
regulatory bone matrix proteins including osteopontin [O'Brien et al 1995; Mohler et
al 1997] and bone morphogenetic protein [Mohler et al 2001],
1.4.3 Similarities and differences with atherosclerosis
Although the similarities with atherosclerosis were recognised as long ago as 1917
[Libman 1917], they were largely disregarded until recently [Roberts 1986; Mohler
2000; Demer 2001]. The histological studies described above have highlighted the
common features but also confirmed differences in the cellular and mineral
components of the two lesions.
Smooth muscle proliferation and lipid-laden macrophages (or foam cells) are
prominent features of vascular atheroma but are virtually absent in stenotic aortic
valves. In addition, mineralisation is an earlier and more extensive feature of aortic
valve lesions compared with atherosclerosis [Otto et al 1994], These differences
may, in part, explain why only 40% of patients with severe aortic stenosis have
significant coronary artery disease [Lombard and Selzer 1987; Vandeplas et al 1988;
Mautner and Roberts 1992; Rapp et al 2001; Peltier et al 2003] and why the majority
of patients with coronary artery disease do not have aortic stenosis. As the
underlying pathology for the two conditions appears to be similar, it is likely that
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other unknown factors influence the development of valvular as opposed to vascular
lesions [Otto and O'Brien 2001],
1.5 CLINICAL PRESENTATION
Patients present with either an incidentally noted asymptomatic systolic murmur or
with symptoms of severe disease including angina, exertional syncope,
breathlessness, and reduced exercise tolerance or lethargy. In simple terms,
progressive obstruction to outflow results in a gradual rise in left ventricular
pressures, left ventricular hypertrophy, and diastolic dysfunction. Once the degree of
stenosis is severe, further small decreases in aortic valve area (AVA) result in large
changes in the pressure gradient across the valve. Symptoms and decompensation
arise due to the development of inadequate cardiac reserve, myocardial oxygen
demand mismatch or pressure overload of the left ventricle. Symptoms rarely occur
unless the degree of stenosis is of at least moderate severity (with an AVA of less
than 1.0 cm2) but patients may remain asymptomatic for long periods with even very
severe stenosis [Lombard and Selzer 1987],
1.5.1 Clinical risk factors
In keeping with the apparent parallels with atherosclerosis, calcific aortic stenosis is
associated with coronary artery disease [Mautner and Roberts 1992; Peltier et al
2003] and many of its risk factors (Table 1.1) [Stewart et al 1997]. Calcific aortic
stenosis is also seen in association with severe homozygous familial
hypercholesterolaemia, and its development appears to be influenced by the length of
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exposure to elevated serum cholesterol concentrations [Rallidis et al 1998],
Interestingly, aggressive lipid-lowering therapy with plasmapheresis has been
reported to regress aortic stenosis in such patients [Keller et al 1986], Milder forms
of hypercholesterolemia have also been associated with calcific aortic stenosis
[Aronow et al 1987; Wilmshurst et al 1997; Chui et al 1999], particularly in patients
with non-rheumatic tricuspid valves [Chui et al 1999],
TABLE 1.1 Risk factors for calcific aortic stenosis
Clinical Biochemical
Age Hyperlipidaemia (LDL and Lp (a))
Male sex Hypercalcaemia







LDL - Low-density lipoprotein; Lp (a) - Lipoprotein a.
Conditions affecting calcium metabolism, such as chronic renal impairment with
secondary hyperparathyroidsim [Maher et al 1987; Straumann et al 1992; Umana et
al 2003] and advanced Paget's disease [Hultgren 1998], predispose individuals to
aortic valve calcification and accelerated stenosis. Such patients also tend to have
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diffuse cardiac calcification affecting the mitral valve, myocardium and conducting
system.
A number of twin studies and case reports suggest that hereditary factors may
influence the development of calcific aortic valve stenosis [Lewis and Henderson
1990; Tentolouris et al 1993], There has been a single report of a genetic association
between aortic stenosis and a vitamin D receptor polymorphism [Ortlepp et al 2001]
but this finding has yet to be confirmed.
1.6 INVESTIGATIONS
The assessment of valvular stenosis and monitoring of disease progression has only
been possible over the last five decades using cardiac catheterisation,
echocardiography and more recently magnetic resonance (MR) imaging and
computed tomography (CT). Magnetic resonance may have some advantages over
echocardiography in assessment of stenosis severity [Didier et al 2000], but its
availability is limited and measurements are time consuming to perform. Although
currently limited to clinical research, electron beam CT has recently been validated
as a means of quantifying aortic valve calcification [MacMillan et al 1988; Lippert et
al 1995; Kizer et al 2001], However, echocardiography remains the current gold
standard for monitoring of disease progression and left ventricular function in
patients with aortic stenosis.
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The severity of aortic valve stenosis is assessed using both two-dimensional and
Doppler echocardiography (Table 1.2). Narrowing of the aortic valve orifice results
in acceleration of blood flow across the valve. Using spectral Doppler, the velocity of
blood passing through the left ventricular outflow tract (pre-valve) and aortic valve
orifice (post-valve) can be measured and is usually expressed in metres per second
(m/s). The peak instantaneous pressure gradient across the aortic valve has a simple
relationship with the peak post-valve velocity and is described as four times the
square of the velocity (modified Bernoulli equation). For example, a peak post-valve
velocity of 4 m/s gives an instantaneous pressure gradient of 4 x 42 = 64 millimetres
ofmercury (mmHg). Where there are concerns that impaired left ventricular function
limits the ability to generate an adequate pressure gradient across the valve,
measurement of the AVA may need to be made using direct planimetry or indirectly
using the continuity equation. On occasions, dobutamine stress echocardiography
may be used as a method of distinguishing true aortic stenosis causing left ventricular
dysfunction from aortic pseudostenosis where the impairment of the left ventricle
causes poor excursion of the aortic valve cusps giving the impression of stenotic
valvular restriction.
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Echocardiography provides the most accurate evaluation of disease progression,
which can be unpredictable and extremely variable. Some individuals show little or
no evidence of deterioration over time, yet others progress rapidly from mild to
severe stenosis within a few years.
In patients with aortic valve sclerosis, progression to stenosis (arbitrarily defined as a
peak post-valve velocity >2.5 m/s, or peak gradient >25 mmHg) is a relatively slow
process with mean increases in peak post-valve velocity and peak gradient of
0.07 m/s and 1.4 mmHg per year respectively [Faggiano et al 2003], However, once
the valve is classified as stenotic, disease progression is more rapid with average
increases of 0.3 m/s and 7-8 mmHg per year, corresponding to a decrease in AVA of
0.1 cm2 per year [Roger et al 1990; Faggiano et al 1992; Peter et al 1993; Brener et
al 1995; Otto et al 1997].
1.6.2 Predictors of disease progression and clinical outcome
Disease progression and clinical outcome have been linked to many of the risk
factors for calcific aortic stenosis including age, male sex, hyperlipidaemia,
hypertension, diabetes mellitus, smoking, hypercalcaemia and chronic renal
impairment [Peter et al 1993; Bahler et al 1999; Palta et al 2000; Ngo et al 2001;
Wongpraparut et al 2002], However, much of the evidence is conflicting and limited
by the retrospective nature of the studies. The most consistent and strongest
predictors of disease progression are severity of stenosis at baseline [Otto et al 1997;
Bahler et al 1999] and degree of valvular calcification [Davies et al 1991;
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Bahler et al 1999], The more severe the stenosis at baseline and the more heavily
calcified the valve, the faster the rate of progression. Clinical outcome is also
influenced by the degree of valvular calcification, with nearly 80% of patients with
moderate to severe calcification who progress rapidly (>0.3 m/s/yr) either dying or
undergoing AVR within 2 years [Rosenhek et al 2000].
1.7 MANAGEMENT OF CALCIFIC AORTIC STENOSIS
At the present time, there is no known therapy that can slow or reverse disease
progression in patients with calcific aortic stenosis. Current management includes
monitoring disease progression, and ensuring patient awareness of the need for
antibiotic prophylaxis against infective endocarditis. For those patients with severe
symptomatic disease, the therapeutic options include conventional medical therapy
for symptom control and AVR.
1.7.1 General advice
All patients should be advised of the need for antibiotic prophylaxis against
endocarditis for dental and other invasive procedures. Patients with moderate or
severe disease should be advised to avoid strenuous physical exercise and
competitive sport because of the risk of sudden death, and to report promptly the
onset of symptoms.
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1.7.2 Monitoring of disease progression
Since disease progression is so unpredictable, the majority of patients should be
reviewed regularly to monitor changes in stenosis severity and watch for the onset of
symptoms. As a rule of thumb, asymptomatic patients with mild to moderate stenosis
require review and echocardiography every 1-2 years, and those with moderate to
severe stenosis every 6-12 months. Patients developing symptoms between
appointments should be reviewed immediately.
1.7.3 asymptomatic severe aortic stenosis
One contentious area of management is determining the optimal timing for AVR. It
is universally accepted that surgery is indicated as soon as symptoms appear in
patients with severe stenosis. Although many cardiologists are loath to refer patients
without symptoms for valve surgery, there are some who feel uncomfortable
managing patients with severe asymptomatic valvular stenosis because of the
potential risk for sudden cardiac death. However, this is rare and occurs in less than
1% of asymptomatic patients per year [Bonow et al 1998], The combined risk of
AVR (2-10% mortality) and prosthesis-related complications (2-3%/yr) is thus
greater than the risk of sudden cardiac death. "Watchful waiting" is therefore
recommended.
The onset of symptoms in patients with severe stenosis may be subtle and insidious,
particularly in the elderly where co-morbidity may mislead or obscure the
presentation. For this reason careful history taking for changes in exercise tolerance
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as well as the classical symptoms of breathlessness, chest pain and syncope is
required. In cases where patients may be underplaying symptoms, attributing them to
"old age", or unknowingly avoiding activity that induces symptoms, physician
supervised exercise testing may be helpful in both revealing symptoms as well as
determining the haemodynamic response to exercise. Patients who develop
symptoms during exercise, become hypotensive, manifest marked ST segment
changes or develop ventricular arrhythmias are at high risk and should be considered
for valve replacement [Chambers 1999; Amato et al 2001; Carabello 2002],
1.7.4 Symptomatic severe aortic stenosis
As soon as patients with severe aortic stenosis develop symptoms the treatment of
choice is AVR because this substantially improves the quality of life and prognosis.
In those patients declining valve surgery, or the frail elderly in whom major cardiac
surgery would be inappropriate, palliation with conventional medical therapy, or in
exceptional circumstances, balloon valvotomy are the only alternatives. Percutaneous
AVR is a promising new technique that is currently under development in highly
selected patient populations [Boudjemline and Bonhoeffer 2002; Cribier et al 2002].
1.7.5 Medical therapy
Breathlessness. Patients with evidence of pulmonary congestion may benefit from
the judicious use of diuretics, vasodilators and positive ionotropic agents such as
digoxin. Excessive use of diuretics should be avoided since patients with severe
aortic stenosis often have diastolic dysfunction and depend on an adequate pre-load
in order to maintain their cardiac output.
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Despite the widespread belief that angiotensin-converting enzyme (ACE) inhibitors
can cause dangerous hypotension in severe aortic stenosis, and are therefore
contraindicated, there are little data to support this. From the limited literature
available, two small studies demonstrated that first dose hypotension did not occur in
patients with severe aortic stenosis, and that cardiac output and symptoms improved
substantially [Grace el al 1991; Martinez-Sanchez et al 1996]. Although further
study is required, some patients with heart failure and severe aortic stenosis could
benefit from ACE inhibitors provided that they are carefully introduced in a hospital
setting. Certainly those patients already established on therapy need not have it
withdrawn since this may precipitate the onset of heart failure.
Digoxin can be helpful in the management of heart failure but should only be used in
the presence of atrial fibrillation or where there is documented evidence of left
ventricular systolic dysfunction. Atrial fibrillation is not well tolerated in the
presence of severe stenosis and restoration to sinus rhythm (through electrical
cardioversion or pharmacological cardioversion using amiodarone) should be
attempted wherever possible.
Angina. In those individuals where angina is the predominant symptom, cautious use
of beta-blockers and nitrates may be of benefit. Where coronary heart disease is
suspected secondary prevention would be appropriate.
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Syncope. Patients with syncope or pre-syncope should be further evaluated with a
24-hour cardiac monitor since aortic stenosis is commonly associated with
atrioventricular block. There is no specific therapy for syncope unless it is caused by
a bradyarrhythmia or tachyarrhythmia, where pacemaker insertion or antiarrhythmic
therapy respectively should be considered.
1.7.6 Balloon valvotomy
Although balloon valvotomy plays an important role in the management of
adolescents and young adults with aortic stenosis, it has largely been abandoned in
older patients. The functional improvement obtained is limited, the re-stenosis and
complication rates high, and the long-term outlook poor (<80% survival at 1 year)
[Robicsek et al 1988; Bonow et al 1998], On rare occasions, balloon valvotomy may
play a role in patients with a limited life expectancy for other reasons, or as a bridge
to AVR in critically ill patients with cardiogenic shock.
1.7.7 Aortic valve replacement
Aortic valve replacement incurs the virtual abolition of symptoms associated with
improvements in physical functioning and quality of life, and a dramatic
improvement in survival. Operative mortality in middle-aged adults is in the region
of 5-8% [Linblom et al 1990; Sprigings and Forfar 1995; Kvidal et al 2000]; 5- and
10-year survival rates after aortic valve replacement are approximately 80%
[Galloway et al 1990; Linblom et al 2000] and 65% respectively [Linblom et al
1990], and are similar to actuarial survival rates for the general population [Linblom
et al 1990].
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Factors associated with a higher operative mortality include increasing age [Sharony
et al 2003], the presence of renal impairment, cerebrovascular and peripheral
vascular disease [Gilbert et al 1999], the presence of impaired left ventricular
function [Sharony et al 2003], and the need for simultaneous coronary artery bypass
grafting [Sprigings and Forfar 1995], Despite the increased operative risk associated
with the presence of left ventricular failure, this is not an absolute contraindication to
surgery. Indeed these patients may have most to gain from valve surgery in terms of
improvements in prognosis.
1.7.8 Aortic valve replacement in octogenarians
Successful AVR is becoming increasingly common in patients over the age of eighty.
Despite evidence suggesting that it should be offered to all suitable patients
regardless of age, several studies have demonstrated a reluctance to refer older
patients for valve surgery [Lindroos et al 1993; Abdul-Hamid and Mulley 1999;
Bouma et al 1999], This probably reflects both patient and physician misconceptions
of the risks and benefits of operative intervention.
Although operative mortality is higher in octogenarians (nearer 5-15%), these
individuals have almost as much to gain as their younger counterparts in terms of
improved prognosis (5-year survival being 55-70%). Of perhaps greater importance
is that the majority of survivors achieve a significant reduction in symptoms [Olsson
et al 1992; Olsson et al 1996; Gilbert et al 1999; Sundt et al 2000; Kohl et al 2001]
associated with a marked improvement in physical functioning and quality of life
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[Olsson et al 1992; Sprigings and Forfar 1995; Olsson et al 1996; Sundt et al 2000].
Although intensive care [Gilbert et al 1999; Sundt et al 2000] and overall hospital
stay [Olsson et al 1992; Sundt et al 2000; Kohl et al 2001] may be longer, the
majority return to their own homes and retain their independence on discharge
[Olsson et al 1992; Gilbert et al 1999], Flowever, post-operative complications are
more common with a higher incidence particularly of stroke (4%) and acute renal
failure (7-10%) [Sundt et al 2000], In contrast with younger patients, octogenarians
are usually offered a bioprosthetic (as opposed to a mechanical) valve, thus reducing
the risk of valve thrombosis and anticoagulant associated haemorrhage.
1.7.9 Potential role for HMG CoA reductase inhibitors
Hydroxymethylglutaryl coenzyme A (F1MG CoA) reductase inhibitors or statins are
now well established in the primary and secondary prevention of coronary artery
disease [Shepherd et al 1995; The Heart Protection Study Collaborative Group
2002], Several studies have also shown that these drugs can cause regression of
coronary artery disease [Zhao et al 1993] as well as reduce the calcific volume of
coronary plaques [Callister et al 1998]. Given the clinical association of calcific
aortic stenosis with hyperlipidaemia and coronary artery disease, and the striking
histological similarities with atheroma, the speculation that statins may have the
potential to influence disease progression in aortic stenosis is an intriguing
hypothesis [Mohler 2000; Pearlman 2002],
Recent retrospective studies [Aronow et al 2001; Novaro et al 2001; Pohle et al
2001; Bellamy et al 2002; Shavelle et al 2002] have demonstrated that statins may
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delay disease progression in aortic stenosis through their lipid-lowering and anti¬
inflammatory actions [Bellamy et al 2002], These observational data should be
interpreted with caution since none of these studies were randomised, and the statin
doses were small. This preliminary evidence has been the rationale for establishing a
randomised controlled trial of statin therapy in patients with aortic stenosis.
1.8 CONCLUSION
The need for an alternative to aortic valve surgery is highlighted by the increasing
longevity of the population and rising prevalence of aortic stenosis. New therapeutic
strategies to limit disease progression are needed in order to delay, and potentially
avoid, the need for valve surgery.
1.9 AIMS AND HYPOTHESES
The aims of this thesis are to evaluate new methods of assessing and monitoring
aortic stenosis, to clarify the factors that influence progression and outcome of aortic
stenosis, and identify novel therapies for the disease. At the same time I sought to
confirm the retrospective data suggesting that lipid-lowering therapy reduces
coronary artery calcification.
The specific aims of the thesis were:
Chapter 3
In patients with calcific aortic stenosis;
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1. to establish the validity and reproducibility of helical CT in the quantification
of aortic valve calcium (AVC) burden.
2. to establish the reproducibility of echocardiographic measures of aortic
stenosis severity.
3. to determine if there was a relationship between the severity of aortic valve
stenosis determined by echocardiography and the degree of valvular
calcification quantified by helical CT.
Hypothesis;
In patients with calcific aortic stenosis, aortic jet velocity, determined by
echocardiography, correlates with the AVC score measured by helical CT.
Chapter 4
4. To conduct a randomised double-blind placebo-controlled trial of high dose
lipid-lowering therapy in patients with calcific aortic stenosis in order to
determine its effect on the progression of aortic stenosis and aortic valve
calcification.
Hypothesis;
In patients with calcific aortic stenosis lipid-lowering therapy will halt the
progression, or induce regression, of the valvular disease process. In particular, lipid-
lowering therapy will:
(i) reduce the peak aortic jet velocity.
(ii) reduce the calcific volume of the aortic valve.
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Chapter 5
5. To prospectively determine the effect of intensive lipid-lowering therapy on
the progression of coronary artery calcification in patients with calcific aortic
stenosis.
Hypothesis;
In patients with calcific aortic stenosis lipid-lowering therapy delays progression of
coronary artery calcification.
Chapter 6
6. To identify prospectively traditional clinical risk factors and other novel
predictors of cardiovascular risk, including inflammatory, vascular and
cardiac markers that are associated with disease progression and clinical
outcome in patients with calcific aortic stenosis.
Hypothesis;






In this thesis, I have explored the interrelationship of atherosclerotic vascular disease
and calcific aortic stenosis. This required a comprehensive assessment of valvular,
myocardial and vascular variables. I have therefore measured valvular, myocardial
and vascular structure and function in patients with calcific aortic stenosis. This has
been complemented by the measurement of biochemical markers of systemic
inflammation, and myocardial disease as well as non-invasive measures of vascular
function such as arterial stiffness.
Echocardiography and CT are complementary methods of assessing the severity of
aortic valve disease and its progression. Computed tomography also allows the
measurement of coronary artery calcium, a marker of coronary artery disease, and
pulse wave analysis provides a measure of arterial stiffness, a marker of peripheral
arterial disease. These modalities have been used as the mainstay for the assessment
of recruited patients.
2.2 THE SALTIRE TRIAL
The Scottish Aortic stenosis and Lipid lowering Therapy Impact on REgression
(SALTIRE) trial was a prospective, randomised, double-blind placebo-controlled
trial designed to assess the influence of high dose statin therapy on disease
progression in patients with calcific aortic stenosis. It was funded by a project grant
from the British Heart Foundation (PG/2000/044) and also supported by an
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unrestricted educational grant award from Pfizer UK, and by the Wellcome Trust
Clinical Research Facility in Edinburgh.
2.2.1 Definition of study population
Patients aged over 18 years with calcific aortic stenosis, an aortic jet velocity of at
least 2.5 m/s, and aortic valve calcification on echocardiography were eligible for
inclusion in the SALTIRE trial.
Exclusion criteria were child-bearing potential without contraception, active or
chronic liver disease, a history of alcohol or drug abuse, severe mitral valve stenosis
(mitral valve area, <1 cm2), severe mitral or aortic regurgitation [Zoghbi et al 2003],
significant left ventricular dysfunction (ejection fraction <35%), planned AVR,
intolerance of statins, current statin therapy or a potential benefit from statin therapy
(according to the treating physician), a baseline serum total cholesterol concentration
of <4.0 mmol/L, and presence of a permanent pacemaker or cardiodefibrillator.
Of the patients screened, 455 were eligible for inclusion, 173 agreed to participate,
and 155 ultimately underwent randomisation.
2.2.2 Study protocol and clinical follow-up
Between March 2001 and April 2002, the blinded study co-ordinator randomly
assigned eligible patients by the minimisation technique [Treasure and MacRae
1998] with the use of a dedicated, locked computer program (Edinburgh University)
incorporating the following eight variables: age, sex, smoking habit, hypertension,
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diabetes mellitus, serum cholesterol concentration, aortic jet velocity, and aortic
valve calcium score. Patients were assigned to either 80 mg of atorvastatin (Lipitor,
Pfizer) or matched placebo as a single daily dose. Numbered containers were used.
Patients were assessed at baseline, at 2 and 6 months, and 6 monthly thereafter for a
minimum of 2 years. The following clinical end-points were recorded throughout the
study; cardiovascular and all cause mortality, AVR (whether for severe symptomatic
stenosis or not), the development of symptoms attributable to severe aortic stenosis
(confirmed by the patient's treating physician), and hospitalisation (both all cause
and cardiovascular causes). Functional status and adverse events were recorded at
each visit. Echocardiography and CT were performed annually.
2.3 BIOCHEMICAL VARIABLES
Fasting venous blood samples were taken annually. Samples for serum electrolytes,
lipid profile and calcium concentrations were sent to the regional clinical laboratory
for immediate analysis. Samples for estimation of serum brain natriuretic peptide
(BNP) and C-reactive protein (CRP) concentrations were centrifuged at 4°C and
stored at -80° C for later analysis.
2.3.1 Inflammatory markers
Serum CRP concentration is a sensitive but non-specific marker of systemic
inflammation that is elevated in patients with vascular disease [Van der Meer et al
2002] and calcific aortic stenosis [Galante et al 2001], It predicts clinical outcome in
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patients with coronary heart disease and in apparently healthy subjects [Ridker et al
1998], Plasma CRP concentrations were measured using a highly sensitive
nephelometric assay with a monoclonal antibody to CRP coated on polystyrene
beads (Dade Behring UK Ltd). The sensitivity of the assay was 0.175 mg/L, with
intra-assay and inter-assay coefficients of variation of less than 5% [Chenillot et al
2000; Jialal et al 2001],
2.3.2 Endogenous cardiac hormones
Natriuretic hormones are endogenous cardiac hormones that are secreted from the
cardiac atria and ventricles. Brain natriuretic peptide and its aminoterminal portion
N-terminal BNP, are released in response to increased wall stretch and effect both
natriuresis and diuresis with a resultant decrease in intravascular volume, blood
pressure and pre-load. Serum concentrations are elevated in left ventricular
dysfunction, and correlate with New York Heart Association (NYHA) class and
prognosis [Tsutamoto et al 1997; McDonagh et al 2001; Berger et al 2002; Lubien et
al 2002], Serum BNP concentrations are also elevated in other structural heart
disease [Nakamura et al 2002] including left ventricular hypertrophy and aortic
stenosis. The N-terminal peptides are inactive and more stable [Boomsma et al
2001], and therefore N-terminal pro-BNP was measured using a chemiluminescent
immunoassay (Roche Diagnostics Ltd, Lewes, UK) on an Elecsys 2010 analyser.
The sensitivity of the assay was 5 pg/mL, with intra-assay and inter-assay
coefficients of variation of <5% [Hartman et al 2004],
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2.4 ECHOCARDIOGRAPHY
Echocardiography, or cardiac ultrasound, relies on the processing of high frequency
sound waves emitted from and received by an ultrasound transducer using a
frequency of 2-5-MHz. It is a non-invasive and relatively quick technique to
determine cardiac structure and function. There are three main modes of operation:
M-mode (single-dimensional), two-dimensional, and Doppler (spectral Doppler and
colour flow mapping). Spectral Doppler includes pulsed and continuous wave
Doppler, which are used to assess velocity of blood flow and cardiac tissue at a given
specific point. Colour flow mapping is superimposed on either one or two-
dimensional images to provide a picture of blood flow using different colours for
opposing directions of flow.
Echocardiography is the gold standard modality for the assessment of stenosis in
patients with aortic valve disease and was the principal modality employed in this
thesis.
2.4.1 Scanning protocol and technique
A single dedicated research sonographer, blinded to treatment allocation and CT
results, performed all echocardiography examinations and analyses. The
echocardiograms were all performed on either an ATL-3000 (Philips Medical
Systems (UK) Ltd, Stevenage, UK), or a Vingmed System 5 Performance (BMS
(Scotland) Ltd, Belshill, UK) cardiac ultrasound machine using a 3-MHz transducer.
Each patient was always scanned using the same equipment. All measurements were
determined online, averaged from three cardiac cycles (five cycles if the patient was
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in atrial fibrillation), and recorded onto super-VHS videotape and optical disk
according to a standard protocol.
Aortic valve calcification was graded using the Rosenhek classification [Rosenhek et
al 2000]. In the presence of calcification bicuspid valves are very difficult to
diagnose using echocardiography, and diagnosis of a bicuspid valve was therefore
only made if the appearance was unequivocal. In uncertain cases the valve was
classified as tricuspid. Severity of aortic valve stenosis was determined using the
peak aortic jet velocity, peak and mean aortic gradient, and AVA. Peak and mean
aortic valve pressure gradients were calculated using the modified Bernoulli
equation. Aortic valve area measured by the continuity equation requires
measurement of left ventricular outflow tract velocity, peak aortic jet velocity and
left ventricular outflow tract diameter.
Left ventricular outflow tract velocity was measured from an apical approach using
pulsed Doppler just proximal to the aortic valve leaflets. Peak aortic jet velocity was
determined using continuous wave Doppler from three sites; the apical long axis
approach, the right upper sternal border, and the suprasternal notch using the stand
alone probe, and the window generating the highest signal was recorded. Left
ventricular outflow tract diameter (LVOTD) was measured in the parasternal long
axis view in mid systole just below the aortic valve. It was measured at baseline and
maintained constant throughout the study, given that LVOTD remains static over
time and variation in the measurement of this dimension results in the greatest
variability in valve area assessment [Myreng et al 1990],
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The above measures of aortic stenosis severity have all been well validated when
compared with invasive data, and as predictors of clinical outcome. Peak aortic jet
velocity is the most reproducible measure, and is the strongest predictor of clinical
outcome [Otto 2006].
2.5 COMPUTED TOMOGRAPHY
Computed tomography allows the generation of anatomical soft tissue images in the
axial plane providing complementary data to echocardiography. Prior to the
development of electron beam and helical CT, conventional CT was limited by slow
scan times, and was therefore unsuitable for the assessment of rapidly moving
cardiac structures. Helical CT, which only become widely available 5 years ago, has
a gantry capable of continuous rotation and very rapid image acquisition.
Technology has advanced dramatically since, such that with the introduction of
multi-slice technology and ECG gating it is now possible to produce images virtually
free of motion artefact. At the inception of the SALTIRE trial helical CT was the
most advanced technology available.
Cardiac CT was initially introduced to look for the presence of coronary artery
calcification as evidence of coronary atheroma, and subsequently to monitor disease
progression in patients with coronary artery disease. Disease severity determined by
invasive coronary angiography correlates well with coronary calcium burden
assessed by both electron beam [Haberl et al 2001] and helical [Achenbach et al
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2001; Nieman et al 2001] CT. In the late 1990's there was limited retrospective
evidence that progression of coronary artery calcification may be delayed by the use
of statin therapy [Callister et al 1998].
Aortic valve calcification is a common incidental finding on cardiac CT and although
not diagnostic of aortic valve stenosis, the more heavily calcified the valve is the
more likely it is that stenosis will be present [Lippert et al 1995]. Electron beam CT
has only recently been validated as a reproducible technique for the quantification of
AVC [Kizer et al 2001], and prior to the commencement of the SALTIRE trial the
validity of helical CT had not been determined. Validation of helical CT was
therefore an integral part of the SALTIRE trial, as well as the assessment of the
relationship between the severity of aortic valve stenosis and calcium burden (see
Chapter 3).
2.5.1 Scanning protocol and technique
Computed tomography was performed using a double-helix scanner (Twin II Flash;
Philips Medical Systems (UK) Ltd, Stevenage, UK). The region of the aortic valve
and coronary arteries was assessed using 2.7 mm slices, with a pitch of 0.7 and an
increment of 1.4 mm during held inspiration. Computed tomography scanner quality
assurance was performed before each examination with calibration against a standard
phantom. A single research radiographer performed all scans, and a single consultant
radiologist performed all analyses, both being blinded to the echocardiography
results. Off-line analysis of the cardiac images was conducted using an automated,
computerised software program (Picker Cardiac Scoring). This employs a modified
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Agatston scoring method [Shemesh et al 1995] that uses a threshold of 90 Hounsfield
Units (HU) to compensate for non-gated imaging. This modification produces
comparable sensitivity and specificity to electron beam CT [Carr et al 2000],
Calcium scores were individually calculated for the aortic valve, and all three
coronary arteries by summing the lesion scores for all sections containing calcium.
2.6 PULSE WAVE ANALYSIS
The link between blood pressure and cardiovascular disease has been clearly
documented [Goldberg et al 1996], Pulse wave analysis (PWA) by applanation
tonography is a simple, non-invasive, reproducible method by which central aortic
pressure waveforms can be determined from waveforms acquired peripherally at for
example, the radial artery. The artery is compressed beneath the micromanometer
probe tip, and arterial pressure is transmitted through the arterial wall to the sensor.
Computer software calculates the central aortic pressure and waveform from the
peripheral waveform using a generalised transfer function calibrated using peripheral
blood pressure.
2.6.1 Scanning protocol and technique
Pulse wave analysis was performed at baseline and 6 monthly intervals thereafter.
Patients were rested supine for 15 minutes prior to study. Radial PWA was
performed using a high-fidelity applanation tonometer (Sphygmocor BPAS; PWV
Medical, Sydney, Australia). After acquiring a series of consecutive waveforms, an
averaged peripheral waveform was acquired and a generalised transfer function was
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used to generate a central aortic pressure waveform from which the pulse pressure,
augmentation pressure and augmentation index were determined. Two measurements
of augmentation within 5 mmHg of each other were recorded on each occasion.
Patients with atrial fibrillation were excluded, and recordings with poor quality
waveforms were discarded: determined by visual inspection (SJC) with a minimum
requirements in pulse height of >100 mmHg, diastolic variation of <5% and pulse
height variation of <5%. Data on 105 patients were available at baseline, of these
20 patients had poor quality recordings and 9 patients were in atrial fibrillation,
leaving a total of 84 patients for analysis.
2.7 DATA ANALYSIS AND STATISTICS
Computed tomography, BNP and CRP data were not normally distributed, and are
expressed as median with interquartile ranges, or as mean with standard deviation
(SD) after logarithmic transformation. Two-sided p values of less than 0.05 were
considered to indicate statistical significance.
2.7.1 Chapter 3
2.7.1.1 Reproducibility
Reproducibility of echocardiographic and CT measures were determined by the
method of Bland and Altman [Bland and Altman 1986] and expressed as the mean of
the differences and the coefficient of repeatability (twice the standard deviation of
the differences). As the difference of the two measures was proportional to their
mean, the data for the AVC score underwent logarithmic transformation [Bland and
Altman 1986]. Data were compared using regression analysis and analysis of
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variance (ANOVA) using StatView version 5.0.1 (SAS Institute Inc., Cary, NC,
USA). Where ANOVA demonstrated significant differences in responses, post-hoc
comparisons were made using Fisher's protected least squares difference (PLSD) test
(StatView version 5.0.1).
2.7.2 Chapter 4
2.7.2.1 Progression ofaortic valve disease
The two primary end-points were progression of stenosis, determined according to
changes in aortic jet velocity on Doppler echocardiography, and progression of
valvular calcification, measured by CT. Secondary end-points were a composite of
clinical end-points (death from cardiovascular causes, AVR, or hospitalisation
attributable to severe aortic stenosis), AVR, death from any cause, hospitalisation for
any cause, and hospitalisation for cardiovascular causes.
On the basis of standard deviations of 0.32 m/s per year [Faggiano et al 1992; Otto et
al 1997] and 1100 arbitrary units (AU) per year [Shemesh et al 1995], we calculated
that the planned sample size of 75 patients per group would give the study a power of
80% at a 5% significance level to detect a difference in the primary end-points of
0.15 m/s per year in aortic jet velocity and 500 AU per year in AVC score. These
differences are equivalent to a reduction of more than 30% in the rate of progression
of aortic stenosis. This would exclude a clinically significant effect in the majority of
older patients with established disease, although a smaller effect may be clinically
relevant in younger patients with mild aortic stenosis.
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2.7.2.2 Interim analysis and data monitoring committee
The data monitoring committee conducted two interim assessments of safety and an
interim assessment of efficacy one year after enrolment began. The trial was to be
terminated early in the event of a negative effect of treatment (i.e. <0.05) or a strong
benefit of treatment (i.e. p<0.001). On the recommendation of the data monitoring
committee, the trial continued until the study was completed.
Analyses were performed using SPSS software, version 12.0, and SAS software,
version 8e. Intention-to-treat analyses were used for all clinical outcome variables.
Disease progression was determined primarily by dividing the change between the
baseline and final scans by the duration of follow-up. Treatment comparisons for the
continuous outcome variables were based on an analysis of covariance, with the pre-
randomisation level of a variable used as a covariate. In a confirmatory analysis of
the primary end-points, random coefficient models were fitted to incorporate all
observations [Brown and Prescott 1999], In the subgroup analyses, interaction terms
between treatment and subgroup have been added to a model incorporating pre-
randomisation level, treatment, and subgroup to identify factors that were associated
with a differential treatment effect within subgroups. Categorical variables have been
analysed using Fisher's exact test. Two-tailed tests were used throughout.
2.7.3 Chapter 5
2.7.3.1 Progression ofcoronary disease
Coronary artery calcium scores are expressed in AU based on the 130 HU threshold.
The primary end-point, the rate of change of coronary calcium scores, was analysed
l~f \
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with random coefficient models [Bland and Altman 1986; Cowell et al 2005], after
logarithmic transormation of the scores. In summarising the data, we calculated the
change in coronary artery calcium scores by dividing the change between the
baseline and final scores by the duration of follow-up. Rate of change in coronary
calcium score is expressed as percentage change per year or as absolute change in the
logarithm of the coronary artery calcium score.
2.7.4 Chapter 6
2.7.4.1 Predictors aortic stenosis progression and clinical outcome
Disease progression was determined by dividing the change between the baseline and
final scans by the duration of follow-up. Clinical end-points were; cardiovascular and
all cause mortality, AVR (whether for severe symptomatic stenosis or not), and the
development of symptoms attributable to severe aortic stenosis (confirmed by the
patient's treating physician). To define predictors of outcome patients who reached a
clinical end-point were compared with those who did not.
Analyses were performed using SPSS software, version 12.0, and SAS software,
version 8e. Predictors of progression were determined using regression analysis for
continuous variables, and Chi-squared tests for categorical variables. Predictors of




AORTIC VALVE CALCIFICATION ON COMPUTED TOMOGRAPHY
PREDICTS THE SEVERITY OF AORTIC STENOSIS
Based on
Cowell SJ, Newby DE, Burton J, White A, Northridge DB, Boon NA, Reid J.
Aortic valve calcification on computed tomography
predicts the severity of aortic stenosis.
Clin Radiol 2003;58(9):712-6.
3.1 SUMMARY
Background Disease progression in patients with aortic stenosis is more rapid in those
with heavy calcification of the valve. The aims of this study were to determine the
reproducibility of AVC scoring using helical CT, and to compare the AVC scores with
the severity of valve stenosis measured by echocardiography.
Methods One hundred and fifty-seven patients aged 68 ±11 years (range 34-85) with
aortic valve stenosis underwent dual array helical CT and Doppler echocardiography
performed by independent blinded observers. The AVC score was determined using
automated computer software calibrated with a phantom.
Results Doppler echocardiography demonstrated a post-valve velocity of
3.45 ± 0.66 m/s and a peak gradient of 49 ± 11 mmHg. Computed tomography showed
excellent reproducibility and the median score was 5858 (interquartile range 1555-
14596) AU. The computed tomography AVC score positively correlated with the
Doppler post-valve velocity and peak gradient (r=0.54, p<0.0001 for both) of the aortic
valve. All patients with severe aortic stenosis had a calcium score of>3700 AU.
Conclusion Helical CT is a reproducible method of quantifying AVC burden.
Calcification of the aortic valve is closely associated with the severity of aortic stenosis




Calcific aortic stenosis is the commonest reason for valve replacement in the developed
world. The condition may be due to progressive calcification of a congenitally bicuspid
valve or 'degenerative' calcification of a morphologically normal valve [Pomerance
1972]. Irrespective of the aortic valve morphology, the histological features are
surprisingly similar to those of coronary atheroma and include lipid deposition, fibrosis
and calcification [Otto et al 1994],
Disease progression in aortic stenosis is variable and unpredictable, but appears to be
most rapid in patients with valvular calcification [Davies et al 1991; Bahler et al 1999].
The presence of AVC more than doubles the annual increase in aortic valve gradient
(9.7 versus 4.4 mmHg/yr), and the echocardiographic grade of calcification correlates
with the rate of disease progression [Davies et al 1991]. Indeed, moderate or severe
aortic valve calcification is the strongest independent risk factor for an adverse clinical
outcome with a 5-fold increase in the rate of death or AVR [Rosenhek et al 2000],
Computed tomography is being increasingly used as a non-invasive method of screening
for atherosclerotic coronary artery disease [Breen et al 1992; Mautner et al 1994] with
80-100% sensitivity and 80% specificity [Harberl et al 2001], There is an association
between coronary artery disease and calcific aortic stenosis with approximately a third
of patients with aortic stenosis having significant coronary stenoses on angiography
[Mautner and Roberts 1992], As a consequence, there have been several reports of
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incidental aortic valve calcification detected during CT examinations with a prevalence
of 10-30% [Woodring and West 1989; Lippert et al 1995]. However, there have been
few reports [Lippert et al 1995] assessing the relationship between the degree of valvular
calcification and the severity of aortic stenosis.
We wished to evaluate the reproducibility of helical CT in the quantification of AVC
burden, and hypothesised that valvular calcification would correlate with the aortic post-
valve velocity in patients with aortic stenosis.
3.3 METHODS
3.3.1 Subjects
One hundred and fifty-seven patients being evaluated for the SALT1RE trial,
participated in this substudy, which was undertaken with the approval of the local
research ethics committee, in accordance with the Declaration of Helsinki, and with the
written informed consent of each subject. Inclusion and exclusion criteria for the
SALTIRE trial are outlined in Chapter 2. One patient, with a previous aortic root
abscess, was excluded because of extensive aortic root calcification that obscured and
prevented assessment of the aortic valve.
All patients underwent both echocardiography and CT within the month before
randomisation to study therapy (atorvastatin 80 mg daily or placebo). Only pre-
intervention baseline data are presented here.
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3.3.2 Echocardiography
The echocardiograms were performed on an ATL-3000 (Philips Medical Systems (UK)
Ltd, Stevenage, UK) or a Vingmed System 5 Performance (BMS (Scotland) Ltd,
Belshill, UK) cardiac ultrasound machine using a 3-MHz transducer for M-mode, and
two-dimensional imaging with integral pulsed and continuous wave Doppler. The peak
instantaneous aortic valve gradient was determined using the modified Bernoulli
equation, and the AVA by the continuity equation. Aortic valve calcification was graded
using the Rosenhek classification [Rosenhek et al 2000]. A single operator blinded to
the results of the CT performed all echocardiography examinations and analyses.
3.3.3 Computed tomography
The computed tomograms were performed using a dual array helical scanner (Twin II
Flash; Philips Medical Systems (UK) Ltd, Stevenage, UK). The region of the aortic
valve and coronary arteries was assessed using 2.7 mm slices, with a pitch of 0.7 and an
increment of 1.4 mm during held inspiration. Operators blinded to the results of the
echocardiogram performed all examinations and analyses. Computed tomography
scanner quality assurance was performed prior to each examination with calibration
against a standard phantom. Off-line analysis of the cardiac images was conducted using
an automated, computerised software program (Picker Cardiac Scoring). This employs a
modified Agatston scoring method [Shemesh et al 1995] that uses a threshold of 90 HU
to compensate for non-gated imaging. This modification produces comparable
sensitivity and specificity to electron beam CT. Calcium scores were individually
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calculated for the aortic valve, and all three coronary arteries by summing the lesion
scores for all sections containing calcium.
3.3.4 Reproducibility
Two unselected random samples of 20 subjects each were taken from the study
population. Subjects underwent repeated CT or echocardiography within 4 weeks of the
first examination and before administration of the study medication.
3.3.5 Data analysis and statistics
Data are expressed as mean ± SD. The calcium scores were not normally distributed and
are expressed as median with interquartile ranges. The aortic valve and coronary artery
calcium volume scores are expressed as AU). Reproducibility was assessed by the
method of Bland and Altman [Bland and Altman 1986], and expressed as the mean of
the differences and the coefficient of repeatability (twice the standard deviation of the
differences). Since the difference of the two measures was proportional to their mean,
the data for the aortic valve calcium score underwent logarithmic transformation [Bland
and Altman 1986]. Data were compared using regression analysis and ANOVA using
StatView v5.0.1 (SAS Institute Inc., Cary, North Carolina, USA). Where ANOVA
demonstrated significant differences in responses, post-hoc comparisons were made




Subject characteristics are shown in Table 3.1. In keeping with the study population,
subjects were predominantly male, elderly and had haemodynamically significant aortic
stenosis. Both echocardiography and CT showed excellent reproducibility (Table 3.2).
All but two patients had significant aortic valve calcification on CT (Figure 3.1). The
median AVC score was 5858 AU. The majority of patients (107/157) had detectable
coronary artery calcification that predominantly affected the left anterior descending
(LAD) coronary artery. There was no correlation between the magnitude of the aortic
valve and total coronary calcium scores (r=0.04, p=0.61).
3.4.1 Comparison between echocardiography and computed tomography
Echocardiographic grade of calcification correlated weakly with the computed
tomography AVC score (r=0.29, p<0.001) and the peak aortic jet velocity (r=0.40,
p<0.001). The aortic valve calcium score correlated strongly with the peak aortic jet
velocity (r=0.54, pcO.OOOl: y=0.00004x +3.09; Figure 3.2) and the mean (r=0.54,
pO.OOOl: y=0.0008x +20.7) and peak gradient (r=0.54, p<0.0001: y=0.0013x +39.1) of
the aortic valve, but only weakly correlated with the aortic valve area (r=0.20, p=0.01).
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TABLE 3.1 Baseline characteristics
Baseline subject characteristics
Number 157
Age 68 ± 11 years





Pre-valve velocity 1.08 ±0.22 m/s
Post-valve velocity 3.45 ± 0.66 m/s
Peak gradient 49 ± 19 mmHg
Mean gradient 27 ± 11 mmHg
Valve area 1.02 ±0.40 cm2
Computed Tomogram*
Aortic Valve 5858 (1555-14596) AU
Coronary Artery
LAD 97 (0-603) AU
Circumflex 0 (0-36) AU
Right 0 (0-0) AU
Total 121 (0-731) AU
Mean ± SD.
*Median (interquartile range).
LAD - left anterior descending.
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Stratifying the patients according to the quintiles of calcification demonstrated a
progressive increase in the mean peak aortic jet velocity (Figure 3.3). All patients with
severe aortic valve stenosis (peak aortic jet velocity >4 m/s) had an AVC score of >3700
AU. This threshold gives a sensitivity of 100% and specificity of 50% that translates into
a negative predictive value of 100% and a positive predictive value of 39% for the
detection of severe aortic stenosis. A threshold of 6000 AU gives a sensitivity of 90%
and specificity of 66% giving a negative predictive value of 95% and a positive
predictive value of 45%.
64





Quintiles ofAortic Valve Calcium Score
ANOVA, p<0.001. Fisher's PLSD test, p<0.03 for all comparisons between the individual
quintiles except quintile 1 versus quintile 2, and quintile 3 versus quintile 4.
PLSD - protected least squares difference.
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3.5 DISCUSSION
In patients with aortic stenosis, we have demonstrated that helical CT is a reproducible
means of quantifying AVC burden. We have also established a close association
between the degree of aortic valve calcification and the haemodynamic severity of aortic
stenosis. In particular, the presence of severe and potentially critical aortic stenosis is
associated with heavy calcification. We suggest that patients found to have incidental
aortic valve calcification on CT require further cardiological assessment for aortic
stenosis, especially when there is heavy calcification.
Recent studies have evaluated electron beam CT in the quantification of AVC burden,
revealing an interscan variability of less than 10% [Pohle et al 2001; Budoff et al 2002],
Here we have confirmed that helical CT also provides accurate quantification of valvular
calcification, with sufficient accuracy to evaluate progression of calcium accumulation
over time. Further studies are required to determine whether different modes of CT
image acquisition are comparable.
This is the first study to compare AVC scores with echocardiogram-derived measures of
valvular gradients in a large number of patients with aortic stenosis. One previous small
study of 19 patients also suggested that there might be an association between the
severity of aortic stenosis and the valvular calcium score [Kizer et al 2001], We have
studied a much larger population with sufficient power to demonstrate a marked
correlation between these parameters. However, because of the selected study
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population, these findings should only be cautiously extrapolated to aortic valve
calcification identified during general population screening or as an incidental finding. A
recent retrospective study suggested a 20% incidence of aortic valve calcification in over
2,000 patients attending for detection of coronary calcification [Kizer et al 2001]. One
retrospective study of 109 such patients who had undergone both CT and
echocardiography, reported a 30% prevalence of aortic valve calcification in which
aortic stenosis was documented in 15% [Lippert et al 1995], In the absence of aortic
valve calcification, none of the patients had significant aortic valve stenosis. In the
current study, only 2 patients (1%) had no detectable valvular calcification suggesting an
excellent negative predictive value. Our study findings additionally suggest that the
likelihood of significant valvular stenosis increases with the severity of calcification.
Echocardiography is the mainstay of clinical monitoring for aortic valve stenosis but
provides only a subjective and semi-quantitative measure of aortic valve calcification.
Computed tomography provides a more accurate method of quantifying calcium that
more closely correlates with the aortic valve gradient than echocardiography-derived
measures of calcification. It may be useful to quantify more accurately the degree of
calcification given that it is the strongest independent risk factor for disease progression
and an adverse clinical outcome [Rosenhek et al 2000]. Further prospective studies are
now needed to assess whether the degree of calcification [Pohle et al 2001] provides
useful additional clinical information that would help guide patient management. Indeed,
it has been suggested that patients with severe aortic stenosis and marked calcification
should undergo AYR even in the absence of symptoms [Rosenhek et al 2000].
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Aortic valve calcification is associated with an increased cardiovascular mortality [Otto
et al 1999; Rosenhek et al 2000]. The underlying pathogenetic process appears to share
many of the features and risk factors for atherosclerosis [Otto et al 1994] including
hypercholesterolemia, [Wilmshurst et al 1997; Chui et al 2001] that is associated with a
more rapid progression of aortic valve calcification [Pohle et al 2001]. There are several
studies, including the SALTIRE trial, that are assessing the impact of lipid-lowering
therapy on the rate of progression of aortic stenosis. Given that statin use is associated
with halting the progression of coronary calcification [Callister et al 1998], the present
study indicates that helical CT is a valuable method of assessing aortic valve
calcification and disease progression in such intervention trials. Indeed, one preliminary
observational study has suggested that statin use is associated with a lower rate of
progression of aortic valve calcification [Shavelle et al 2002],
Using our methodology, we have found a close correlation between echocardiographic
measures of aortic stenosis and AVC scores measured by multi-slice helical CT. The
applicability of our findings to the latest CT scanners with differing specifications such
as 64 slice multidetector array acquisition, or imaging parameters, such as slice
thickness, pitch and ECG gating, is unknown. However, there is a high degree of
agreement between different machines and coronary calcium scores [Carr et al 2000],
and we believe that our findings will be applicable to other CT equipment. The reference
ranges of the AVC scores are likely to be dependent on the imaging protocol and CT
equipment used. However, broadly speaking, poorly defined or diffuse segments of
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calcium usually represent a minor aortic valve gradient. In contrast, coalescent calcium
centred on the aortic valve is likely to represent moderate stenosis where as very heavy
calcification almost invariably represents a significant degree of valvular stenosis
(Figure 3.1).
In conclusion, quantification of aortic valve calcification by helical CT is a reproducible
technique. Calcification of the aortic valve is closely associated with the severity of
aortic stenosis and heavy calcification suggests the presence of severe aortic stenosis
that requires prompt cardiological assessment. Patients with lesser degrees of aortic
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Background Calcific aortic stenosis has many characteristics in common with
atherosclerosis including hypercholesterolemia. We hypothesised that intensive lipid-
lowering therapy would halt the progression or induce regression of calcific aortic
stenosis.
Methods In this double-blind placebo-controlled trial, patients with calcific aortic
stenosis were randomised to either atorvastatin 80 mg daily or matched placebo. Aortic
valve stenosis and calcification were assessed using Doppler echocardiography and
helical CT respectively. The primary end-points were change in aortic jet velocity and
AVC score.
Results Seventy-seven patients were assigned to atorvastatin and 78 to placebo with a
median follow-up of 25 months (range 7-36). Serum low-density lipoprotein cholesterol
concentration remained at 3.4 ± 0.8 mmol/L in the placebo group, and fell to
1.7 ± 0.6 mmol/L in the atorvastatin group (p<0.001). Increase in aortic jet velocity was
0.199 + 0.210 m/s per year in the atorvastatin group, and 0.203 ± 0.208 m/s per year in
the placebo group (p=0.95: difference 0.002; 95% confidence interval (CI), -0.066 to
0.070 m/s/yr). Progression in valvular calcification was 22.3 ± 21.0% per year in the
atorvastatin group and 21.7 ± 19.8% per year in the placebo group (p=0.93: ratio of post-
treatment AVC score: 0.998; 95% CI, 0.947 to 1.050).
Conclusion This is the first double-blind randomised controlled trial of lipid-lowering
therapy in patients with calcific aortic stenosis. It has clearly demonstrated that whilst
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high dose atorvastatin more than halves serum LDL cholesterol concentrations, it does
not halt the progression or induce regression of the valvular disease process.
4.2 INTRODUCTION
In the western world, calcific aortic stenosis is the commonest form of valvular heart
disease and its incidence increases with age such that 3% of adults over 75 years of age
have aortic stenosis [Stewart et al 1997]. It is a gradually progressive disease,
characterised by a long asymptomatic phase lasting several decades, followed by a
shorter symptomatic phase associated with severe narrowing of the aortic valve orifice.
Once symptoms occur, the prognosis is poor and usually mandates surgery. Calcific
aortic stenosis is now the leading indication for valve replacement in North America and
Europe. However, there are currently no effective disease modifying treatments and the
possibility of halting, or even inducing regression of, the disease process would
represent a major therapeutic advance.
Calcific aortic stenosis is mediated by a chronic active inflammatory disease process that
has many similarities with atherosclerosis and includes infiltration of inflammatory cells,
lipoproteins, lipids, extracellular bone matrix proteins and bone mineral [Olsson et al
1994; Otto et al 1994; O'Brien et al 1996; Olsson et al 1999]. Consistent with these
observations, clinical studies have revealed a strong association with coronary artery
disease [Mautner and Roberts 1992; Peltier et al 2003] and many of its risk factors
including hypercholesterolaemia [Stewart et al 1997]. Disease progression in aortic
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stenosis is variable and is influenced by several factors including degree of stenosis
[Otto et al 1997], valvular calcification [Davies et al 1991; Bahler et al 1999; Rosenhek
et al 2000] and hypercholesterolemia [Palta et al 2000; Nassimiha et al 2001], Indeed,
calcific aortic stenosis is a feature of severe homozygous familial hypercholesterolaemia
[Rallidis et al 1998] and intensive lipid-lowering therapy with plasmapheresis has been
reported to regress valvular stenosis in these patients [Keller et al 1986],
Hydroxymethylglutaryl coenzyme A reductase inhibitors, or statins, are now established
treatments for the primary and secondary prevention of coronary artery disease
[Shepherd et al 1995; The Heart Protection Study Collaborative Group 2002]. Several
studies have shown that these drugs can halt the progression of coronary artery disease
[Zhao et al 1993; Jukema et al 1995; Pitt et al 1995] as well as reduce the calcific
volume of coronary plaques [Callister et al 1998; Budoff et al 2000; Achenbach et al
2002]. Given the clinical association with hypercholesterolaemia and coronary artery
disease, and the striking histological similarities with atheroma, it has been suggested
that statin therapy may halt the progression, or even induce regression, of calcific aortic
stenosis. This hypothesis is supported by numerous retrospective observational studies
[Arnow et al 2001; Novaro et al 2001; Pohle et al 2001; Bellamy et al 2002; Shavelle et
al 2002; Rosenhek et al 2004] showing that concomitant statin therapy was associated
with a delay in the progression of the aortic jet velocity of 0.30 m/s per year and
calcification by 30% per year.
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The aim of the SALTIRE trial was to establish whether intensive lipid-lowering therapy
with atorvastatin 80 mg daily would halt the progression, or induce regression, of the
aortic jet velocity on Doppler echocardiography, and the AVC score on CT, in patients
with calcific aortic stenosis.
4.3 METHODS
The SALTIRE trial was a randomised double-blind placebo-controlled trial. The
investigation conformed to the Declaration of Helsinki, and all participating regional
ethics committees approved the study protocol. All patients gave written informed
consent.
4.3.1 Patient population
Patients from the south-east of Scotland attending seven district and two regional centres
were approached for enrolment by the study co-ordinator between December 2001 and
April 2002. Eligible individuals were identified from outpatient clinics and
echocardiography databases. Those aged over 18, with calcific aortic stenosis, an aortic
jet velocity of >2.5 m/s, and grade 1-3 calcification of the aortic valve on
echocardiography [Rosenhek et al 2000] were included. Exclusion criteria are detailed
in Chapter 2. Of the patients screened, 455 were eligible for inclusion, 173 agreed to
participate and 155 were ultimately randomised to treatment.
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4.3.2 Study protocol
Between March 2001 and the end of April 2002, the blinded study co-ordinator
randomised 155 eligible patients by the minimisation technique [Treasure and MacRae
1998] using a dedicated locked computer programme (Edinburgh University) which
incorporated eight baseline variables: age, sex, smoking habit, hypertension, diabetes
mellitus, serum cholesterol concentration, aortic jet velocity, and AVC score. Patients
were assigned to either atorvastatin 80 rng daily or matched placebo (Pfizer Ltd, UK) as
a single daily dose using numbered containers.
Patients were assessed at baseline, 2 months, 6 months and every 6 months thereafter for
between 2 and 3 years. Clinical evaluation included assessment of functional status and
adverse events as well as blood analysis of renal function, liver function, creatine kinase
and lipid profile. Echocardiography and CT were performed at baseline, at each annual
visit and prior to withdrawal from the study. Randomised patients who were
subsequently commenced on open label statin therapy by their attending physician were
immediately scanned and then withdrawn from the study.
4.3.2.1 Echocardiography
Assessment of valvular stenosis was determined by a single dedicated research
ultrasonographer. All scans were performed on one of two dedicated ultrasound
machines Vingmed System 5 Performance (BMS (Scotland) Ltd, Belshill, UK), or ATL-
3000 cardiac ultrasound machine (Philips Medical Systems (UK) Ltd, Stevenage, UK)
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that were maintained constant for each patient throughout the study. Patients were
studied using a 3-MHz transducer for M-mode, and two-dimensional imaging with
integral pulsed and continuous wave Doppler. All measurements were determined on¬
line, averaged from three cardiac cycles (five cycles if in atrial fibrillation), and recorded
onto Super-VHS video and optical disk using a standardised proforma. Aortic jet
velocity was recorded from the window generating the highest signal (apical, right
parasternal or suprasternal). Left ventricular outflow tract velocity was measured from
an apical approach just proximal to the aortic valve leaflets. Peak and mean aortic valve
gradients were calculated using the Bernoulli equation, and AVA using the continuity
equation. The left ventricular outflow tract diameter was measured at baseline and
maintained constant throughout the study.
4.3.2.2 Computed tomography
Computed tomography was performed by a single operator using a double-helix scanner
(Twin II Flash; Philips Medical Systems (UK) Ltd, Stevenage, UK) and calibrated
against a standard phantom. The region of the aortic valve was imaged with a spiral
acquisition using 2.7 mm slices, with a pitch of 0.7 and an increment of 1.4 mm during
held inspiration. All images were analysed by a single operator using an automated
computerised software program (Picker Cardiac Scoring). This employs a modified
Agatston scoring method [Shemesh et al 1995] that uses a threshold of 90 HU to
compensate for non-gated imaging.
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Reproducibility of echocardiographic and CT assessments was determined in two
subsets of 20 patients as described in Chapter 3 [Cowell et al 2003], Coefficients of
reproducibility for aortic jet velocity and AVC score were 0.32 m/s and 0.07 pAU
respectively [Cowell et al 2003],
4.3.3 Data and statistical analysis
The study was designed to assess the two primary end-points: progression of stenosis
determined by change in aortic jet velocity on Doppler echocardiography, and
progression of valvular calcification measured by CT. Secondary end-points were a
composite clinical end-point (cardiovascular mortality, AVR) or hospitalisation
attributable to severe aortic stenosis), AVR, all cause hospitalisation and cardiovascular
hospitalisation. The planned sample size of 75 patients per group gave 80% power at a
5% significance level to detect a difference in the primary end-points of 0.15 m/s per
year in aortic jet velocity [Faggiano et al 1992; Otto et al 1997] and 500 AU in the AVC
score [Shemesh et al 1995].
The Data Monitoring Committee conducted two interim assessments of safety, as well as
an interim assessment of efficacy one year after randomisation. The trial was to be
terminated early in the event of a negative treatment effect (p<0.05), or strong treatment
benefit (p<0.001). On the recommendation of the Data Monitoring Committee, the trial
continued until study completion.
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Analyses were performed by RP using SPSS Version 12.0. All outcome variables were
analysed by intention-to-treat. Disease progression was determined by calculating the
rate of change between the baseline and final scans. Treatment comparisons for the
continuous outcome variables were based on an analysis of covariance, with the pre-
randomisation level of that variable used as a covariate. In the subgroup analyses,
interaction terms between treatment and subgroup have been added to a model
incorporating pre-randomisation level, treatment and subgroup to assess whether there is
any evidence of a differential treatment effect in subgroups. Categorical variables have
been analysed using Fisher's exact test. Two-tailed tests are employed throughout.
Statistical significance was taken as p<0.05.
4.4 RESULTS
Seventy-seven patients were assigned to atorvastatin and 78 to placebo with a median
follow-up of 25 months (range 7-36) (Figure 4.1). As a consequence of minimisation,
the baseline characteristics were well matched (Table 4.1). All patients had good left
ventricular function except one patient who had mild impairment of systolic function.
Mean aortic jet velocity was 3.43 ± 0.64 (range 2.5-5.0) m/s, and median AVC score
was 5920 (interquartile range 2485-14231) AU. There were 119 patients with mild to
moderate aortic stenosis (aortic jet velocity, 2.5 to 3.9 m/s), and 36 with severe stenosis
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4.4.1 Serum cholesterol concentrations
The mean serum low-density lipoprotein cholesterol concentration remained at
3.4 ± 0.8 mmol/L in the placebo group, and fell to a mean on treatment of
1.7 ± 0.6 mmol/L in the atorvastatin group (p<0.001). This equates to a 53% reduction in
LDL cholesterol in the atorvastatin group (Figure 4.2c). Serum total cholesterol was
5.5 ± 0.9 mmol/L and 3.5 ± 0.7 mmol/L in the placebo and atorvastatin groups
respectively (p<0.001) and is in keeping with pill count compliance that averaged 97%
in both treatment groups.
4.4.2 Impact of atorvastatin on disease progression
Intensive lipid-lowering therapy with atorvastatin 80 mg daily had no effect on the rate
of change in aortic jet velocity or valvular calcification (Table 4.2; Figure 4.2). Serum
LDL cholesterol concentrations did not correlate with disease progression on
echocardiography (r=0.021, p=0.81) or CT (r=-0.109, p=0.21) (Figure 4.3). The
proportion of patients reaching secondary clinical end-points appeared to be fewer in the
atorvastatin group but none of the comparisons achieved statistical significance (Table
4.3).
4.4.3 Subgroup analyses
Pre-specified subgroup analysis of the primary end-point data was conducted in patients
with mild to moderate (aortic jet velocity of <4.0 m/s) and severe (aortic jet velocity
>4.0 m/s) aortic stenosis at baseline. As anticipated from earlier studies, patients with
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Figure 4.2 Progression in aortic valve stenosis and serum LDL cholesterol concentrations in






















































LDL - low-density lipoprotein; CT - computed tomography; AVC - aortic valve calcium;
Log - logarithm; AU - arbitrary units.
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TABLE 4.3 Secondary end-points
Atorvastatin Placebo P value
(n = 77) (n = 78) (Fisher's
Exact Test)
Composite secondary end-point 13 21 0.19
Hospitalisation for severe aortic stenosis 3 5 0.73
Aortic valve replacement 11 19 0.17
Cardiovascular mortality 3 3 1.00
All cause mortality 3 5 0.73
All cardiac admissions 10 12 0.84
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severe stenosis at baseline progressed more rapidly (p=0.04), but the study findings were
consistent irrespective of baseline stenosis severity (Table 4.4). Likewise, length of
follow-up did not influence outcome. In those followed up for >24 months, increase in
aortic jet velocity was 0.21 ± 0.20 m/s per year in the atorvastatin group and
0.17 ±0.14 m/s per year in the placebo group (Table 4.4).
4.4.4 Adverse events
High dose atorvastatin was well tolerated: the frequency of adverse events was similar in
the two treatment groups. Discontinuation of the study drug occurred in 4 patients (5%)
of the placebo group and 7 patients (9%) of the atorvastatin group (Fisher's exact test,
p=0.52), predominantly as a result of gastrointestinal symptoms. Three patients in the
atorvastatin group experienced an increase in creatine kinase to greater than five times
the upper limit of normal without symptoms of myositis; one of whom was withdrawn at
the request of the Data Monitoring Committee. There were no cases of rhabdomyolysis
and no serious adverse events.
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TABLE 4.4 Subgroup analyses of disease progression
Baseline severity of stenosis: Atorvastatin Placebo
Mild to moderate
(Baseline aortic jet




































































This is the first double-blind randomised controlled trial of lipid-lowering therapy in
patients with calcific aortic stenosis. It has clearly demonstrated that whilst high dose
atorvastatin more than halves serum LDL cholesterol concentrations, it does not halt the
progression or induce regression of the valvular disease process. This has been
demonstrated using two distinct measures of disease severity: aortic jet velocity
determined by Doppler echocardiography and valvular calcification by helical CT.
Moreover, there was no relationship between serum LDL cholesterol concentrations and
the progression of aortic stenosis, nor was there a demonstrable effect of high dose
atorvastatin on clinical end-points. Thus, irrespective of the method of assessing disease
progression, we have consistently demonstrated the continued deterioration of aortic
stenosis despite intensive reductions in serum cholesterol concentrations.
In this trial, there was a single co-ordinating centre with a consistent and reproducible
approach to assessing the severity of aortic stenosis [Cowell et al 2003], High dose
atorvastatin therapy achieved the anticipated dramatic reduction in serum LDL
cholesterol concentrations [Jones et al 1998], and disease progression was determined
using two independent but complementary techniques. The trial employed a double-
blind randomisation incorporating the minimisation technique to ensure no baseline
inequalities between the treatment groups but, despite this rigorous methodology, we
were unable to demonstrate a major impact on disease progression in these patients.
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Several factors may have influenced our ability to detect an effect of statin therapy on
the progression of aortic stenosis in this trial.
First, as a consequence of our inclusion criteria, we recruited some patients with
advanced disease and an aortic jet velocity of >4 m/s and it could be argued that lipid-
lowering therapy is unlikely to influence such an advanced stage of the disease. We
therefore conducted a pre-specified subgroup analysis excluding patients with a baseline
aortic jet velocity >4 m/s. Our findings were consistent irrespective of baseline stenosis
severity and atorvastatin had no effect on disease progression even in the majority of
individuals with mild to moderate stenosis. We excluded patients with aortic jet
velocities below 2.5 m/s and we acknowledge that intervening at this earlier stage of the
disease process may have been more beneficial. However, such patients do not
commonly present to routine clinical practice.
Second, the length of treatment may have been inadequate and 2 years may not have
been sufficient to influence the natural history of the disease. We assessed this
possibility by determining if patients with longer-term follow-up demonstrated a
treatment benefit. In patients maintained on nearly 3 years of treatment with intensive
statin therapy, no trend towards a beneficial effect of atorvastatin was apparent. We
therefore do not believe that the absence of an effect was due to an inadequate treatment
period.
89
Finally, although this is the largest randomised controlled trial to date, our study was
only designed to detect a substantial delay in disease progression and was not powered
to assess meaningful effects on clinical end-points, such as valve replacement and
cardiovascular death. Whilst we can exclude a treatment benefit of the magnitude
previously reported in retrospective observational studies (aortic jet velocity, 0.30 m/s/yr
[Rosenhek et al 2004] and valvular calcification, 30% per year [Pohle et al 2001;
Shavelle et al 2002]), the 95% confidence intervals indicate that we may have missed a
modest treatment benefit (a delay in disease progression of <0.07 m/s/yr, and <5%/yr
respectively). Although such modest reductions are unlikely to be meaningful in the
majority of older patients, a small decrease in disease progression may be clinically
important in younger patients with mild disease who may progress over many years.
Given the strength of the data linking aortic stenosis with atherosclerosis and
hypercholesterolemia, why have we have failed to halt the progression of calcific aortic
stenosis? One potential explanation is that, whilst these features may drive the initiation
of aortic stenosis, disease progression may be dependent upon other factors. The aortic
valve is subject to continuous dynamic mechanical stress, and leaflet plasticity and
structure can have an overriding influence, such as with a bicuspid valve. Moreover, in
contrast to atherosclerosis, aortic stenosis is associated with a virtual absence of smooth
muscle cell proliferation and lipid-laden macrophages [Otto et al 1994], and dominated
by earlier and more extensive mineralisation. Decreasing the lipid pool and increasing
the fibrous cap may be less relevant to the progression of aortic stenosis than it is for the
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reduction in atherosclerotic plaque rupture with statin therapy in patients with coronary
heart disease.
Statin therapy in patients with aortic stenosis may confer secondary preventative benefits
that are independent of its effects on the valvular disease process because of the
association between aortic stenosis and coronary artery disease. The current study was
not powered to assess the benefits of lipid-lowering therapy on cardiovascular end-
points such as non-fatal and fatal myocardial infarction. It remains a possibility that
aortic stenosis and sclerosis [Otto et al 1999] may be important markers of occult
vascular disease and thereby identify patients who would gain from the preventative
benefits of statin therapy.
We conclude that intensive lipid-lowering therapy with atorvastatin 80 mg daily does
not halt the progression, or induce the regression, of calcific aortic stenosis.
Nevertheless, this trial does not exclude a modest reduction in the rate of disease
progression or a significant reduction in major clinical end-points. Our study reinforces
the need for a long-term large scale randomised controlled trial of intensive lipid-
lowering therapy in patients with calcific aortic stenosis. In the meantime we do not
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Background Observational studies have suggested that statin therapy may induce
regression of coronary artery calcification. In a substudy of a trial recruiting patients
with calcific aortic stenosis, we evaluated the effect of intensive lipid-lowering therapy
on coronary artery calcification.
Methods In a double-blind randomised controlled trial, 102 patients with calcific aortic
stenosis and coronary artery calcification were randomised using the minimisation
technique to atorvastatin 80 mg daily or matched placebo. Coronary artery calcification
was assessed annually by helical CT.
Results Forty-eight patients were randomised to atorvastatin and 54 to placebo with a
median follow-up of 24 months (interquartile range 24-30). Baseline characteristics and
coronary artery calcium scores were similar in both groups. Atorvastatin therapy
reduced serum low-density lipoprotein cholesterol (-53%; p<0.001) and CRP (-49%;
p<0.001) concentrations whilst there was no change with placebo (-7% and +17%;
p>0.95 for both). The rate of change in coronary artery calcification was 26% per year
(0.234 (standard error (SE) 0.037) log AU/yr; n=39) in the atorvastatin group and 18%
per year (0.167 (SE 0.034) log AU/yr; n=49) in the placebo group: geometric mean
difference of +7% per year (95% CI -3% to +18%; p=0.18). There was no correlation
between serum low-density lipoprotein concentrations and the rate of progression of
coronary calcification (r=0.05, p=0.62).
Conclusion In contrast to previous observational studies, this randomised controlled
trial has shown that, despite reducing systemic inflammation and halving serum
93
low-density lipoprotein cholesterol concentrations, statin therapy does not have a major
effect on the rate of progression of coronary artery calcification.
5.2 INTRODUCTION
Coronary artery calcification is an independent risk factor for coronary heart disease
with even low coronary calcium scores doubling the risk of coronary events [Pletcher et
al 2004], The relative risk associated with coronary calcification is greater than that
associated with established factors such as smoking, hypertension and diabetes mellitus.
Progression of coronary artery calcification is associated with a higher incidence of
coronary events even in those people who are asymptomatic at the time of initial
scanning [Raggi et al 2003] Thus, the presence of coronary artery calcification is not
only indicative of atheromatous plaque disease, but its progression may correspond with
cardiovascular event rates.
Statin therapy has a proven role in the primary [Shepherd et al 1995; Downs et al 1998]
and secondary prevention [The Scandinavian Simvastatin Survival Study (4S) 1994;
Lewis et al 1998; The LIPID Study Group 1998; The Heart Protection Study
Collaborative Group 2002] of cardiovascular disease with incremental benefits seen with
more intensive reductions in serum cholesterol concentrations [The Heart Protection
Study Collaborative Group 2002]. Previous studies [Callister et al 1998; Achenbach et
al 2002] have reported that statins can halt the progression and may even induce
regression of coronary artery calcification. Indeed, the rate of progression of coronary
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artery calcification correlates with the average serum LDL cholesterol concentration
[Callister et al 1998]. This has led to the use of CT to monitor disease progression and
response to treatment, particularly statin therapy. However, two recent trials have failed
to demonstrate a benefit of statin therapy on the progression of coronary artery
calcification in asymptomatic individuals [Arad et al 2005; Raggi et al 2005].
The Scottish Aortic Stenosis Lipid lowering Therapy, Impact on REgression trial was a
prospective double-blind randomised controlled study of intensive lipid-lowering
therapy in patients with calcific aortic stenosis [Cowell et al 2005], As part of this trial,
aortic valve and coronary artery calcium scores are measured using helical CT. The aim
of this substudy was to assess the effect of atorvastatin 80 mg daily on the rate of
progression of coronary artery calcification in patients with calcific aortic stenosis.
5.3 METHODS
5.3.1 Patient population
Patients aged >18 years, with calcific aortic stenosis (grade 1-3 calcification on
echocardiography [Rosenhek et al 2000]) and a peak post-valve velocity of >2.5 m/s
were recruited from eight hospital centres across the South East of Scotland. Exclusion
criteria are outlined in Chapter 2. For the purposes of the substudy, we also excluded
patients who had no coronary artery calcification on CT. The study was conducted with
the approval of all regional research ethics committees and in accordance with the
Declaration ofHelsinki. Written informed consent was obtained from each subject.
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5.3.2. Study protocol
Between March 2001 and April 2002, the blinded study co-ordinator randomised
eligible patients by the minimisation technique [Treasure and MacRae 1998] using a
dedicated locked computer program (Edinburgh University) which incorporated eight
baseline variables: age, sex, smoking habit, hypertension, diabetes mellitus, serum
cholesterol concentration, peak aortic jet velocity and aortic calcium score. Patients were
assigned either to atorvastatin 80 mg daily or matched placebo (Pfizer Ltd., Tadworth,
UK) as a single daily dose using numbered containers.
Patients were assessed at baseline, 2 months, 6 months and every 6 months thereafter for
a minimum of 2 years. Clinical evaluation included assessment of functional status,
adverse events and biochemical blood analysis. Serum highly sensitive C-reactive
protein (hsCRP) concentrations were determined using a highly sensitive
immunonephelometric method (Dade Behring Ltd, Milton Keynes, UK) as previously
described [Carr et al 2000]. All patients underwent CT within the month before
randomisation to study therapy and at each annual visit. Randomised patients who were
subsequently commenced on open label statin therapy by their attending physician were
immediately scanned and withdrawn from further observation.
5.3.3 Computed tomography
Computed tomography was performed by a single-blinded operator using a double-helix
scanner (Twin II Flash; Philips Medical Systems (UK) Ltd, Stevenage, UK) and
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calibrated against a standard phantom. Images were acquired in 2.7 mm slices (with a
0.75 s full 360° scan mode) through the region of the coronary arteries with a pitch of
0.7 and an increment of 1.3 mm during held inspiration. Exposure factors were 120 kV
at 270 mAs and the scan angle was 360°. Off-line analyses were conducted using an
automated, computerised software program (Picker Cardiac Scoring). This employs an
Agatston scoring method [Agatston et al 1990], producing sensitivity and specificity
comparable to electron beam CT [Carr et al 2000], Scans were scored using both the
Agatston (130 HU threshold) and the modified Agatston (90 HU threshold) methods
[Shemesh et al 1995], The former has been shown to reduce interobserver and interscan
variation compared to the threshold of 90 HU [Goldin et al 2001], To assess the
reproducibility of the method, repeated baseline CT scans were performed within
4 weeks of each other in an unselected random sample of 16 patients.
5.3.4. Data analysis and statistics
Coronary artery calcium scores are expressed in AU using the 130 HU threshold. The
calcium scores and hsCRP concentrations were not normally distributed and data are
presented as median with interquartile ranges or mean and standard deviation following
logarithmic transformation. The primary end-point, the rate of change of coronary
calcium scores, was analysed using random coefficient models [Bland and Altman 1986;
Cowell et al 2005] after logarithmic transformation of the scores. In summarising the
data, the change in coronary artery calcium scores was calculated by dividing the change
between the baseline and final scores by the duration of follow-up. Rate of change in
coronary calcium score is expressed as percentage change per year or as absolute change
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in the logarithm of the coronary artery calcium score. Reproducibility was assessed
using the method of Bland and Altman [Bland and Altman 1986], As well as tests of
significance, 95% confidence intervals are reported as appropriate. Statistical
significance was taken as a two-sided p value <0.05.
5.4 RESULTS
Of 155 patients recruited into the SALT1RE trial, 102 had coronary calcification at
baseline (Figure 5.1) of whom 88 had at least two scans. Coronary calcification
predominated in the left anterior descending coronary artery (100% of patients) although
it was also present in the circumflex (33%) and right (27%) coronary arteries. Baseline
characteristics and coronary artery calcium scores were well matched in both treatment
groups (Table 5.1) in the 88 evaluable subjects.
5.4.1 Reproducibility
The reproducibility of the LAD coronary score and of the total coronary score was
examined using the approach of Bland and Altman [Bland and Altman 1986]. Without
transformation, the difference between replicate observations tended to increase with the
magnitude of the measurement. After logarithmic transformation, higher values showed
stable differences, but differences were higher at the lowest scores. Overall, the
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TABLE 5.1 Baseline subject characteristics
Atorvastatin Placebo
(n = 39) (n = 49)
Age (years) 70 (8) 70 (9)
Sex (% male) 74 78




Diabetes mellitus 0 2
Current smoker 5 10
Cardiovascular Disease
Coronary heart disease 7 13
Cerebrovascular disease 5 7
Peripheral vascular disease 3 7
Drug History
Aspirin 17 26




Systolic blood pressure 143 (18) 140(19)
Diastolic blood pressure 82 (11) 78(11)
Lipid Profde
Total cholesterol (mmol/L) 5.7 (0.9) 5.5 (0.9)
LDL cholesterol (mmol/L) 3.6 (0.8) 3.4 (0.7)
HDL cholesterol (mmol/L) 1.5 (0.4) 1.5 (0.4)
Cholesterol: HDL ratio 4.2(1.2) 4.0(1.0)
Triglycerides (mmol/L) 1.5 (0.8) 1.4 (0.7)
Coronary calcification score (AU)
Left anterior descending 112(40-285) 207 (76-461)
Circumflex 0 (0 - 9) 0 (0 - 4)
Right 0 (0-29) 0 (0 - 0)
Total coronary score 195 (57-448) 235 (83 -526)
Log total coronary score (LogAU) 2.16(0.68) 2.30(0.65)
Continuous variables stated as mean (SD) or median (interquartile range).
Categorical variables stated as per cent.
ACE - angiotensin-converting enzyme; LDL - low-density lipoprotein; HDL - high-density
lipoprotein; Log - logarithm.
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differences on the log scale correspond to a coefficient of variation of 28% for both
variables, but when restricted to the ten pairs with a geometric mean score above 100,
the coefficient of variation was 10% for both variables.
5.4.2 Effect of atorvastatin treatment
Patients were followed-up for a median of 24 months (interquartile range 24-30).
Atorvastatin 80 mg daily more than halved serum LDL cholesterol concentrations (53
(SD 19) %; p<0.001), whilst placebo had no effect (Figure 5.2). This reduction in serum
LDL cholesterol concentrations was associated with a marked decrease in serum CRP
concentrations from 1.95 (interquartile range 1.15-4.86) to 1.00 (0.49-2.31) mg/L
(Wilcoxon Signed Rank, p<0.001; Figure 5.2). Atorvastatin was well tolerated with
discontinuation of study medication in 2 patients on placebo and 5 patients on
atorvastatin, predominantly as a result of gastrointestinal upset. One patient on
atorvastatin had an increase in creatine kinase of >5 times the upper limit of normal
without symptoms of myositis, and was withdrawn at the request of the Data Monitoring
Committee. There were no cases of rhabdomyolysis.
5.4.3 Coronary Artery calcium score
Atorvastatin did not affect the rate of progression of coronary artery calcium score
(Figure 5.2). Similar results were obtained when employing the 90 HU threshold (42
(SD 73) %/yr in the atorvastatin group and 29 (SD 37) %/yr in the placebo group;
p=0.24). Serum LDL cholesterol concentrations did not correlate with the rate of
progression of coronary artery calcification (r=0.05, p=0.62).
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Figure 5.2 Progression of (A) coronary artery calcification, (B) serum C-reactive protein
concentrations (p <0.001, atorvastatin versus placebo), and (C) serum low-density lipoprotein (LDL)
cholesterol concentrations (p s<0.001, atorvastatin versus placebo) in patients treated with



































LDL - low-density lipoprotein; Log - logarithm; AU - arbitrary units.
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The primary analysis of the rates of change of coronary artery calcium scores was
conducted on the logarithms of the scores using random coefficients models [Brown and
Prescott 1999]. This showed no difference between the average rates of change in the
two treatment arms (p=0.18). The mean coronary calcium score increased by 0.234 (SE
0.037) log AU per year in the atorvastatin group and 0.167 (SE 0.034) log AU per year
in the placebo group. These figures correspond to a 26% per year increase in the
atorvastatin group and 18% per year in the placebo group. The geometric mean (adjusted
for baseline) is 7% higher at one year on atorvastatin compared to placebo, with 95%
confidence limits ranging from 3% lower to 18% higher. The observed annual changes
in coronary calcium scores, calculated from the first to the last visit, are summarised in
Figure 5.3.
As anticipated in such a small clinical trial, there were no significant differences in all
cause mortality, cardiovascular mortality or cardiovascular hospitalisation between the
two groups.
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We have confirmed that, despite marked reductions in serum LDL cholesterol and CRP
concentrations, atorvastatin 80 mg daily did not halt the progression, or induce
regression, of coronary artery calcification in patients with calcific aortic stenosis.
Consistent with recent trials of asymptomatic individuals [Arad et al 2005; Raggi et al
2005], our findings are in marked contrast to previous observational studies and suggest
that the potential beneficial effects of statin therapy on coronary artery calcification have
been over estimated.
Previous observational and non-randomised prospective studies [Callister et al 1998;
Achenbach et al 2002] have suggested that reductions in serum LDL cholesterol
concentrations decrease the progression of coronary calcification. However, not all
observational studies have demonstrated consistent findings. In the largest observational
study of 182 patients, Hecht and colleagues recently found no difference in the
progression of coronary calcium scores in patients who were maintained on lipid-
lowering therapy and achieved significant reductions in serum LDL cholesterol
concentrations [Hecht and Harman 2003], Observational data may be misleading and
prospective randomised controlled trials are necessary to confirm or to refute these
interesting preliminary observations. The recent BELLES trial [Raggi et al 2005] found
no differential effect of pravastatin (40 mg daily) and atorvstatin (80 mg daily) on the
progression of coronary artery calcification in 615 hyperlipidaemic post-menopausal
women. However, study follow-up was brief (1 year) and there was no placebo control
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group. The St Francis Heart Study [Arad et al 2005] randomised 1,005 asymptomatic
middle-aged men and women with high coronary artery calcium scores to combination
atorvastatin 20 mg, vitamin C 1 g and vitamin E (alpha tocopherol) 1,000 units daily or
matching placebos. After 4.3 years of follow-up, there were no differences in the rate of
progression of coronary artery calcification.
We have conducted a double-blind randomised controlled trial using helical CT in
patients with aortic stenosis. Minimisation technique ensured good matching of the
baseline characteristics of the patient population and reproducibility studies confirmed
the validity of our repeated assessments. Although documenting very similar rates of
progression of coronary calcification to previous studies [Callister et al 1998;
Achenbach et al 2002; Hecht and Harman 2003], we have not observed a reduction in
coronary calcification with intensive lipid-lowering therapy despite more than halving
serum LDL cholesterol concentrations.
Statin therapy has been extremely successful in the primary and secondary prevention of
cardiovascular disease. Why then have we and others not observed a beneficial effect of
statin therapy on coronary artery calcification? Unstable atherosclerotic plaques have a
large 1 ipid-rich core, a preponderance of macrophages and foam cells, and a thin fibrous
cap containing few smooth muscle cells [Davies 1997], It has been suggested that
calcified lesions may be relatively more stable [Mintz et al 1995], indicating a possible
protective role of calcification in coronary plaques. Statin therapy produces many of its
beneficial effects through plaque stabilisation. In both primate [Stary 2001] and swine
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[Daoud et al 1981] models, anti-atherosclerotic interventions are associated with an
increase in vascular fibrous tissue and calcification. This calcium deposition continues
during the initial phase of plaque regression due to the death of foam cells and an
increase in necrotic tissue. Thus vascular calcification may play a role in the initial
stabilisation of atherosclerotic plaques. This is consistent with our findings and would
account for the lack of effect on the progression of coronary artery calcification despite a
reduction in serum CRP concentrations.
After the initial stabilisation of the atherosclerotic plaque, it would be anticipated that
subsequent progression of coronary calcification would be inhibited. The present study
was brief, and follow-up was only continued for a median of 2 years. It would be
important to extend our observations to 5 or more years to assess properly the impact of
statin therapy on the long-term progression of coronary artery calcification. However, it
should be acknowledged that the clinical benefits of statin therapy are apparent within
the first few years [Lewis et al 1998; The LIPID Study Group 1998; The Heart
Protection Study Collaborative Group 2002], and in some cases the first few months
[Schwartz et al 1998], of therapy. Moreover, the St Francis Heart Study demonstrated no
beneficial effects despite 4.3 years of follow-up [Arad et al 2005],
On the basis of previous non-randomised studies [Achenbach et al 2002], the practice of
performing serial CT scans to monitor disease progression and the response to treatment
has become widespread, especially in North America. Our data, and that of the St
Francis Heart Study [Arad et al 2005] and the BELLES study [Raggi et al 2005],
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indicate that repeated scanning to assess response to statin therapy is not justified.
Indeed, the radiation dose incurred for such serial scans poses potential health risks,
particularly when employing multidetector CT scanners.
5.5.1 Study limitations
There are several factors that should be taken into account when considering the results
of our study. This was a substudy of the SALT1RE trial [Cowell et al 2005] that
recruited only patients with calcific aortic stenosis. However, our findings are consistent
with two recent randomised controlled trials in asymptomatic younger individuals
without valvular heart disease [Arad et al 2005; Raggi et al 2005]. Our study therefore
suggests that failure of statins to restrict the progression of coronary artery calcification
can be extended to include patients with valvular heart disease as well as more elderly
populations. Moreover, our findings suggest that lack of benefit seen in the St Francis
Heart Study is not attributable to the modifying effects of antioxidant vitamins [Arad et
al 2005],
When compared with electron beam CT, the accuracy of helical CT in detecting
coronary artery calcification has been questioned [Carr et al 2000; Qanadli et al 2001],
Technological advances have also meant that double-helical scanners have now been
overtaken by 64 or higher slice scanners. At trial inception, the double-helix scanner was
"state-of-the-art" and it would have been inappropriate to replace the scanner during the
conduct of the trial. Moreover, our approach has been previously validated [Bland and
Altman 1986] and we have demonstrated good reproducibility of coronary artery
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calcification scores in patients with scores of greater than 100 AU. We do not believe
the absence of a major beneficial effect on coronary artery calcification is attributable to
our methodology. We acknowledge the fact that our population size is modest; however,
the 95% confidence intervals are able to exclude a relative reduction in progression of
coronary artery calcification of >3% per year. We therefore suggest that if lipid-lowering
therapy does reduce the progression of coronary artery calcification then the effect is
rather small.
Controversy exists over the method of quantification of coronary artery calcification.
The Agatston method is traditionally employed but this may overestimate the coronary
calcium score in newer generation scanners with reduced slice thickness due to partial
voluming. More recent methods include the volume [Callister et al 1998] and the
coronary calcium mass [Hong et al 2002] scores, although neither are superior to the
Agatston score in terms of reproducibility from consecutive scans in an individual
patient [Rumberger and Kaufman 2003].
5.6 CONCLUSION
We conclude that intensive lipid-lowering therapy does not halt the progression, or
induce regression, of coronary artery calcification. Although coronary artery calcium
scores correlate well with the presence of atherosclerosis and predict future coronary
risk, our findings confirm that there is currently no role for monitoring progression of
coronary artery calcification in order to assess the response to lipid-lowering therapy.
109
CHAPTER 6
PREDICTORS OF DISEASE PROGRESSION AND
CLINICAL OUTCOME IN PATIENTS WITH
CALCIFIC AORTIC STENOSIS
6.1 SUMMARY
Background Calcific aortic stenosis results from an active inflammatory process
closely resembling atherosclerosis. We hypothesised that risk factors for
atherosclerosis would predict disease progression and clinical outcome of patients
with calcific aortic stenosis.
Methods Patients (n=155; 68 ±11 yrs) with calcific aortic stenosis participating in
the SALTIRE trial (randomised comparison of atorvastatin 80 mg daily or matched
placebo) were followed-up for 26 ± 7 months. Severity of aortic valve stenosis and
calcification was assessed longitudinally using echocardiography and helical CT
respectively.
Results Aortic jet velocity progressed by 0.20 ± 0.21 m/s per year and calcification
by 29 ± 30% per year and was unaffected by atorvastatin therapy. Disease
progression was predicted by age (p<0.01), sex (p=0.02), height (p=0.03),
hypertension (p=0.03), serum BNP concentration (p=0.002), and baseline valve
disease severity as determined by both aortic jet velocity (p<0.001) and valvular
calcification (p<0.001). Clinical outcome was predicted by baseline and rate of
progression of aortic stenosis severity (p<0.002) and serum BNP concentrations
(p<0.02). Clinical and biochemical markers of atherosclerosis, including serum CRP
and cholesterol concentrations, did not predict disease progression or clinical
outcome.
Conclusions The major predictors of disease progression and clinical outcome in
patients with aortic stenosis are measures of disease severity; namely aortic jet
velocity, aortic valve calcification and serum BNP concentration. With the exception
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of hypertension the presence of clinical atherosclerotic risk factors do not influence
the rate of progression.
6.2 INTRODUCTION
Aortic stenosis is the commonest adult heart valve condition seen in the western
world affecting 2% of individuals over the age of 65 [Cowell et al 2004], Thickening
and calcification of the valve leaflets progresses slowly over many years. The
outlook for patients with asymptomatic aortic stenosis is generally good, but
although prognosis is similar to life table estimates for age and sex matched controls
[Pellikka et al 1990], there is an increased risk of unrelated cardiovascular events
[Iivanainen et al 1996; Otto et al 1999; Rosenhek et al 2004], In patients with severe
stenosis, the onset of symptoms dramatically changes the outlook with 2-year
survival rates falling to 50% [Otto et al 1999; Rosenhek et al 2000], At the present
time, the only treatment option of prognostic benefit is aortic valve replacement.
Calcific aortic stenosis has for many decades been attributed to age-associated "wear
and tear", but a third of individuals over the age of 80 [Lindroos et al 1993] have no
evidence of aortic valve calcification or stenosis. Moreover, histological examination
of stenotic aortic valves reveals features of chronic inflammation that resemble those
seen in atherosclerosis, and are distinct from those changes occurring with ageing
alone [Olsson et al 1994; Otto et al 1994], In addition, calcific aortic stenosis is
associated with coronary artery disease and its risk factors including age, male sex,
112
smoking, hypertension, diabetes mellitus, coronary artery disease and
hyperlipidaemia [Cowell et al 2004],
Disease progression in aortic stenosis is variable and unpredictable. Both disease
progression and clinical outcome have been linked to many of the risk factors for
aortic stenosis, but much of the evidence is conflicting and based on retrospective
studies [Peter et al 1993; Bahler et al 1999; Palta et al 2000; Ngo et al 2001;
Wongpraparut et al 2002], The most consistent and strongest predictors of disease
progression appear to be severity of stenosis [Otto et al 1997; Bahler et al 1999] and
the degree of valvular calcification [Davies et al 1991; Bahler et al 1999; Rosenhek
et al 2004a], The more severe the stenosis and the more heavily calcified the valve,
the faster the rate of disease progression. Clinical outcome is influenced by the rate
of disease progression as well as the degree of valvular calcification, with nearly
80% of patients with moderate to severe calcification who progress rapidly (>0.3
m/s/yr) either dying or undergoing AVR within 2 years [Rosenhek et al 2000],
Using the SALTIRE trial population [Cowell et al 2005], we wished to identify
prospectively the clinical and biochemical variables associated with disease
progression and clinical outcome in patients with calcific aortic stenosis. We
assessed clinical risk factors as well as other novel predictors of cardiovascular risk
including inflammatory, vascular and cardiac markers. In particular, we hoped to
identify modifiable risk factors, with the potential of delaying or avoiding the need
for AVR. Identification of markers capable of predicting risk might also facilitate the




All 155 patients randomised to the SALTIRE trial (a randomised controlled trial
assessing the effects of atorvastatin therapy on the progression of aortic valve
stenosis and calcification) [Cowell et al 2005] were included in this substudy.
Patients aged >18 years with calcific aortic stenosis, an aortic jet velocity of
>2.5 m/s, and grade 1-3 calcification of the aortic valve on echocardiography were
included. Exclusion criteria are detailed in Chapter 2. All patients had asymptomatic
aortic stenosis at entry into the study, and were randomised to receive either
atorvastatin 80 mg daily or matched placebo. The investigation conformed to the
Declaration of Helsinki, and was approved by all regional ethics committees. All
patients gave written informed consent.
6.3.2 Study protocol
Patients were assessed at baseline, at 2 and 6 months, and 6 monthly thereafter for a
minimum of 2 years. Baseline characteristics evaluated included demographics,
cardiovascular risk factors, functional status (NYHA classification), blood pressure,
arterial stiffness (pulse wave analysis), and biochemical variables including lipid
profile, renal function, BNP, CRP and calcium concentrations. Subsequent
evaluation comprised assessment of biochemical blood analysis, arterial stiffness and
adverse clinical events. Echocardiography and CT were performed at baseline, at
each annual visit or prior to withdrawal from the study.
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6.3.3 Echocardiography
Assessment of valvular stenosis was determined by a single dedicated research
ultrasonographer. Patients were studied using a 3-MHz transducer for M-mode, and
two-dimensional imaging with integral pulsed, continuous wave and tissue Doppler.
All measurements were determined on-line, averaged from three cardiac cycles (five
cycles if in atrial fibrillation), and recorded onto Super-VHS video and optical disk
using a standardised proforma. Peak and mean aortic valve gradients were calculated
using the Bernoulli equation, and AVA using the continuity equation.
6.3.4 Computed tomography
Computed tomography was performed by a single operator using a double-helix
scanner (Twin II Flash; Philips Medical Systems Ltd, Stevenage, UK) and calibrated
against a standard phantom. The region of the aortic valve was imaged with a spiral
acquisition using 2.7 mm slices, with a pitch of 0.7 and an increment of 1.4 mm
during held inspiration. All images were analysed by a single operator using
automated computerised software (Picker Cardiac Scoring). This employs a modified
Agatston scoring method [Shemesh et al 1995] that uses a threshold of 90 HU to
compensate for non-gated imaging.
Reproducibility of echocardiography and CT assessments was determined in two
subsets of 20 patients as described in Chapter 3. Coefficients of reproducibility for
aortic jet velocity and AVC score were 0.32 m/s and 0.07 pAU respectively.
115
6.3.5 Biochemical variables
Fasting venous blood samples were taken annually. Samples for serum electrolytes,
lipid profile and calcium concentrations were sent to the regional clinical laboratory
for immediate analysis. Samples for estimation of serum BNP and CRP
concentrations were centrifuged at 4°C and stored at -80° C for later analysis. N-
terminal pro-BNP was measured using a chemiluminescent immunoassay (Roche
Diagnostics Ltd, Lewes, U.K.) on an Elecsys 2010 analyser. Serum highly sensitive
CRP concentrations were determined using a highly sensitive immunonephelometric
method (Dade Behring Ltd, Milton Keynes, UK).
6.3.6 Pulse wave analysis
Pulse wave analysis was performed at baseline and 6 monthly intervals thereafter.
Patients were rested supine for 15 minutes prior to study. Radial pulse wave analysis
was performed using a high-fidelity applanation tonometer (Sphygmocor BPAS;
PWV Medical, Sydney, Australia). After acquiring a series of consecutive
waveforms, an averaged peripheral waveform was acquired and a generalised
transfer function was used to generate a central aortic pressure waveform from which
the pulse pressure, augmentation pressure and augmentation index were determined.
Two measurements of augmentation within 5 mmHg of each other were recorded on
each occasion. Patients with atrial fibrillation were excluded, and recordings with
poor quality waveforms were discarded: determined by visual inspection (SJC) with
minimum requirements in pulse height of >100 mmHg, diastolic variation of <5%
and pulse height variation of <5%. Data on 105 patients were available at baseline, of
these 20 patients had poor quality recordings and 9 patients were in atrial fibrillation,
leaving a total of 84 patients for analysis.
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6.3.7 Clinical follow-up
The following clinical end-points were recorded throughout the study; cardiovascular
and all cause mortality, AVR (whether for severe symptomatic stenosis or not), and
the development of symptoms attributable to severe aortic stenosis (confirmed by the
patient's treating physician).
6.3.8 Data analysis and statistics
Disease progression was determined by measuring the annual rate of change in aortic
jet velocity on echocardiography, and the change in aortic valve calcification on CT
by dividing the difference between baseline and final scans by the duration of follow-
up. The CT, BNP and CRP data were log transformed prior to analysis as the data
were not normally distributed. Predictors of progression were determined using
regression analysis for continuous variables, and Chi-squared tests for categorical
variables. Predictors of outcome were determined using Chi-squared tests for
categorical variables, /-tests for continuous variables. Statistical significance was
taken as two-sided p<0.05.
6.4 RESULTS
One hundred and fifty-five patients (mean age 68 years, 70% male) with calcific
aortic stenosis were randomised to the SALTIRE trial [Cowell et al 2005] and were
followed-up for a median of 25 months (range 7-36).
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At baseline (Table 6.1) mean aortic jet velocity was 3.42 ± 0.64 m/s (range 2.5-5.0),
and increased by 0.20 ± 0.21 m/s per year (Table 6.2). Median AVC score at baseline
was 5920 AU (interquartile range 2485-14231 AU), and increased by 29 ± 30% per
year. A number of patients had risk factors for cardiovascular disease (Table 6.1) and
at baseline the mean total cholesterol was 5.7 mmol/L. As previously reported
(Chapter 4) [Cowell et al, 2005], there was no difference between the treatment
groups despite a 53% reduction in serum LDL cholesterol concentrations (p<0.001)
in the atorvastatin group. Given the absence of a treatment effect, all patients have
been included in the subsequent analyses.
6.4.1 Disease progression
The results of univariate analyses are presented in Tables 6.3 and 6.4. In keeping
with previous observation studies [Bahler et al 1999], we have now demonstrated
prospectively that progression of aortic jet velocity is strongly correlated with
baseline aortic jet velocity (p<0.001; Table 6.3), and furthermore is correlated with
baseline and progressive increases in the absolute AVC score (p=0.004 and p=0.002
respectively). Annual progression in aortic jet velocity was also strongly associated
with age (p=0.006), baseline log BNP (p=0.003) and the rate of change in log BNP
per year (p=0.002), but only weakly with height (p=0.03), male sex (p=0.02) and the
presence of hypertension (p=0.03) (Tables 6.3 and 6.4).
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Age (years) 67.8 (10.6)




Diabetes Mellitus 5 (3.2%)
Current smoker 33 (21.3%)
Cardiovascular Disease
Coronary artery disease 30(19.4%)
Cerebrovascular disease 16(10.3%)








Class II 125 (80.6%)
Class III 18 (11.6%)
Class IV 0
Physical Examination
Height (cm) 168.5 (8.3)
Weight (Kg) 79.3 (14.8)
Heart rate (beats/min) 67(11.6)
Systolic blood pressure (mmHg) 144(19.8)
Diastolic blood pressure (mmHg) 81.8 (11.0)
Electrocardiography
Sinus rhythm 144 (93%)
Atrial fibrillation 10(6.5%)
Echocardiography
Bicuspid valve 5 (3.2%)
Tricuspid valve 150 (96.8%)
\ continued
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TABLE 6.1 Baseline Characteristics continued /
Echocardiography n = 155
Peak aortic jet velocity (m/s) 3.42 (0.64)
Peak gradient (mmHg) 48.6(18.4)
Aortic valve area (cm ) 1.02 (0.4)
LV mass (g) 354 (110)
LV mass index (g/m2) 176 (55)
Fractional shortening (%) 40 (8.4)
Computerised Tomography n = 155
AV calcium score (AU) j" 5920 (2485-14231)
Mean Log AV calcium score (LogAU) 3.67 (0.53)
Pulse Wave Analysis n = 110
Pulse pressure, PP (mmHg) 61 (17)
Augmentation pressure, AG (mmHg) 16 (9)
Augmentation index AG/PP (%) 31 (12)
Augmentation index P2/P1 (%) 149(29)
Serum Biochemistry n = 155
Total cholesterol (mmol/L) 5.7(1.0)
HDL cholesterol (mmol/L) 1.5 (0.4)
HDL:Total cholesterol ratio 4.1 (1.2)
Triglycerides (mmol/L) 1.5 (0.7)
LDL cholesterol (mmol/L) 3.5 (0.8)
Urea (mmol/L) 6.5 (5.0)
Creatinine (pmol/L) 92 (21.4)
Glucose (mmol/L) 5.3 (1.2)
Calcium (mmol/L) 2.32 (0.10)
Brain Natriuretic Peptide (pg/ml) n = 134
Mean (SD) 465 (633)
Median (Range) 200(14-3640)
Log BNP (Log pg/ml) 2.37 (0.52)
C-Reactive Protein (mg/L) n = 135
Mean (SD) 4.3 (6.2)
Median (Range) 2.35 (0.16-38.0)
Log CRP (Log mg/L) 0.39 (0.5)
Categorical variables stated as number, n (%). Continuous variables stated as mean (standard
deviation). | Median (Range).
ACE - angiotensin-converting enzyme; NYHA - New York Heart Association; LV - left
ventricular; AV - aortic valve; Log - logarithm; HDL - high-density lipoprotein; LDL - low -
density lipoprotein; BNP - brain natriuretic peptide.
120
TABLE 6.2 Progression of aortic valve stenosis and calcification
Progression of stenosis n = 134
(Echocardiography)
Peak velocity (m/s/yr) 0.20 (0.21)
Peak gradient (mmHg/yr) 6.5 (7.2)
2
Aortic valve area (cm /yr) -0.08 (0.11)
Progression of calcification n = 133
(Computed Tomography)
Absolute change AVC score (AU/yr)
Per cent change absolute AVC score (%/yr)
1608 (1865)
29 (30)
Log AVC score (LogAU) 0.09(0.10)
Variables stated as mean (standard deviation).
AVC - aortic valve calcium; Log - logarithm.
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TABLE 6.3 Predictors of Disease Progression
Change in Change in Change in Per cent
peak velocity absolute Log change in AVC
(m/s/yr) AVC score AVC score score
(AU/yr) (LogAU/yr) (%/yr)
R P R P R P R P
Baseline demographics
Age (years) +0.24 0.006 +0.21 0.02 -0.10 0.24 -0.03 0.71
Height -0.19 0.03 +0.23 0.01 -0.15 0.09 -0.12 0.19
Weight -0.13 0.15 +0.12 0.18 +0.05 0.56 +0.17 0.06
Baseline disease severity
Peak velocity +0.32 <0.001 +0.48 <0.001 -0.05 0.60 -0.02 0.80
Absolute AVC score +0.25 0.004 +0.49 <0.001 -0.26 0.003 -0.30 <0.001
Log AVC score +0.26 0.003 +0.47 <0.001 -0.32 <0.001 -0.40 <0.001
Disease progression
Change peak velocity/yr +0.27 0.002 -0.02 0.83 +0.05 0.58
Change absolute AVC/yr +0.27 0.002 +0.2 0.02 +0.27 0.002
Change log AVC/yr -0.01 0.88 +0.20 0.02 +0.94 <0.001
Per cent change AVC/yr +0.05 0.54 +0.27 0.002 +0.94 <0.001
Blood pressure (mmHg)
Baseline systolic BP -0.04 0.68 -0.01 0.94 +0.14 0.11 +0.19 0.03
Baseline diastolic BP +0.04 0.67 +0.05 0.59 +0.13 0.15 +0.13 0.15
Mean study systolic BP <-0.01 0.98 -0.01 0.92 +0.06 0.48 +0.18 0.04
Mean study diastolic BP +0.11 0.22 +0.03 0.71 +0.06 0.46 +0.11 0.20
Baseline scrum biochemistry
Urea (mmol/L) -0.12 0.15 -0.07 0.41 +0.08 0.33 +0.20 0.02
Creatinine (pmol/L) <-0.01 0.95 -0.04 0.62 -0.06 0.49 -0.07 0.39
Calcium (mmol/L) +0.02 0.86 -0.12 0.17 -0.03 0.77 +0.21 0.02
Total cholesterol (mmol/L) +0.14 0.10 -0.11 0.22 -0.03 0.75 -0.07 0.40
HDL cholesterol (mmol/L) +0.16 0.06 +0.12 0.17 +0.17 0.05 +0.16 0.06
LDL cholesterol (mmol/L) +0.11 0.21 -0.10 0.27 -0.06 0.51 -0.11 0.20
Mean on treatment serum
biochemistry
Urea (mmol/L) -0.05 0.59 -0.02 0.79 -0.09 0.33 +0.06 0.48
Creatinine (pmol/L) -0.14 0.10 <-0.01 0.99 -0.08 0.38 -0.05 0.58
Calcium (mmol/L) +0.11 0.22 -0.10 0.25 +0.20 0.02 +0.24 0.007
Total cholesterol (mmol/L) +0.05 0.58 -0.02 0.79 -0.09 0.33 -0.10 0.24
HDL cholesterol (mmol/L) +0.14 0.11 +0.14 0.10 +0.14 0.10 +0.14 0.10
LDL cholesterol (mmol/L) +0.03 0.70 -0.03 0.71 -0.11 0.23 -0.12 0.17
C-reactivc protein
Log baseline CRP -0.14 0.11 -0.13 0.12 -0.17 0.05 -0.15 0.09
Log mean study CRP -0.10 0.25 -0.04 0.62 -0.15 0.08 -0.13 0.15
Change log CRP/year +0.07 0.42 +0.01 0.91 -0.04 0.68 +0.03 0.75
Brain natriuretic peptide
Log baseline BNP +0.26 0.003 +0.11 0.21 -0.17 0.06 -0.08 0.36
Change log BNP/year +0.26 0.002 +0.32 <0.001 -0.05 0.61 +0.05 0.57
AVC - aortic valve calcium; Log - logarithm; BP - blood pressure; HDL - high-density lipoprotein;
LDL - low-density lipoprotein; CRP - C-reactive protein; BNP - brain natriuretic peptide.
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Progression of valvular calcification was predicted by the baseline AVC score
(p<0.001) and the rate of change in log BNP per year (p<0.001). Age (p=0.02),
height (p=0.009), mean study systolic blood pressure (p=0.04) and serum calcium
concentrations (p=0.02) and the presence of hypertension (p=0.03) also correlated
with progression in aortic valve calcification (Tables 6.3 and 6.4).
There was a weak negative correlation with smoking (p=0.03), the presence of
vascular disease (p=0.01) and male sex (p=0.03). Progression in aortic jet velocity
was not associated with the presence of hyperlipidaemia, ischaemic heart disease,
smoking, or any of the biochemical markers of atherosclerosis (Tables 6.3 and 6.4).
Furthermore, neither progression in aortic jet velocity (r=0.03, p=0.70) nor AVC
score (r=-0.11, p=0.23) correlated with mean on treatment serum LDL cholesterol
concentrations [Cowell et al 2005],
6.4.1.1 Inflammation
At baseline, serum CRP concentrations were the same in both treatment groups
(p=0.76), but fell with 80 mg of atorvastatin (p=0.001). Baseline CRP concentrations
did not correlate with baseline severity of stenosis (aortic jet velocity, p=0.95), or
extent of valvular calcification (log AVC score, p=0.82). Furthermore neither
baseline nor mean on treatment CRP concentrations correlated with disease
progression or clinical outcome (Table 6.3).
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6.4.1.2 Arterial stiffness
Augmentation pressure and pulse pressure, but not augmentation index, correlated
with age, height, systolic blood pressure, and mean arterial pressure. No measures of
arterial stiffness correlated with baseline severity of aortic valve stenosis or valvular
calcification, nor were there any associations between arterial stiffness and disease
progression.
6.4.1.3 Brain natriuretic peptide
Serum BNP concentrations at baseline were the same in both treatment groups
(p=0.37) and were not influenced by atorvastatin therapy (p=0.33). However, serum
BNP concentrations at baseline did correlate with baseline severity of stenosis
(r=0.27, p=0.002) as well as with the extent of valvular calcification on CT (r=0.18,
p=0.04). The progression in aortic jet velocity correlated with basal and rate of
change in serum BNP concentrations (r=0.26, p=0.003 and r=0.26, p=0.002
respectively).
6.4.2 Clinical outcome
During the study follow-up period, 43 patients (28%) reached a pre-defined clinical
end-point (Table 6.5). Six patients died, 2 secondary to malignant disease. The
remaining 4 were cardiovascular deaths; one patient with severe asymptomatic aortic
stenosis collapsed and died of an acute myocardial infarction (diagnosed at
postmortem), one patient with severe symptomatic aortic stenosis who had declined
surgery had a sudden cardiac death, and 2 patients died in hospital whilst awaiting
urgent valve replacement for severe symptomatic stenosis associated with heart
failure.
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TABLE 6.5 Clinical end-points
Clinical end-points Number Per cent




Aortic valve replacement 30 19.4
Severe symptomatic aortic stenosis 28
Severe asymptomatic aortic stenosis prior to non-cardiac surgery 1
Aortic root dilatation and mild aortic stenosis 1
Severe symptomatic aortic stenosis 7 4.5
Referred for AVR 5
For medical management 2
Total number end-points reached 43 27.7
AVR - aortic valve replacement.
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Thirty patients underwent AVR, 28 of which were for severe symptomatic aortic
stenosis. One patient underwent AVR for severe but asymptomatic aortic stenosis
prior to lung resection, and another for mild aortic stenosis and a dilated aortic root.
Seven further patients developed symptoms secondary to severe aortic stenosis, of
whom five were awaiting valve surgery at the time of study completion. The
remaining 2 patients were deemed unfit for major cardiac surgery due to frailty and
co-morbidity.
Overall fewer clinical end-points appeared to have been reached in the statin treated
group, however numbers were small and the difference was not statistically
significant (Chapter 4) [Cowell et al 2005], Clinical outcome was only predicted by
baseline and subsequent rate of progression of aortic stenosis severity and
calcification (p <0.001), as well as by baseline (p=0.02) and rate of progression
(p<0.001) of serum BNP concentrations. However, neither clinical nor biochemical
markers of atherosclerosis and cardiovascular risk, including serum cholesterol and
CRP concentrations were associated with clinical outcome (Table 6.6 and 6.7).
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Table 6.6 Predictors of clinical outcome
No Event Event /-test
P value
Baseline demographics
Age (years) 67(11) 69(9) 0.47
Height (cm) 168 169 0.46
Weight (Kg) 79(15) 81(15) 0.41
Blood Pressure
Baseline systolic BP 145(20) 141(18) 0.19
Baseline diastolic BP 82(11) 81(11) 0.36
Mean study systolic BP 143(18) 138(16) 0.14
Mean study diastolic BP 81(8) 80(11) 0.77
Disease severity
Baseline Vmax 3.20 (0.53) 4.0 (0.54) <0.001
Baseline CT AVC 6686 (7351) 11401 (9081) 0.001
Baseline Log CT AVC 3.57 (0.55) 3.93 (0.35) <0.001
Disease progression
Change peak velocity/yr 0.13 (0.16) 0.37(0.21) <0.001
Change absolute AVC/yr 1129 (1328) 2850 (2429) <0.001
Change log AVC/yr 0.09 (0.12) 0.10(0.06) 0.68
Per cent change AVC/yr 28.7 (32.7) 30.7 (23.6) 0.73
Baseline serum biochemistry
Urea (mmoI/L) 6.7(5.8) 6.1(1.7) 0.52
Creatinine (pmol/L) 92(22) 92(19) 0.86
Calcium (mmol/L) 2.29(0.11) 2.29(0.10) 0.97
Total cholesterol (mmol/L) 5.7(0.9) 5.7(1.1) 0.98
HDL cholesterol (mmol/L) 1.5(0.5) 1.6(0.4) 0.25
LDL cholesterol (mmol/L) 3.5(0.8) 3.5(1.0) 0.96
Mean on treatment serum
biochemistry
Urea (mmol/L) 6.2(1.9) 6.2 (1.7) 0.96
Creatinine (pmol/L) 92 (21) 93 (24) 0.68
Calcium (mmol/L) 2.29 (0.09) 2.29 (0.10) 0.86
Total Cholesterol (mmol/L) 4.6(1.3) 4.7(1.5) 0.86
HDL cholesterol (mmol/L) 1.4 (0.4) 1.5 (0.4) 0.26
LDL cholesterol (mmol/L) 2.8 (1.2) 2.8(1.3) 0.83
C-reactive protein
Log baseline CRP 0.42 (0.50) 0.32 (0.48) 0.32
Log mean study CRP 0.28(0.54) 0.41(0.52) 0.23
Change log CRP/year -0.08(0.18) 0.03(0.33) 0.016
Brain natriuretic peptide
Log baseline BNP 2.30 (0.56) 2.54 (0.38) 0.02
Rate of change BNP/yr 0.08 (0.13) 0.18(0.20) <0.001
Variables stated as mean (SD).
BP - blood pressure; Vmax - peak velocity; CT - computed tomography; AVC - aortic
valve calcium; HDL - high-density lipoprotein; LDL - low-density lipoprotein;
CRP - C-reactive protein; Log - logarithm; BNP - brain natriuretic peptide.
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TABLE 6.7 Clinical risk factors predicting clinical outcome
No Event Event Chi2-test
Clinical Risk Factors (n = 112) (n = 43) p value
Hyperlipidaemia 7(6) 3(7) 0.89
Hypertension 56 (50) 23 (53) 0.83
Ischaemic heart disease 23 (20) 7(16) 0.71




Current smoker 28 (25) 5(12) 0.11
78(70) 30(72) 0.93
Male sex
Categorical variables stated as, n (%).
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6.5 DISCUSSION
Using a cohort of patients with aortic stenosis, we have prospectively demonstrated
that the major predictors of disease progression and clinical outcome remain
measures of disease severity; namely aortic jet velocity, aortic valve calcification and
serum BNP concentration. With the exception of hypertension, the presence of
atherosclerotic risk factors and vascular disease were not predictive.
It is clear that patients with symptomatic aortic stenosis require urgent aortic valve
surgery. The timing of surgery in patients with asymptomatic severe aortic stenosis
remains controversial and clinical practice varies. Given the morbidity and mortality
associated with valve surgery, many argue that surgery should be delayed until the
onset of symptoms. The concern is that patients do not always accurately report the
onset of symptoms. This may arise because patients do not recognise the significance
of symptoms, particularly mild dyspnoea or fatigue that may be wrongly attributed to
age, or subconsciously reduce activity levels in order to avoid symptoms. It would
therefore be useful to have biochemical or clinical markers that help identify those
patients with severe disease who might benefit from prompt aortic valve surgery.
6.5.1 C-REACTIVE PROTEIN
Serum CRP concentration is a sensitive but non-specific marker of systemic
inflammation that is elevated in patients with vascular disease [Van der Meer et al
2002], It is an independent predictor of future cardiovascular events in healthy adults
and in those with established disease [Ridker et al 1998], Furthermore serum CRP
concentrations are elevated in patients with calcific aortic stenosis, even in the
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absence of other overt vascular disease [Galante et al 2001], In severe aortic stenosis,
valvular CRP concentrations correlate with serum CRP concentrations [Skowash et
al 2006], and serum CRP concentrations fall following AVR [Gerber et al 2003].
This is in keeping with histological studies suggesting that the aortic valve is a site of
active inflammation. Could serum CRP concentrations provide a marker to predict
disease progression or clinical outcome in patients with calcific aortic stenosis?
Serum CRP concentrations do not correlate with the severity of aortic stenosis
[Gunduz et al 2003] and no study has to date evaluated its relationship with clinical
outcome. One preliminary study has suggested that disease progression was more
rapid in those with higher CRP concentrations [Sanchez et al 2006 ] but conclusions
were limited by the small sample size (n=~20 per group), length of follow-up
(6 months) and the single baseline CRP measurement. We have here looked at
relationship between serum CRP concentrations and (a) the severity of valvular
stenosis at baseline, (b) the rate of disease progression, and (c) clinical outcome. We
were unable to demonstrate any association between serum CRP concentrations and
any of these measures despite being able to reproduce the well-described reductions
of serum CRP concentrations with atorvastatin therapy in our patient group [Houslay
et al 2006],
6.5.2 Arterial stiffness
Decreased vascular distensibility is a marker of arterial disease and is associated with
increased cardiovascular risk. Arterial stiffness increases with age [Mitchell et al
2004] and smoking [Mahmud and Feely 2003], and is associated with certain disease
states including atherosclerosis [van Popele et al 2001], hypertension [Laurent et al
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1994], coronary artery disease [Hayashi et al 2002] diabetes mellitus [Salomaa et al
1995], and hypercholesterolaemia [Wilkinson et al 2002], Clinical studies
demonstrate that increased arterial stiffness is an independent predictor of
cardiovascular risk [Weber et al 2005], premature coronary artery disease [Weber et
al 2004], and mortality in patients with hypertension [Laurent et al 2001] and end-
stage renal failure [Blacher et al 1999; London et al 2001], Little is known about the
associations between aortic stenosis and arterial stiffness but given that calcific aortic
stenosis is a condition associated with progressive rigidity and thickening of the
aortic valve cusps [Newby et al 2006], we wished to explore whether there was a
relationship between arterial stiffness and aortic stenosis and whether this could be
used to predict disease progression or clinical outcome.
One small study (n=30) has previously suggested that invasive measurements of
aortic pulse wave velocity correlate with the severity of aortic stenosis
(Liu et al 2004). However, we were unable to find any association between non¬
invasive measures of arterial stiffness, and basal severity, disease progression or
clinical outcome. In a limited number of patients (n=18), we did measure pulse wave
velocity but again demonstrated no associations with disease severity, progression or
outcome. This lack of association suggests that the pathophysiological processes
underlying arterial stiffness and aortic stenosis are distinct and independent.
We do accept that we may have missed a weak association and that many of the
principles and assumptions employed by pulse wave analysis to generate measures of
arterial stiffness may not be valid in patients with aortic stenosis. Nevertheless, we
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were able to confirm previous associations between measures of arterial stiffness and
age, height and blood pressure.
6.5.3 Brain natriuretic peptide
Brain natriuretic peptide is elevated in both symptomatic and asymptomatic left
ventricular dysfunction, and serum concentrations correlate with NYHA class and
prognosis [Tsutamoto et al 1997; McDonagh et al 2001; Berger et al 2002; Lubien et
al 2002], Serum BNP concentrations are also elevated in other structural heart
disease [Nakamura et al 2002] including left ventricular hypertrophy and aortic
stenosis. Recent studies have demonstrated that serum BNP concentrations correlate
with the severity of aortic stenosis and NYHA class [Gerber et al 2003; Lim et al
2004], In patients with severe aortic stenosis, BNP is an independent predictor of
symptom free survival [Bergler-Klein et al 2004] and clinical outcome [Lim et al
2004],
We have established, for the first time, that basal and subsequent increases in serum
BNP concentrations predict both disease progression and clinical outcome in a large
cohort of patients. This predictive power is perhaps not unsurprising given that serum
BNP concentrations correlate with the baseline severity of aortic stenosis, which in
turn is a major predictor of disease progression and clinical outcome. It is likely
therefore that serum BNP concentrations are acting as a marker of disease severity
through the association with left ventricular hypertrophy and systolic dysfunction.
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6.5.4 Study limitations
In the SALTIRE trial, we excluded patients with coronary artery disease who were
receiving or had an indication for statin therapy. Although atherosclerotic risk factors
may have a more important role in the progression of aortic stenosis in these patients,
they will require risk factor management irrespective of their valvular heart disease.
Moreover, our patient population was representative of the population of patients
with aortic stenosis seen in clinical practice with a broad age range and significant
cardiovascular co-morbidity.
We have to date conducted only univariate analyses. Given the potential
interdependency of some of the variables, a step-wise multiple logistic regression
analysis is underway. This may help identify independent predictors of disease
progression and clinical outcome, but is unlikely to alter our main conclusions.
6.6 CONCLUSIONS
The major predictors of disease progression and clinical outcome in patients with
aortic stenosis remain measures of disease severity. Estimation of serum BNP
concentration may be helpful in the monitoring of patients with severe aortic stenosis
particularly where there is clinical uncertainty or where incomplete clinical
information is available such as poor quality echocardiographic imaging.
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CHAPTER 7
CONCLUSIONS AND FUTURE DIRECTIONS
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7.1 CONCLUSIONS
7.1.1 Helical computed tomography in the quantification of aortic
valve calcium
Severity of valvular calcification has been reported to be a strong predictor of
clinical outcome in patients with aortic stenosis. Echocardiography is the gold
standard for assessing patients with valvular heart disease, but only provides a semi¬
quantitative measure of calcification. Computed tomography has recently been
identified as a potential tool for more accurate quantification of AVC content.
Electron beam CT derived calcium scores demonstrate good reproducibility with
interscan variation of 7-9% [Pohle et al 2001; Budoff et al 2002], and correlate
closely with calcium deposition in excised valvular tissue [Messika-Zeitoun et al
2004].
At inception of the SALTIRE trial, reproducibility of AVC scores quantified by
helical CT had not been determined, nor had there been a direct comparison with
electron beam CT. A number of studies quantifying coronary artery calcium content
have subsequently demonstrated a good correlation between calcium scores
determined using multi-slice and electron beam CT [Carr et al 2000; Becker et al
2001],
We have demonstrated that the measurement of AVC content using helical CT
reveals very good interscan reproducibility when assessed in a cohort of 20 patients
undergoing repeated assessment. Our figures indicate that helical CT is a useful tool
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for determining the severity of valvular calcification and in monitoring the
progression of calcium accumulation. This suggests that it may be valuable in
assessing the influence of pharmacological therapy on disease progression.
7.1.2 Relationship between aortic valve calcium content and severity
of aortic stenosis
In patients with aortic stenosis, disease progression and clinical outcome are
influenced by baseline severity of stenosis, as well as the extent of valvular
calcification [Davies and Gershlick 1991; Bahler et al 1999; Rosenhek et al 2000],
Until recently the relationship between the Doppler-derived severity of stenosis and
extent of valve calcification was not clear. Calcification of the aortic valve reduces
leaflet flexibility, with a resultant acceleration of blood flow across the narrowed
orifice, and hence an increase in aortic jet velocity. It is important to remember that
jet velocity will be determined by other factors influencing the haemodynamic load
on the left ventricle including the presence of hypertension or coronary artery
disease. Although an association between valve calcification and severity of stenosis
seems likely, this had not been clearly demonstrated in a prospective trial.
We have prospectively demonstrated in a large cohort of patients that severity of
stenosis determined by Doppler echocardiography is strongly correlated with the
degree of aortic valve calcification on helical CT. This suggests that the CT derived
calcium score provides complementary information to the jet velocity, and that AVC
accumulation over time may provide additional prognostic information independent
of the aortic jet velocity.
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7.1.3 Influence of statin therapy on the progression of calcific aortic
stenosis
Hydroxymethylglutary] coenzyme A reductase inhibitors or statins are now well
established in the primary and secondary prevention of coronary artery disease.
Several studies have suggested that these drugs can cause regression of coronary
artery disease as well as reduce the calcific volume of coronary plaques [Callister et
al 1998], Given the clinical association of calcific aortic stenosis with
hyperlipidaemia and coronary artery disease, and the striking histological similarities
with atheroma, the speculation that statins may have the potential to influence
disease progression in aortic stenosis is an intriguing hypothesis [Mohler 2000],
Recent retrospective studies [Aronow et a 2001; Novaro et al 2001; Bellamy et al
2002; Rosenhek et al 2004] have suggested that statins may delay disease
progression in aortic stenosis (Table 7.1) through their lipid-lowering and anti¬
inflammatory actions. These observational data should be interpreted with caution
since none of these studies were prospective randomised trials, serum LDL
cholesterol concentrations did not correlate with disease progression, and the statin
doses were small. There may also be some publication bias with studies reporting
negative findings under-represented in the literature [Samal et al 2002; Antonini-
Canterin et al 2005],
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TABLE7.1Summaryoftrialsasse singprogressionrticsteno ibyrep atedechoc rd ography DesignAronowetalNovaroBell myR senhekSamalAnto ini-C w lt
Canterinetal
Retrospectiveetrospectivei Observationalti albs rve a on l
Prospective Randomised Controlled Trial
Patients180 Patientso62 statin Meanage(yr)82 Meanfollow-up33 (months) Totalcholesterol (mmol/L) Correlationof progressionwith LDLcholesterol ReduceYes progressionwith statintherapy
174 57 68 21 5.5 Yes/No Yes
156 38 77 44 5.8 No Yes
211 50 70 24 5.8 No Yes
112 55 73 Yes
No
242 121 68 54 No No
134 65 68 25 5.7
No No
LDL-low-densityipoprot i .
The SALTIRE trial [Cowell et al 2005] is the first double-blind randomised
controlled trial of lipid-lowering therapy to be completed in patients with calcific
aortic stenosis. This trial of 155 patients demonstrated that, whilst atorvastatin 80 mg
daily more than halved serum LDL cholesterol concentrations, it did not halt the
progression or induce regression of the valvular disease process as measured by both
Doppler echocardiography and helical CT. Indeed no relationship between serum
LDL cholesterol concentrations and the progression of aortic stenosis was apparent,
nor was there a demonstrable effect of high dose atorvastatin on clinical end-points.
Thus, irrespective of the method of assessing disease progression, we have
consistently demonstrated the continued deterioration of aortic stenosis despite
intensive reductions in serum cholesterol concentrations.
7,1.4 Influence of statin therapy on the progression of coronary
artery calcification
Coronary artery calcification is an independent risk factor for coronary heart disease,
and progresses over time at a rate of 20-30% per year [Callister et al 7998; Budoff et
al 2000; Schmermund et al 2001]. Calcium burden may be determined using CT, and
quantity of coronary artery calcium correlates with overall coronary plaque burden
[Mautner et al 1994; Rumberger et al 1995; Sangiorgi et al 1998], Several non-
randomised observational studies have reported a reduction in coronary calcium
accumulation in patients taking statin therapy [Callister et al 1998; Achenbach et al
2002], but no placebo-controlled trials have been published substantiating these
results.
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In using helical CT to determine AVC content in the SALTIRE trial, we had the
opportunity to assess prospectively the effect of intensive lipid-lowering therapy on
coronary calcification. We demonstrated good reproducibility of coronary scores and
progression of coronary artery calcification by 20% per year. However, intensive
lipid-lowering therapy did not delay the progression or induce regression of coronary
artery calcium burden. This is despite a 50% reduction in serum LDL cholesterol and
CRP concentrations.
Our findings indicate that earlier observational studies have overestimated the
potential beneficial effects of statins on coronary artery calcification, and indeed
more recent prospective randomised controlled trials [Arad et al 2005; Raggi et al
2005] have also failed to find an effect. Although coronary artery calcium scores
correlate well with the presence of atherosclerosis and predict future coronary risk,
our findings indicate that there is currently no role for monitoring progression of
coronary artery calcification to assess the effects of lipid-lowering therapy out with a
clinical trial setting.
7.1.5 Factors influencing the progression of aortic stenosis and
clinical outcome
Calcific aortic stenosis is common, and gradually progresses over time. Rates of
disease progression vary widely between individuals, and as soon as patients with
severe stenosis develop symptoms, AVR is indicated. In general, patients with milder
forms of disease have a better outlook, but there is an increased risk of unrelated
cardiovascular events.
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Mechanical injury is thought to initiate the disease process, inducing endothelial
disruption that is followed by an inflammatory process closely resembling
atherosclerosis. In keeping with this observation, the clinical risk factors for aortic
stenosis include those for cardiovascular disease, as well as conditions affecting
calcium metabolism. However, the clinical factors associated with disease
progression are less well defined, with many mainly retrospective studies reporting
conflicting outcomes. Clinical outcome, however, is strongly predicted by baseline
aortic jet velocity, rate of change in jet velocity, the extent of valvular calcification
and functional status [Otto et al 1997; Rosenhek et al 2000]. We wished to define
predictors of disease progression and clinical outcome more clearly, and to identify
new modifiable markers.
In patients with calcific aortic stenosis we have prospectively demonstrated that the
major predictors of disease progression and clinical outcome remain measures of
disease severity; namely aortic jet velocity, aortic valve calcification and serum BNP
concentration. With the exception of hypertension, the presence of atherosclerotic
risk factors and vascular disease were not predictive.
We have established, for the first time, that basal and subsequent increases in serum
BNP concentrations predict both disease progression and clinical outcome in a large
cohort of patients. This predictive power is perhaps not unsurprising given that
serum BNP concentrations correlate with the baseline severity of aortic stenosis,
which in turn is a major predictor of disease progression and clinical outcome. It is
likely therefore that serum BNP concentrations are acting as a marker of disease
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severity through the association with left ventricular hypertrophy and systolic
dysfunction.
7.2 FUTURE DIRECTIONS AND CLINICAL IMPLICATIONS
7.2.1 Computed tomography in the assessment of aortic valve
calcification and stenosis
Although we have clearly demonstrated that helical (two detector array, or double-
helix) CT is a reproducible means of measuring valvular calcium content, it is
unlikely that such scanners will be utilised in the future given rapid technological
advances that have taken place in recent years. Factors influencing the
reproducibility of calcium scores include cardiac and respiratory motion artefact,
method of image acquisition and reconstruction, the use of phantom calibration, and
the method of calcium score calculation. The latest multi-slice scanners with up to
64 detector arrays acquire multiple images at different levels simultaneously in sub-
second time, and reconstruct images using ECG gating. Movement artefact and
partial-volume effects are reduced [Willmann et al 2002; Morgan-Hughes et al
2003], and it seems logical to assume that more accurate quantification of valvular
calcification and improved specificity will result.
Alternative methods of quantifying calcification have been evaluated, including
volume and mass scores that have been shown to improve the reproducibility of
coronary calcium scores [Callister et al 1998], These scoring methods have also been
utilised in recent aortic valve studies [Morgan-Hughes et al 2003; Koos et al 2005],
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but further evaluation is required to determine which is the most reproducible using
the very latest scanning equipment.
Computed tomography imaging has improved to the extent that direct measurement
of aortic stenosis severity is now also possible. Valve area determined by planimetry,
is comparable to that derived by transthoracic and transoesophageal
echocardiography [Alkadhi et al 2006; Feuchtner et al 2006], Given the radiation
doses involved, it is unlikely that CT will supersede echocardiography in the
assessment of stenosis severity, it may however, prove a useful non-invasive
technique in patients with poor ultrasound images.
7.2.2 Potential therapies or aortic valve stenosis
The current management of patients with aortic stenosis includes monitoring disease
progression, and ensuring patient awareness of the need for antibiotic prophylaxis
against the relatively low risk of infective endocarditis. For those patients with
severe symptomatic disease, AVR is a priority with conventional medical therapy
reserved for symptom control in inoperable cases. However, the majority of patients
with aortic stenosis do not have symptoms or an indication for surgery. Are there any
interventions that can halt or slow the progression of the disease process?
Theoretically, anti-inflammatory and anti-proliferative agents would be anticipated
to alter the natural history of aortic stenosis. Statin and ACE inhibitor therapies are
two commonly used treatments that have proven secondary preventative benefits in
cardiovascular disease and exhibit some of these desirable anti-inflammatory and
anti-proliferative properties.
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7.2.2.1 Hydroxymetliylglutaryl coenzymeA reductase inhibitors (statins)
In the SALTIRE trial, intensive lipid-lowering therapy with 80 mg atorvastatin daily
did not halt the progression or induce regression of calcific aortic stenosis. Given the
data linking aortic stenosis with atherosclerosis and hypercholesterolaemia, this
result is surprising. One potential explanation is that, whilst these features may drive
the initiation of aortic stenosis, disease progression may be dependent upon other
factors. The aortic valve is subject to continuous dynamic mechanical stress, and
leaflet plasticity and structure can have an overriding influence, such as with a
bicuspid valve. Moreover, in contrast to atherosclerosis (Figure 7.1), aortic stenosis
is associated with a virtual absence of smooth muscle cell proliferation and lipid-
laden macrophages, and dominated by earlier and more extensive mineralisation.
Decreasing the lipid pool and increasing the fibrous cap may be less relevant to the
progression of aortic stenosis than it is for the reduction in atherosclerotic plaque
rupture with statin therapy in patients with coronary heart disease. Whilst
stabilisation and calcification of plaques is beneficial and reduces cardiovascular
events in patients with coronary artery disease, reduced inflammation, promotion of
healing and increased calcification may lead to progression of aortic stenosis.
It could be argued that lipid-lowering therapy is unlikely to influence disease
progression in the presence of significant aortic stenosis. Patients with aortic
velocities below 2.5 m/s were excluded from the SALTIRE trial and intervening at
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this earlier stage of the disease process may have been more beneficial. However,
such patients do not commonly present to routine clinical practice and their
identification would potentially require population screening. Moreover, the
SALTIRE trial was unable to exclude a modest treatment benefit (a delay in disease
progression of <0.07 m/s/yr or <5% aortic valve calcification/yr). Although such
modest reductions are unlikely to be meaningful in the majority of older patients, a
small decrease in disease progression may be clinically important in younger patients
with mild disease who may progress over many years. Indeed, a small preliminary
observational study suggests that statin therapy may reduce disease progression in
patients with aortic sclerosis [Antonini-Canterin et al 2005] and this finding warrants
prospective evaluation.
Statin therapy in patients with aortic stenosis may confer secondary preventative
benefits that are independent of its effects on the valvular disease process because of
the association between aortic stenosis and coronary artery disease. The SALTIRE
trial was not powered to assess the benefits of lipid-lowering therapy on
cardiovascular end-points, such as non-fatal and fatal myocardial infarction, but there
was a trend in favour of reduced clinical events. It is likely that aortic stenosis and
sclerosis may be important markers of occult vascular disease and thereby identify
patients who would gain from the preventative benefits of statin therapy. Several
larger clinical end-point trials (including the SEAS and ASTRONOMER trials
[Rajamannan 2006]) are currently underway that will be able to address this issue.
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Finally, for many patients with aortic stenosis, the first symptom to develop is chest
pain and this precipitates the decision to undertake AVR. Flowever, this may be
driven by concomitant coronary artery disease rather than progression of valvular
stenosis. Previous secondary prevention trials in coronary heart disease have reported
a reduction in coronary artery bypass graft surgery rates [The Heart Protection Study
Collaborative Group 2002], Thus, the larger clinical end-point trials of statin therapy
in aortic stenosis may suggest a reduction in the rate of valve surgery but this may be
driven by patients with aortic stenosis who undergo combined aortic valve and
bypass surgery for symptoms of angina pectoris. If statin therapy truly reduces
disease progression then a reduction in isolated AVR would be anticipated.
At present we cannot recommend the use of statin therapy in patients with isolated
aortic stenosis in the absence of other cardiovascular risk factors. Indeed recently
published American Heart Association and American College of Cardiology
guidelines suggest awaiting the outcome of further prospective trials in patients with
mild disease that are followed up for a longer period [Bonow et al 2006],
Furthermore, evaluation of the effects of statins in younger patients with aortic valve
sclerosis, prior to the development of significant haemodynamic change and
progression to valve stenosis, will be required.
7.2.2.2 Angiotensin-converting enzyme inhibition
There are several reasons to believe that ACE inhibitor therapy may have a role in
the management of patients with aortic stenosis. First, in contrast to normal valves,
sclerotic aortic valves have demonstrable tissue expression of angiotensin II and
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ACE [Helske et al 2004; O'Brien et al 2005] and these may contribute to valvular
inflammation, calcification and disease progression. Second, the pressure overload
induced by aortic stenosis has several effects on the myocardium including left
ventricular hypertrophy, apoptosis and fibrosis. This may accelerate the left
ventricular systolic and diastolic dysfunction associated with aortic stenosis. Animal
models of outflow obstruction using aortic banding have demonstrated improvement
in diastolic function [Litwin et al 1995] and survival [Weinberg et al 1994; Turcani
and Rupp 2000] with ACE inhibitor treatment, and in patients with aortic stenosis
intra-coronary infusion of ACE inhibitor resulted in immediate improvement in
diastolic function [Friedrich et al 1994], This suggests that ACE inhibitors have the
potential to influence clinical outcome through their effect on left ventricular
diastolic function and remodelling. Finally, blood pressure lowering will indirectly
reduce the pressure overload of the left ventricle as well as potentially reduce the
mechanical stress and strain on the aortic valve.
Two preliminary observational studies with ACE inhibitor therapy in patients with
aortic stenosis have been conflicting. In a retrospective analysis of 211 patients,
Rosenhek and colleagues [Rosenhek et al 2004] failed to demonstrate a delay in the
progression of aortic stenosis in patients maintained on ACE inhibitor therapy.
Furthermore, the presence of hypertension did not appear to influence the outcome.
In contrast, O'Brien and colleagues [O'Brien et al 2005] found that ACE inhibitor
therapy was associated with a 71% reduction in the progression of aortic valve
calcification in 123 patients with aortic stenosis undergoing electron beam CT.
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However, such retrospective observational data are difficult to interpret and the study
findings have wide confidence intervals.
Historically, ACE inhibition was said to be contraindicated in patients with aortic
stenosis. This has primarily been due to the concern of invoking profound peripheral
vasodilatation that would result in haemodynamic compromise, collapse and
potentially death. However, ACE inhibitors are very well tolerated when initiated in
patients with aortic stenosis [Chockalingham et al 2004; O'Brien et al 2004] and
many patients (-30%) with aortic stenosis are unknowingly established on such
therapy without compromise. Indeed, the use of ACE inhibitors appears to confer
long-term survival benefit in patients considered to have a contraindication including
those with aortic stenosis [Ahmed et al 2005], The potential beneficial
haemodynamic and cardiac effects of ACE inhibition are increasingly being
recognised [Routledge and Townsend 2001] and warrant further study in patients
with aortic stenosis.
7.2.3 Statin therapy and coronary artery calcification
Despite the evidence that statin therapy is extremely successful in the primary and
secondary prevention of cardiovascular disease, we have not demonstrated a
beneficial effect of statin therapy on coronary artery calcification. It has been
suggested that calcified atherosclerotic plaques may be relatively more stable [Mintz
et al 1995], indicating a possible protective role of calcification in coronary plaques.
Statin therapy is thought to produce many of its beneficial effects through plaque
stabilisation. Thus vascular calcification may play a role in the initial stabilisation of
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atherosclerotic plaques. This is consistent with our findings and would account for
the lack of effect on the progression of coronary artery calcification despite a
reduction in serum CRP concentrations.
After the initial stabilisation of the atherosclerotic plaque, it would be anticipated
that subsequent progression of coronary calcification would be inhibited. The present
study was brief, and follow-up was only continued for a median of 2 years. It would
be important to extend our observations to 5 or more years to assess properly the
impact of statin therapy on the long-term progression of coronary artery calcification.
However, it should be acknowledged that the clinical benefits of statin therapy are
apparent within the first few years [Lewis et al 1998; The LIPID Study Group 1998;
The Heart Protection Study Collaborative Group 2002] and in some cases the first
few months [Schwartz et al 1998] of therapy. Moreover, the St Francis Heart Study
demonstrated no beneficial effects despite 4.3 years of follow-up [Arad et al 2005].
7.2.4 Disease progression and clinical outcome in calcific aortic
stenosis
Aortic stenosis is the commonest adult heart valve condition seen in the western
world. It is a gradually progressive disease, characterised by a long asymptomatic
phase, followed by a shorter symptomatic phase usually associated with severe
narrowing of the aortic valve orifice. Despite the favourable outlook in those patients
with mild asymptomatic disease, there is an increased risk of cardiovascular events
unrelated to the aortic valve disease.
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Historically, calcific aortic stenosis has been attributed to prolonged "wear and tear"
and age-associated valvular degeneration. However, recent evidence suggests that
calcific aortic stenosis may result from an active inflammatory process resembling
atherosclerosis (Figure 7.1) but also involving biochemical, humoral and genetic
factors. Endothelial injury or disruption is thought to allow lipids to penetrate the
valvular interstitial tissue [O'Brien et al 1996] and accumulate in areas of
inflammation [O'Brien et al 1996; Olsson et al 1999]. Mineralisation is a
characteristic of both atherosclerotic and aortic valve lesions, and arises in close
proximity to areas of inflammation. Histological studies have highlighted the
common features but also confirmed differences in the cellular and mineral
components of the two lesions.
These differences may, in part, explain why only 40% of patients with severe aortic
stenosis have significant coronary artery disease [Peltier et al Cardiol 2003] and why
the majority of patients with coronary artery disease do not have aortic stenosis. As
the underlying pathology for the two conditions appears to be similar, it is likely that
other unknown factors, including genetic factors, influence the development of
valvular as opposed to vascular lesions [Otto and O'Brien 2001],
Predictors of disease progression have not previously been clearly defined. We have
now prospectively demonstrated that the strongest predictors of both disease
progression and clinical outcome are baseline severity of stenosis, BNP and extent of
valve calcification. The more severe the stenosis and the more heavily calcified the
valve, the higher the BNP and the faster the rate of disease progression. However,
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although severity of stenosis correlates with the extent of valvular calcification, the
spectrum of calcification for a given aortic jet velocity varies widely, and this
diversity is likely to be important in evaluating patients approaching the need for
AVR.
7.2.5 Future evaluation of progression and clinical outcome
Our findings highlight the importance of evaluating stenosis severity, calcium burden
and BNP in monitoring patients with aortic stenosis. Larger clinical trials are needed
to evaluate their influence on clinical outcome. Identification of patients at highest
risk will facilitate appropriate disease monitoring, with the potential to determine
optimal timing ofAVR and influence surgical outcome.
7.3 SUMMARY
Calcific aortic stenosis is no longer regarded as an age-related degeneration, but an
active disease process. The need for an alternative to aortic valve replacement is
highlighted by the rising prevalence of aortic stenosis. New therapeutic strategies to
limit disease progression are needed in order to delay, and potentially avoid, the need
for valve surgery. Statin and ACE inhibitor therapies are two potential and promising
therapies that may have beneficial effects in patients with aortic stenosis. They may
reduce cardiovascular events rather than disease progression per se, but may prove to
be valuable preventative therapy. We must, however, await the results of ongoing
large randomised controlled trials to define the role of statin therapy, and consider
prospective trials of drugs influencing the renin-angiotensin system, and other anti¬
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Aortic Valve Calcification on Computed Tomography
Predicts the Severity of Aortic Stenosis
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AIM: Incidental aortic valve calcification is often detected during computed tomography. The aim
was to compare the severity of valvular stenosis and calcification in patients with aortic stenosis.
MATERIALS AND METHODS: One hundred and fifty-seven patients aged 68 ± 11 years (range:
34-85) with aortic valve stenosis underwent multislice helical computed tomography and Dopplcr
echocardiography performed by independent, blinded observers. The aortic valve calcium score was
determined using automated computer software calibrated with a phantom.
RESULTS: Dopplcr echocardiography demonstrated a post-valve velocity of 3.45 ± 0.66 m/s and a
peak gradient of 49 ± 11 mmHg. Computed tomography showed excellent reproducibility and the
median aortic valve calcium score was 5858 AU (interquartile range, 1555-14,596). The computed
tomography aortic valve calcium score positively correlated with the Dopplcr post-valve velocity and
peak gradient (r = 0.54, p < 0.0001 for both) of the aortic valve. All patients with severe aortic
stenosis had a calcium score of >3700 AU.
CONCLUSION: Calcification of the aortic valve is closely associated with the severity of aortic
stenosis, and heavy calcification suggests the presence of severe aortic stenosis that requires urgent
cardiological assessment. Patients with lesser degrees of aortic valve calcification should be screened
for aortic stenosis and monitored for disease progression. Cowell, S.J. el al. (2003). Clinical Radiology
58: 712-716.
© 2003 Published by Elsevier Science Ltd on behalf of The Royal College of Radiologists.
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INTRODUCTION
Calcific aortic stenosis is the commonest reason for valve
replacement in the developed world. The condition may be
due to progressive calcification of a congenitally bicuspid
valve or "degenerative" calcification of a morphologically
normal valve [1], Irrespective of the aortic valve mor¬
phology, the histological features are surprisingly similar to
those of coronary atheroma and include lipid deposition,
fibrosis and calcification [2].
The rate of progression of aortic stenosis appears to be most
rapid in those patients with severe calcific disease [3,41. The
annual increase in aortic valve gradient is more than twice that
seen in patients with non-calcific disease (9.7 versus
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4.4 mmHg/ycar) and the grade of calcification correlates with
the rate of disease progression [5], Indeed, moderate or severe
aortic valve calcification is the strongest independent risk factor
for an adverse clinical outcome with a five-fold increase in the
rate of death or aortic valve replacement [4],
Computed tomography is being increasingly used as a non¬
invasive method of screening for atherosclerotic coronary
artery disease [6,7] with 80-100% sensitivity and 80%
specificity [8]. There is an association between coronary artery
disease and calcific aortic stenosis, with approximately a third
of patients with aortic stenosis having significant coronary
stenoses on angiography [9]. As a consequence, there have
been several reports of incidental aortic valve calcification
detected during computed tomography examinations with a
prevalence of 10-30% [10,11]. However, there have been few
reports [11] assessing the relationship between the degree of
valvular calcification and the severity of aortic stenosis. We
hypothesized that valvular calcification would correlate with
the aortic post-valve velocity in patients with aortic stenosis.
© 2003 Published by Elsevier Science Ltd on behalf of The Royal College of Radiologists.
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MATERIALS AND METHODS
Subjects
One hundred and fifty-seven patients participated in the
study, which was undertaken with the approval of the local
research ethics committee, in accordance with the Declaration
of Helsinki, and with the written informed consent of each
participant. This is a sub-study of the Scottish Aortic stenosis
and Lipid-lowering Therapy, Impact on REgression (SALT-
IRE) trial that is evaluating the effect of lipid lowering therapy
on the rate of progression of aortic stenosis. Patients with aortic
stenosis were approached for inclusion in the trial if they were
older than 18 years and had a peak aortic valve velocity of
£2.5 m/s on Doppler echocardiography. Patients were
excluded if they were women of child-bearing potential, had
active liver disease, were planned to receive or were receiving
lipid-lowering therapy, had severe mitral valve disease, aortic
regurgitation or planned valve replacement. One patient, with a
previous aortic root abscess, was excluded because of extensive
aortic root calcification that obscured and prevented assessment
of the aortic valve.
All patients underwent both echocardiography and
computed tomography within the month before randomization
to study therapy (atorvastatin 80 mg daily or placebo). Only
pre-intervention baseline data are presented here.
Echocardiography
The echocardiograms were all performed on an ATL-3000
cardiac ultrasound machine [Philips Medical Systems (UK)
Limited, Stevenage, UK] using a 3 MHz transducer for
M-mode, and two-dimensional imaging with integral pulsed
and continuous wave Doppler. The peak instantaneous aortic
valve gradient was determined using the modified Bernoulli
equation, and the aortic valve area by the continuity equation.
Aortic valve calcification was graded using the Rosenhek
classification [4], A single operator blinded to the results of
the computed tomogram performed all echocardiographic
examinations and analyses.
Computed Tomography
The computed tomography was performed using a multislice
helical scanner [Twin II Flash; Philips Medical Systems (UK)
Limited, Stevenage, UK]. The region of the aortic valve and
coronary arteries was assessed using 2.7 mm slices, with a pitch of
0.7 and an increment of 1.4 mm during held inspiration. Operators
blinded to the results of the echocardiogram performed all
examinations and analyses. CT scanner quality assurance was
performed before each examination with calibration against a
standard phantom. Off-line analysis of the cardiac images was
conducted using an automated, computerized software program
(Picker Cardiac Scoring). This employs a modified Agatston
scoring method [ 12] that uses a threshold of 90 HU to compensate
for non-gated imaging. This modification produces comparable
sensitivity and specificity to electron beam CT. Calcium scores
were individually calculated for the aortic valve, and all three
coronary arteries by summing the lesion scores for all sections
containing calcium.
Reproducibility
Two unselected random samples of 20 patients each were
taken from the study population. Subjects underwent repeated
computed tomography or echocardiography within 4 weeks of
the first examination and before administration of the study
medication.
Data Analysis and Statistics
Data are expressed as mean ± standard deviation of the
mean (SD). The calcium scores were not normally distributed
and are expressed as median with interquartile ranges. After
calibration with the study phantom, the aortic valve and
coronary artery calcium volume scores are expressed as
arbitrary units (AU). Reproducibility was assessed by the
method of Bland and Altman [13], and expressed as the mean
of the differences and the coefficient of repeatability (twice the
standard deviation of the differences). As the difference of
the two measures was proportional to their mean, the data for
the aortic valve calcium score underwent logarithmic trans¬
formation [13]. Data were compared using regression analysis
and analysis of variance (ANOVA) using StatView version
5.0.1 (SAS Institute Inc., Cary, NC, USA). Where ANOVA
demonstrated significant differences in responses, post-hoc
comparisons were made using the Fisher's protected least
squares difference (PLSD) test (StatView version 5.0.1).
Statistical significance was taken at the 5% level.
RESULTS
Patient characteristics arc listed in Table 1. In keeping with
the study population, patients were predominantly male, elderly
and had haemodynamically significant aortic stenosis. Both
echocardiography and computed tomography showed excellent
reproducibility (Table 2).
Table 1 - Baseline subject characteristics
Number 157
Age (years) 68 ± 11
Sex (male) 71%
Bicuspid aortic valve 5
Atrial fibrillation 11
Echocardiogram
Pre-valve velocity (m/s) 1.08 ± 0.22
Post-valve velocity (m/s) 3.45 ± 0.66
Peak gradient (mmHg) 49 ± 19
Mean gradient (mmHg) 27 ± 11
Valve area (cm2) 1.02 ± 0.40
Computed tomogram*






Mean ± SD; LAD, left anterior descending. AU, arbitrary units.
Median (interquartile range).
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All but two patients had significant aortic valve calcification
on computed tomography (Fig. 1). The median aortic valve
calcium score was 5858 AU. The majority of patients (107/157)
had detectable coronary artery calcification that predominantly
affected the left anterior descending coronary artery. There was
no correlation between the magnitude of the aortic valve and
total coronary calcium scores (r = 0.04, p = 0.61).
Comparison Between Echocardiography and
Computed Tomography
Echocardiographic grade of calcification correlated weakly
with the computed tomography aortic valve calcium score
(r = 0.29, p < 0.001) and the peak post-aortic valve velocity
(r = 0.40, p < 0.001). The computed tomography aortic valve
calcium score correlated strongly with the post-valve velocity
(r = 0.54, p < 0.0001: y = 0.00004;t + 3.09; Fig. 2) and the
mean (r = 0.54, p < 0.0001; y = 0.0008-t + 20.7) and peak
gradient (r = 0.54, p < 0.0001 : y = 0.0013x + 39.1) of the
aortic valve, but only weakly correlated with the aortic valve
area (r = 0.20, p = 0.01).
Stratifying the patients according to the quintilcs of
calcification demonstrated a progressive increase in the mean
peak post-aortic valve velocity (Fig. 3). All patients with severe
aortic valve stenosis (post-valve velocity >4 m/s) had an aortic
valve calcium score of >3700AU. This threshold gives a
sensitivity of 100% and specificity of 50% that translates into a
negative predictive value of 100% and a positive predictive
value of 39% for the detection of severe aortic stenosis. A
threshold of 6000 AU gives a sensitivity of 90% and specificity
of 66% giving a negative predictive value of 95% and a positive
predictive value of 45%.
DISCUSSION
In patients with aortic stenosis, we have demonstrated a
close association between the degree of aortic valve calcifica¬
tion and the haemodynamic severity of aortic stenosis. In
particular, the presence of severe and potentially critical aortic
stenosis is associated with heavy calcification. We suggest that
patients found to have incidental aortic valve calcification on
computed tomography require further cardiological assessment
for aortic stenosis, especially when there is heavy calcification.
This is the first study to compare aortic valve calcium scores
with echocardiogram-dcrived measures of valvular gradients in
a large number of patients with aortic stenosis. One previous
study of 19 patients also suggested that there may be an
association between the severity of aortic stenosis and
the valvular calcium score [14]. We have studied a larger
population with sufficient power to demonstrate a marked
correlation between these parameters. However, because of the
selected study population, these findings should only be
cautiously extrapolated to aortic valve calcification identified
during general population screening or as an incidental finding.
A recent retrospective study suggested a 20% incidence of
aortic valve calcification in over 2000 patients attending for
detection of coronary calcification [14], One retrospective
study of 109 such patients who had undergone both computed
tomography and echocardiography, reported a 30% prevalence
of aortic valve calcification in which aortic stenosis was
documented in 15% [II], In the absence of aortic valve
calcification, none of the patients had significant aortic valve
stenosis. In the current study, only two patients (1%) had no
detectable valvular calcification suggesting an excellent
negative predictive value. Our study findings additionally
suggest that the likelihood of significant valvular stenosis
increases with the severity of calcification.
Echocardiography is the mainstay of clinical monitoring for
aortic valve stenosis but provides only a subjective and semi¬
quantitative measure of aortic valve calcification. Computed
tomography provides a more accurate method of quantifying
calcium that more closely correlates with the aortic valve
gradient than echocardiography-derived measures of calcifica¬
tion. It may be useful to quantify more accurately the degree of
calcification given that it is the strongest independent risk
factor for disease progression and an adverse clinical outcome
[4], Further prospective studies are now needed to assess
whether the degree of calcification [15] provides useful
additional clinical information that would help guide patient
management. Indeed, it has been suggested that patients with
severe aortic stenosis and marked calcification should undergo
aortic valve replacement even in the absence of symptoms [4],
Aortic valve calcification is associated with an increased
cardiovascular mortality [16]. The underlying pathogenetic
process appears to share many of the features and risk factors
for atherosclerosis [2] including hypercholesterolemia [17,18]
that is associated with a more rapid progression of aortic valve
calcification [15]. There are several ongoing studies, including
the SALTIRE trial, that are assessing the impact of lipid-
lowering therapy on the rate of progression of aortic stenosis.
Given that statin use is associated with halting the progression
of coronary calcification [19], the present study indicates that
multislicc helical computed tomography is a valuable method
Table 2 - Reproducibility of echocardiographic and computed tomographic assessments of the aortic valve (« — 20)
Mean Mean of differences Standard deviation of differences Coefficient of repeatability
Echocardiogram
Post-valve velocity (m/s) 3.20 ± 0.11 0.0 0.16 0.32
Peak gradient (mmHg) 41.7 ± 3.0 0.0 4.1 8.2
Mean gradient (mmHg) 21.6 ± 1.8 0.2 3.8 7.6
Valve Area (cm2) 1.17 ± 0.10 0.06 0.39 0.78
Computed tomography*
Valve calcium score (pAU) 3.86 ± 0.49 0.01 0.04 0.07
*
Aortic valve calcium score has undergone logarithmic transformation.
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Fig. 1 - Representative computed tomograms showing mild, moderate and severe calcification of the aortic valve.
of assessing aortic valve calcification and disease progression
in such intervention trials. Indeed, one preliminary observa¬
tional study has suggested that statin use is associated with a
lower rate of progression of aortic valve calcification [20].
Using our methodology, we have found a close correlation
between echocardiographic measures of aortic stenosis and
aortic valve calcium scores measured by multislice helical
computed tomography. The applicability of our findings to
other CT machines with differing specifications, such as 2, 4 or
16 slice acquisitions, or imaging parameters, such as slice
thickness and pitch, is unknown. However, there is a high
degree of agreement between different machines and coronary
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Fig. 2 - Correlation of aortic valve calcification and peak post-aortic valve
velocity (r = 0.54, p < 0.001).
applicable to other computed tomography equipment. The
reference ranges of the aortic valve calcium scores are likely to
be dependent on the imaging protocol and CT equipment used.
However, broadly speaking, poorly defined or diffuse segments
of calcium usually represent a minor aortic valve gradient. In
contrast, coalescent calcium centred on the aortic valve is likely
to represent moderate stenosis whereas very heavy calcification
almost invariably represents a significant degree of valvular
stenosis (Fig. 1).
In conclusion, calcification of the aortic valve is closely
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Fig. 3 - Mean (±SD) post-aortic valve velocity in the quintiles of aortic
valve calcification. ANOVA p < 0.001. Fisher's PLSD test p < 0.03 for all
comparisons between the individual quintiles except quintile 1 vs quintile 2,
and quintile 3 versus quintile 4.
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calcification suggests the presence of severe aortic stenosis that
requires urgent cardiological assessment. Patients with lesser
degrees of aortic valve calcification should be screened for
aortic stenosis and monitored for disease progression.
Acknowledgements. This study was supported by a grant from the
British Heart Foundation (PG/2000/044) and the additional support of the
Wellcome Trust Clinical Research Facility in Edinburgh.
REFERENCES
1 Pomerance A. Pathogenesis of aortic stenosis and its relation to age. Br
Heart J, 1972;34:569-574.
2 Otto CM, Kuusisto J, Reichenbach DD, et al. Characterization of the
early lesion of "degenerative" valvular aortic stenosis: histologic and
immunohistochemical studies. Circulation, 1994;90:844-853.
3 Wagner S, Selzer A. Patterns of progression of aortic stenosis: a
longitudinal hemodynamic study. Circulation, 1982;65:709-712.
4 Rosenhek R, Binder T, Porenta G, et al. Predictors of outcome in severe,
asymptomatic aortic stenosis. N Engl J Med, 2000;343:611-617.
5 Davies SW, Gcrshlick AH, Balcon R. Progression of valvar aortic
stenosis: a long-term retrospective study. Eur Heart J, 1991;12:10-14.
6 Breen JF, Sheedy PF, Schwartz RS, et al. Coronary artery calcification
detected with ultrafast CT as an indication of coronary artery disease.
Radiology, 1992;185:435-439.
7 Mautner GC, Mautner SL, Froehlich J, et al. Coronary artery
calcification: assessment with electron beam CT and histomorpho-
metric correlation. Radiology, 1994;192:619-623.
8 Haberl R, Becker A, Leber A, et al. Correlation of coronary
calcification and angiographically documented stenoses in patients
with suspected coronary artery disease: results of 1764 patients. J Am
Coll Cardiol, 2001;37:451-457.
9 Mautner GC, Roberts WC. Reported frequency of coronary arterial
narrowing by angiogram in patients with valvular aortic stenosis. Am J
Cardiol, 1992;70:539-540.
10 Woodring JH, West JW. CT of aortic and mitral valve calcification. J Ky
Med Assoc, 1989;87:177-180.
11 Lippert JA, White CS, Mason AC, Plotnick GD. Calcification of aortic
valve detected incidentally on CT scans: prevalence and clinical
significance. AJR Am J Roentgenol, 1995;164:73-77.
12 Shemesh J, Apter S, Rozenman J, et al. Calcification of coronary
arteries: detection and quantification with double-helix CT. Radiology,
1995;197:779-783.
13 Bland JM, Altman DG. Statistical methods for assessing agreement
between two methods of clinical measurement. Lancet, 1986;i:
307-310.
14 Kizer JR, Gefter WB, deLemos AS, et al. Electron beam computed
tomography for the quantification of aortic valvular calcification.
J Heart Valve Dis, 2001;10:361-366.
15 Pohle K, Mafifert R, Ropers D, et al. Progression of aortic valve
calcification: association with coronary atherosclerosis and cardiovas¬
cular risk factors. Circulation, 2001;104:1927-1932.
16 Otto CM, Lind BK, Kitzman DW, et al. Association of aortic valve
sclerosis with cardiovascular mortality and morbidity in the elderly. N
Engl J Med, 1999;341:142-147.
17 Wilmshurst PT, Stevenson RN, Griffiths H, Lord JR. A case control
investigation of the relation between hyperlipidaemia and calcific aortic
valve stenosis. Heart, 1997;78:475-479.
18 Chui MCK, Newby DE, Panarelli M, et al. Association between calcific
aortic stenosis and hypercholesterolemia: is there a need for a
randomised controlled trial of cholesterol lowering therapy? Clin
Cardiol, 2001;24:52-55.
19 Callister TQ, Raggi P, Cooil B, et al. Effect of HMG-CoA reductase
inhibitors on coronary artery disease as assessed by electron-beam
computed tomography. N Engl J Med, 1998;339:1972-1978.
20 Shavelle DM, Takasu J, BudoffMJ, et al. HMG CoA reductase inhibitor
(statin) and aortic valve calcium. Lancet, 2002;359:1125-1126.
21 Carr JJ, Crouse JR, Goff DC, et al. Evaluation of subsecond gated
helical CT for quantification of coronary artery calcium and comparison
with electron beam CT. AJR Am J Roentgenol, 2000;174:915-921.
Age and Ageing Advance Access published August 12, 2004
Age and Ageing Age and Ageing © British Geriatrics Society 2004; all rights reserved
doi: 10.1093/ageing/afh 175
REVIEW
Calcific aortic stenosis: same old story?
S. Joanna Cowell', David E. Newby2, Nicholas A. Boon', Andrew T. Elder3
' Department of Cardiology, Royal Infirmary, 5 I Little France Crescent, Edinburgh EH 16 4SA, UK
2Chancellor's Building, Royal Infirmary, 49 Little France Crescent, Edinburgh EH 16 4SB, UK
department of Medicine for the Elderly, Western General Hospital, Crewe Road, Edinburgh EH4 2XU, UK
Address correspondence to: S. J. Cowell. Fax: (+44) 13 I 242 6422. Email: jo.cowell@ed.ac.uk
Abstract
Calcific aortic stenosis is the commonest adult valvular heart condition seen in the western world. Its prevalence is continu¬
ing to rise, with predominance in older patients who are frequendy undergoing successful aortic valve replacement. This
review discusses the natural history of calcific aordc stenosis, highlights recent insights into its pathogenesis, and oudines
current medical and surgical management. The potential role of novel therapeutic interventional strategies is discussed.
Keywords: aortic stenosis, aetiology, pathogenesis, management, medical therapy, elderly
Introduction
Aortic stenosis is the commonest adult heart valve condition
seen in the western world. Over the last 30-50 years, its
diagnosis and management have been revolutionised by the
development of invasive (cardiac catheterisation) and non¬
invasive (echocardiography) haemodynamic assessments as
well as potentially curative cardiac surgery. Recent insights have
been made into the pathogenesis of calcific aortic stenosis,
resulting in speculation that the disease mimics atheroscle¬
rosis and progression could be delayed or prevented by the use
of lipid lowering therapy. This exciting concept is currently
under investigation in a number of centres and, if success¬
ful, may potentially reduce the need for aortic valve surgery.
Epidemiology
Calcific aortic stenosis was first documented in 1904 [1] and
at that time was regarded as uncommon. In the 19th cen¬
tury, calcific aortic stenosis was not recognised as a clinical
entity since pathological studies revealed only cusp thicken¬
ing and sclerosis [2]. As a result, aortic valve sclerosis (thick¬
ening without stenosis) and aortic valve stenosis were regarded
as different pathological conditions for many decades.
Recent evidence, however, suggests that they represent dif¬
ferent stages of the same disease process [3-5]: sclerosis
arising from the development of valvular calcific lesions
that progress slowly over several decades before ultimately
causing aortic stenosis [6]. The current prominence of cal¬
cific aortic valve disease is likely to represent increased
human longevity associated with the declining prevalence of
rheumatic fever.
Aortic valve sclerosis is present in 20-30% of individu¬
als over 65 years and 48% over 85 years [7], and aortic sten¬
osis in 2% and 4%, respectively [3, 7, 8], Calcific sclerosis
and valvular stenosis occur in patients with both a normal
tricuspid aortic valve as well as in those with a bicuspid
valve. The prevalence of bicuspid aortic valves is difficult to
determine but is estimated to affect 1-2% of the general
population [9], Up to 70% of patients with a bicuspid aortic
valve develop valvular stenosis [9] and will require aortic
valve replacement 1—2 decades earlier in life (5th—6th decade)
than in those with a tricuspid aortic valve.
Natural history
Prior to the introduction of haemodynamic assessment and
cardiac surgery, the natural history of aortic stenosis was
described by its clinical presentation. Calcific aortic stenosis
is a gradually progressive disease, characterised by a long
asymptomatic phase lasting several decades, followed by a
shorter symptomatic phase usually associated with severe
narrowing of the aortic valve orifice.
The outlook for patients with asymptomatic aortic stenosis
is generally good and closely matches that of life table esti¬
mates for age- and sex-matched controls [10]. A striking feature
of aortic stenosis is that the prognosis changes dramatically
with the onset of symptoms in association with severe out¬
flow obstruction: a 2-year survival rate of 50%. Although few
studies specifically assessed the influence of age, patients
over the age of 70 have a worse prognosis with 2- and 3-year
survival rates of 37% and 25%, respectively [11]. The
prognosis also depends upon the clinical presentation with a
mean survival of 3 years for those presenting with angina
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and syncope, 2 years with the onset of breathlessness, and
as little as 1 year in those who develop overt left ventricular
failure [12, 13],
Other cardiovascular events
Despite the favourable outlook in those patients with mild
asymptomatic disease, there is an increased risk of cardio¬
vascular events unrelated to the aortic valve disease. Otto
and colleagues demonstrated that, in patients with aortic
sclerosis, there is a 50% increased risk of myocardial infarc¬
tion and cardiovascular death even in the absence of signi¬
ficant outflow tract obstruction [7]. The Helsinki Aging
Study also suggested that patients with moderate to severe
aortic stenosis had higher all cause and cardiovascular mor¬
tality irrespective of associated symptoms. In particular, a
higher rate of stroke related death was noted although the
majority of these patients had atrial fibrillation [14].
Pathology of calcific aortic stenosis
For many decades, calcific aortic stenosis has been attri¬
buted to prolonged 'wear and tear' and age-associated val¬
vular degeneration. Contrary to this supposition, however,
is the absence of aortic valve calcification or stenosis on
echocardiography in a third of individuals over the age of
80 [8]. Recent evidence suggests that calcific aortic stenosis
may result from an active inflammatory process involving
biochemical, humoral and genetic factors.
Histology
Normal aortic valve leaflets are macroscopically smooth,
thin and opalescent, with clearly defined tissue layers at a
microscopic level and very few cells [15]. Increasing age
gives rise to non-specific thickening of the tips of the valve
leaflets, with an increase in the number of adipose cells and
thinning of tissue layers [16]. In calcific aortic stenosis, there
is characteristic leaflet thickening, with irregular nodular
masses on the aortic aspect of the valve. Microscopic
assessment of both mild and severely affected valves reveals
endothelial and basement membrane disruption, with
underlying subendothelial thickening. The lesion itself con¬
tains disorganised collagen fibres, chronic inflammatory
cells, lipoproteins, lipid, extracellular bone matrix proteins
and bone mineral [15, 16].
Pathogenesis
The histological features described closely resemble those
seen in atherosclerosis and are strongly suggestive of chronic
inflammation. In calcific aortic stenosis, the factors initiat¬
ing the inflammatory process have not been identified but
mechanical injury to the endothelium is thought to pave the
way for subsequent inflammation. This concept is supported
by the pattern of aortic valve cusp involvement that corres¬
ponds to areas of low shear and high tensile stress: namely
the aortic surface of the leaflets and predilection for the
non-coronary cusp [17-20]. Congenitally bicuspid aortic
valves are less efficient than tricuspid valves at distributing
mechanical stress and this may account for the more rapid
development of stenosis [21].
Role of lipids
Endothelial injury or disruption may allow circulating lipids
to enter the valvular interstitial tissue [22] and accumulate in
areas of calcification and inflammation [22, 23], The lipo¬
proteins implicated in atherogenesis, including low-density
lipoprotein (LDL) and lipoprotein (a), are present in early
aortic valve lesions [22] and undergo oxidative modification
[23], These oxidised lipoproteins are highly cytotoxic [24]
and capable of stimulating inflammatory activity [25, 26]
and mineralisation [27-29],
Inflammation
Both macrophages and activated T lymphocytes are present
in the early and advanced lesions of congenitally bicuspid
[30] and tricuspid aortic valves [15, 16]. Migration of these
effector inflammatory cells appears to be mediated through
increased endothelial expression of cellular adhesion mole¬
cules such as E-selectin, intercellular adhesion molecule-1
(ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1)
[31, 32]. Once recruited into the subendothelium, the
inflammatory cells release enzymes, such as matrix metallo-
proteinases, that cause degradation of collagen, elastin and
proteoglycans within the aortic valve cusps [33],
Calcification
Mineralisation is a characteristic of both atherosclerotic and
aortic valve lesions, and arises in close proximity to areas of
inflammation. It is a prominent feature in calcific aortic
stenosis and has been demonstrated in early [16] as well as
advanced lesions [34]. Surgically excised valves have even
revealed areas of mature lamellar bone, haemopoietic mar¬
row and bone remodelling [34]. Several features suggest the
presence of an active highly regulated process closely
resembling developmental bone formation [35, 36],
The initiation of mineralisation (nucleation) may be
stimulated by the presence of cellular degradation products
following apoptosis [37] or by the presence of oxidised
lipids [23, 34]. In vitro studies of cultured explants of stenotic
valves have identified cells with osteoblastic characteristics
capable of phenotypic differentiation and spontaneous
calcification [38], Their origin is unknown but they may be
derived from a pool of circulating immature pluripotent
mesenchymal cells [39]. These osteogenic cells or 'calcifying
valvular cells' express and produce a variety of regulatory
bone matrix proteins including osteopontin [40, 41] and
bone morphogenetic protein [34],
Similarities and differences with atherosclerosis
Although the similarities with atherosclerosis were recog¬
nised as long ago as 1917 [42], they were largely disregarded
until recendy [43—45]. The histological studies described
above have highlighted the common features but also con¬
firmed differences in the cellular and mineral components
of the two lesions.
Smooth muscle proliferation and lipid-laden macro¬
phages (or foam cells) are prominent features of vascular
atheroma but are virtually absent in stenotic aortic valves. In
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addition, mineralisation is an earlier and more extensive fea¬
ture of aortic valve lesions compared with atherosclerosis
[16]. These differences may, in part, explain why only 40%
of patients with severe aortic stenosis have significant coro¬
nary artery disease [46-50] and why the majority of patients
with coronary artery disease do not have aortic stenosis. As the
underlying pathology for the two conditions appears to be
similar, it is likely that other unknown factors influence the
development of valvular as opposed to vascular lesions [51].
Clinical presentation
Padents present with either an incidentally noted asympto¬
matic systolic murmur or with symptoms of severe disease
including angina, exertional syncope, breathlessness, and
reduced exercise tolerance or lethargy. In simple terms, pro¬
gressive obstruction to outflow results in a gradual rise in
left ventricular pressures, left ventricular hypertrophy, and
diastolic dysfunction. Once the degree of stenosis is severe,
further small decreases in aortic valve area result in large
changes in the pressure gradient across the valve. Symptoms
and decompensation arise due to the development of inade¬
quate cardiac reserve, myocardial oxygen demand mismatch
or pressure overload of the left ventricle. Symptoms rarely
occur unless the degree of stenosis is of at least moderate
severity (with an aortic valve area of less than 1.0 cm2) but
patients may remain asymptomatic for long periods with
even very severe stenosis [46].
Clinical risk factors
In keeping with the apparent parallels with atherosclerosis,
calcific aortic stenosis is associated with coronary artery
disease [48, 50] and many of its risk factors (Table 1) [3].
Calcific aortic stenosis is also seen in association with severe
homozygous familial hypercholesterolaemia, and its devel¬
opment appears to be influenced by the length of exposure
to elevated serum cholesterol concentrations [52]. Interest-
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ingly, aggressive lipid lowering therapy with plasmapheresis
has been reported to regress aortic stenosis in such patients
[53]. Milder forms of hypercholesterolaemia have also been
associated with calcific aortic stenosis [54, 55, 56], particu¬
larly in patients with non-rheumatic tricuspid valves [54],
Conditions affecting calcium metabolism, such as chronic
renal impairment with secondary hyperparathyroidsim [57—
59] and advanced Paget's disease [60], predispose individuals
to aortic valve calcification and accelerated stenosis. Such
patients also tend to have diffuse cardiac calcification affect¬
ing the mitral valve, myocardium and conducting system.
A number of twin studies and case reports suggest that
hereditary factors may influence the development of calcific
aortic valve stenosis [61, 62]. There has been a single report
of a genetic association between aortic stenosis and a vita¬
min D receptor polymorphism [63] but this finding has yet
to be confirmed.
Investigations
The assessment of valvular stenosis and monitoring of dis¬
ease progression has only been possible over the last five
decades using cardiac catheterisation, echocardiography and
more recently magnetic resonance (MR) imaging and com¬
puted tomography (CT). Magnetic resonance may have
some advantages over echocardiography in assessment of
stenosis severity [64], but its availability is limited and meas¬
urements are time consuming to perform. Although cur¬
rently limited to clinical research, CT has recently been
validated as an accurate means of quantifying aortic valve
calcification, a measure that correlates well with the severity
of stenosis estimated by echocardiography [65]. Echocardi¬
ography remains the current gold standard for monitoring
of disease progression and left ventricular function in
patients with aortic stenosis.
The severity of aortic valve stenosis is assessed using
both two-dimensional and Doppler echocardiography
(Table 2). Narrowing of the aortic valve orifice results in
acceleration of blood flow across the valve. Using spectral
Doppler, the velocity of blood passing through the left
ventricular outflow tract (pre-valve) and aortic valve orifice
(post-valve) can be measured and is usually expressed in
metres per second. The peak instantaneous pressure gradi¬
ent across the aortic valve has a simple relationship with the
peak post-valve velocity and is described as four times the
square of the velocity (modified Bernoulli equation). For
example, a peak post-valve velocity of 4m/s gives an
instantaneous pressure gradient of 4 x 42=64mmHg. Where
there are concerns that impaired left ventricular function
limits the ability to generate an adequate pressure gradient
across the valve, measurement of the aortic valve area may
Table 2. Echocardiographic measures of severity of aortic stenosis (AS)
Normal Mild AS Moderate AS Severe AS
Peak post-valve velocity (m/s) 0.9-1.8 2.5-3.0 3.0-4.0 >4.0
Peak gradient (mmHg) <25 25-36 36-64 >64
Aortic valve area (em2) 2.0-3.5 1.0-2.0 0.5-1.0 <0.5
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need to be made using direct planimetry or indirectly using
the continuity equation. On occasions, dobutamine stress
echocardiography may be used as method of distinguishing
true aortic stenosis causing left ventricular dysfunction from
aortic pseudostenosis where the impairment of the left ven¬
tricle causes poor excursion of the aortic valve cusps giving
the impression of stenotic valvular restriction.
Disease progression
Echocardiography provides the most accurate evaluation
of disease progression, which can be unpredictable and
extremely variable. Some individuals show little or no evid¬
ence of deterioration over time, yet others progress rapidly
from mild to severe stenosis within a few years.
In patients with aortic valve sclerosis, progression to ste¬
nosis (arbitrarily defined as a peak post-valve velocity >2.5m/s,
or peak gradient >25mmHg) is a relatively slow process
with mean increases in peak post valve velocity and peak
gradient of 0.07m/s and 1.4mmHg per year, respectively [66].
However, once the valve is classified as stenotic, disease
progression is more rapid with average increases of 0.3 m/s
and 7—8mmHg per year, corresponding to a decrease in
aortic valve area of 0.1 cm2 per year [67-71],
Predictors of progression and clinical outcome
Disease progression and clinical outcome have been linked
to many of the risk factors for calcific aortic stenosis,
including age, male sex, hyperlipidaemia, hypertension, dia¬
betes mellitus, smoking, hypercalcaemia and chronic renal
impairment [69, 72, 73-75]. However, much of the evidence
is conflicting and limited by the retrospective nature of the
studies. The most consistent and strongest predictors of
disease progression are severity of stenosis at baseline [71]
and degree of valvular calcification [72, 76, 77]. The more
severe the stenosis at baseline and the more heavily calcified
the valve, the faster the rate of progression. Clinical outcome
is also influenced by the degree of valvular calcification,
with nearly 80% of patients with moderate to severe calcifi¬
cation who progress rapidly (>0.3m/s/yr) either dying or
undergoing aortic valve replacement within 2 years [77].
Management of calcific aortic stenosis
At the present time, there is no known therapy that can slow
or reverse disease progression in patients with calcific aortic
stenosis. Current management includes monitoring disease
progression, and ensuring patient awareness of the need for
antibiotic prophylaxis against infective endocarditis. For
those patients with severe symptomatic disease, the thera¬
peutic options include conventional medical therapy for
symptom control and aortic valve replacement.
General advice
All patients should be advised of the need for antibiotic
prophylaxis against endocarditis for dental and other inva¬
sive procedures. Patients with moderate or severe disease
should be advised to avoid strenuous physical exercise and
competitive sport, and to report prompdy the onset of
symptoms.
Monitoring of disease progression
Since disease progression is so unpredictable, the majority
of patients should be reviewed regularly to monitor changer,
in stenosis severity and watch for the onset of symptoms.
As a rule of thumb, asymptomatic patients with mild to
moderate stenosis require review and echocardiography every
1—2 years, and those with moderate to severe stenosis every
6 12 months. Patients developing symptoms between app¬
ointments should be reviewed immediately.
Asymptomatic severe aortic stenosis
One contentious area of management is determining the
optimal timing for aortic valve replacement. It is universally
accepted that surgery is indicated as soon as symptoms
appear in patients with severe stenosis. Although many
cardiologists are loath to refer patients without symptoms
for valve surgery, there are some who feel uncomfortable
managing patients with severe asymptomatic valvular steno¬
sis because of the potential risk for sudden cardiac death.
However, this is rare and occurs in less than 1% of asymp¬
tomatic patients per year [78]. The combined risk of aortic
valve replacement (2—10% mortality) and prosthesis-related
complications (2-3%/year) is thus greater than the risk of
sudden cardiac death. "Watchful waiting' is therefore recom¬
mended.
The onset of symptoms in patients with severe stenosis
may be subtle and insidious, particularly in the elderly where
co-morbidity may mislead or obscure the presentation. For
this reason careful history taking for changes in exercise tol¬
erance as well as the classical symptoms of breathlessness,
chest pain and syncope is required. In cases where patients
may be underplaying symptoms, attributing them to 'old
age', or unknowingly avoiding activity that induces symp¬
toms, physician supervised exercise testing may be helpful
in both revealing symptoms as well as determining the
haemodynamic response to exercise. Patients who develop
symptoms during exercise, become hypotensive, manifest
marked ST segment changes or develop ventricular arrhyth¬
mias are at high risk and should be referred for valve
replacement [79-81],
Symptomatic severe aortic stenosis
As soon as patients with severe aortic stenosis develop
symptoms the treatment of choice is aortic valve replace¬
ment because this substantially improves quality of life and
prognosis. In those patients declining valve surgery, or the
frail elderly in whom major cardiac surgery would be
inappropriate, palliation with conventional medical therapy,
or in exceptional circumstances, balloon valvotomy are the
only alternatives. Percutaneous aortic valve replacement is a
promising new technique that is currently under develop¬
ment in highly selected patient populations [82, 83],
Medical therapy
Breathlessness
Patients with evidence of pulmonary congestion may bene¬
fit from the judicious use of diuretics, vasodilators and
positive inotropic agents such as digoxin. Excessive use of
diuretics should be avoided since patients with severe aortic
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stenosis often have diastolic dysfunction and depend on an
adequate pre-load in order to maintain their cardiac output.
Despite the widespread belief that ACE inhibitors can
cause dangerous hypotension in severe aortic stenosis, and
are therefore contraindicated, there are little data to support
this. From the limited literature available, two small studies
demonstrated that first dose hypotension did not occur in
patients with severe aortic stenosis, and that cardiac output
and symptoms improved substantially [84, 85]. Although
further study is required, some patients with heart failure
and severe aortic stenosis could benefit from ACE inhibi¬
tors provided that they are carefully introduced in a hospital
setting. Certainly those patients already established on ther¬
apy need not have it withdrawn since this may precipitate
the onset of heart failure.
Digoxin can be helpful in the management of heart failure
but should only be used in the presence of atrial fibrillation or
where there is documented evidence of left ventricular sycto
lie dysfunction. Atrial fibrillation is not well tolerated in the
presence of severe stenosis and restoration to sinus rhythm
(through DC cardioversion or pharmacological cardioversion
using amiodarone) should be attempted wherever possible.
Angina
In those individuals where angina is the predominant symp¬
tom, cautious use of beta blockers and nitrates may be of
benefit.
Syncope
Patients with syncope or pre-syncope should be further
evaluated with a 24-hour cardiac monitor since aortic stenosis
is commonly associated with atrioventricular block. There in
no specific therapy for syncope unless it is caused by a brady-
arrhythmia or tachyarrhythmia, where pacemaker insertion
or antiarrhythmic therapy, respectively, should be considered.
Balloon valvotomy
Although balloon valvotomy plays an important role in the
management of adolescents and young adults with aortic
stenosis, it has largely been abandoned in older patients.
The functional improvement obtained is limited, the re¬
stenosis and complication rates are high, and the long term
outlook poor (<80% survival at 1 year) [78, 86]. On rare
occasions, balloon valvotomy may play a role in patients
with a limited life expectancy for other reasons, or as a
budge to aortic valve replacement in critically ill patients
with cardiogenic shock.
Aortic valve replacement
Aortic valve replacement incurs the virtual abolition of
symptoms associated with improvements in physical fun¬
ctioning and quality of life, and a dramatic improvement in
survival. Operative mortality in middle-aged adults is in the
region of 5-8% [87, 88, 89] with 5- and 10-year survival
rates of approximately 80% [87, 90] and 65%, respectively
[87], which approaches actuarial survival rates for the gen¬
eral population 187].
Factors associated with a higher operative mortality
include increasing age [91], the presence of renal impairment,
cerebrovascular and peripheral vascular disease [92], the
presence of impaired left ventricular function [91], and the
need for simultaneous coronary artery bypass grafting [88].
Despite the increased operative risk associated with the
presence of left ventricular failure, this is not an absolute
contra-indication to surgery. Indeed these patients may have
the most to gain from valve surgery in terms of improvements
in prognosis.
Aortic valve replacement in octogenarians
Successful aortic valve replacement is becoming increas¬
ingly common in patients over the age of 80. Despite evid¬
ence suggesting that it should be offered to all suitable
patients regardless of age, several studies have demonstrated
a reluctance to refer older patients for valve surgery [8, 93, 94].
This probably reflects both patient and physician miccon
ceptions of the risks and benefits of operative intervention.
Although operative mortality is higher in octogenarians
(nearer 5-15%), these individuals have almost as much to
gain as their younger counterparts in terms of improved
prognosis (5-year survival being 55-70%). Of perhaps
greater importance is that the majority of survivors achieve
a significant reduction in symptoms [92, 95, 96, 97, 98] asso¬
ciated with a marked improvement in physical functioning
and quality of life [88, 95, 96, 98], Although intensive care
[92, 98] and overall hospital stay [95, 97, 98] may be longer,
the majority return to their own homes and retain their
independence on discharge [92, 95]. However, post-operative
complications are more common with a higher incidence
particularly of stroke (4%) and acute renal failure (7-10%)
[98]. In contrast to younger patients, octogenarians are usu¬
ally offered a bioprocthetic (as opposed to a mechanical)
valve, thus reducing the risk of valve thrombosis and anti¬
coagulant associated haemorrhage.
Potential role for HMG CoA reductase inhibitors
Hydroxymethylglutaryl coenzyme A (HMG CoA) reduct¬
ase inhibitors or statins are now well established in the
primary and secondary prevention of coronary artery dis
ease [99, 100]. Several studies have also shown that these
drugs can cause regression of coronary artery disease [101]
as well as reduce the calcific volume of coronary plaques
[102], Given the clinical association of calcific aortic steno¬
sis with hyperlipidaemia and coronary artery disease, and
the striking histological similarities with atheroma, the
speculation that statins may have the potential to influence
disease progression in aortic stenosis is an intriguing
hypothesis [103, 104].
Recent retrospective studies [105-109] have demon¬
strated that statins may delay disease progression in aortic
stenosis through their lipid-lowering and anti-inflammatory
actions [109], These observational data should be interpreted
with caution since none of these studies was randomised,
and the statin doses were small. This preliminary evidence
has been the rationale for establishing several ongoing
randomised controlled trials of statin therapy in patients
with aortic stenosis, such as the Scottish Aortic stenosis and
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Lipid lowering Therapy, Impact on REgression (SALTIRE)
and Simvastatin and Ezetimibe in Aortic Stenosis (SEAS)
trials.
Conclusion
The need for an alternative to aortic valve surgery is high¬
lighted by the increasing longevity of the population and ris¬
ing prevalence of aortic stenosis. New therapeutic strategies
to limit disease progression are needed in order to delay,
and potentially avoid, the need for valve surgery. The out¬
comes of several ongoing randomised controlled trials
investigating the role of lipid-lowering therapy in aortic ste¬
nosis are awaited with interest.
Key points
• Aortic stenosis is increasingly common.
• Severe aortic stenosis in the presence of symptoms car¬
ries a very poor prognosis.
• Aortic valve replacement dramatically improves survival
and quality of life, even in octogenarians.
• Too few older patients are offered aortic valve replacement.
• Lipid-lowering therapy may have a potential role in the
prevention of disease progression.
Conflicts of interest declaration
The authors are currently involved in the SALTIRE trial
funded by the British Heart Foundation with an additional
educational grant award from Pfizer (IIK) Limited, as well
as the SEAS study which is sponsored by Merck Sharp and
Dohme Limited.
Please note
The very long list of references supporting this review has
meant that only the most important are listed here and are
represented by bold type throughout the text. The full list of
references is available on the journal website (http://www.
ageing.oupjournals.org).
References
3. Stewart BF, Siscovick D, Lind BK ct al. for the Cardiovascular
Health Study. Clinical factors associated with calcific aortic
valve disease. J Am Coll Cardiol 1997; 29: 630—4.
7. Otto CM, Lind BK, Kitzman DW, Gersch BJ, Siscovick DS.
Association of aortic-valve sclerosis with cardiovascular mor¬
tality and morbidity in the elderly. N Engl J Med 1999; 341:
142-7.
8. Lindroos M, Kupari M, Heikkila J, Tilvis R. Prevalence of aor¬
tic valve abnormalities in the elderly: an echocardiographic
study of a random population sample. J Am Coll Cardiol 1993;
21: 1220-5.
14. livanainen AM, Lindroos M, Tilvis R, Heikkila, Kupari M.
Natural history of aortic valve stenosis of varying severity in
the elderly. Am J Cardiol 1996; 78: 97—101.
16. Otto CM, KuusistoJ, Reichenbach DD, Gown AM, O'Brien
KD. Characterization of the early lesion of 'degenerative' val¬
vular aortic stenosis: histologic and immunohistochemical
studies. Circulation 1994; 90: 844—53.
22. O'Brien KD, Reichenbach DD, Marcovina SM, Kuusisto J,
Alpers CE, Otto CM. Apolipoprotein B, (a), and E accumulate
in the morphologically early lesion of 'degenerative' valvular aor¬
tic stenosis. Arterioscler Thromb Vase Biol 1996; 16: 523-32.
23. Olsson M, ThybergJ, Nilsson J. Presence of oxidised low den¬
sity lipoprotein in nonrheumatic stenotic aortic valves. Arteri¬
oscler Thromb Vase Biol 1999; 19: 1218—22.
29. Parhami F, Morrow AD, Balucan J et al. Lipid oxidation prod¬
ucts have opposite effects on calcifying vascular cell and bone
cell differentiation. A possible explanation for the paradox of
arterial calcification in osteoporotic patients. Arterioscler
Thromb Vase Biol 1997; 17: 680-7.
34. Mohler ER 3rd, Gannon F, Reynolds C, Zimmerman R,
Keane MG, Kaplan FS. Bone formation and inflammation in
cardiac valves. Circulation 2001; 103: 1522-8.
36. Demer LL. A skeleton in the atherosclerosis closet. Circu¬
lation 1995; 92: 2029-32.
45. Demer LL. Cholesterol in vascular and valvular calcification.
Circulation 2001; 104: 1881—3.
50. Peltier M, Trojette F, Sarano ME, Grigioni F, Slama MA,
Tribouilloy CM. Relation between cardiovascular risk factors
and nonrheumatic severe calcific aortic stenosis among
patients with a three-cuspid aortic valve. Am J Cardiol 2003;
91:97-9.
51. Otto CM, O' Brien KD. Why is there discordance between
calcific aortic stenosis and coronary artery disease? Heart
2001; 85: 601-2.
54. Chui MC, Newby DE, Panarelli M, Bloomfield P, Boon NA.
Calcific aortic stenosis and hypercholesterolemia: a causal
association? Heart 1999; 81:171.
65. Cowell SJ, Newby DE, Burton J et al. Aortic valve calcification
on computed tomography predicts the severity of aortic steno¬
sis. Clin Radiol 2003; 58: 712—6.
66. Faggiano P, Antonini-Canterin F, Erlicher A et al. Progression
of aortic valve sclerosis to aortic stenosis. Am J Cardiol 2003;
91: 99-101.
71. Otto CM, Burwash IG, Legget ME ct al. Prospective study of
asymptomatic valvular aortic stenosis. Clinical, echocardio¬
graphic, and exercise predictors of outcome. Circulation 1997;
95: 2262-70.
73. Palta S, Pai AM, Gill KS, Pai RG. New insights into the
progression of aortic stenosis. Implications for secondary pre¬
vention. Circulation 2000; 101: 2497—502.
77. Rosenhek R, Binder T, Porenta G et al. Predictors of outcome
in severe, asymptomatic aortic stenosis. N Engl J Med 2000;
343:611-17.
78. Bonow RO, Carabello B, de Leon AC ct al. ACC/AHA guide
lines for the management of patients with valvular heart dis¬
ease. J Am Coll Cardiol 1998; 32: 1486-588.
81. Carabello BA. Evaluation and management of patients with
aortic stenosis. Circulation 2002; 105: 1746—50.
87. Linblom D, Lindblom U, Qvist J, Lundstrom. Long-term sur¬
vival rates after heart valve replacement. J Am Coll Cardiol
1990; 15: 566-73.
88. Sprigings DC, Forfar JC. How should we manage symp¬
tomatic aortic stenosis in the patient who is 80 or older? Br
Heart J 1995; 74: 481-4.
93. Bouma BJ, van den Brink RBA, van der Meulen JHP et al. To
operate or not on elderly patients with aortic stenosis: the
decision and its consequences. Heart 1999; 82: 143—8.
Page 6 of 7
Calcific aortic stenosis
94. Abdul-Hamid AR, Mulley GP. Why do so few older people
with aortic stenosis have valve replacement surgery? Age
Ageing 1999; 28: 261-4.
97. Kohl P, Kerzmann A, Lahaye L, Gerard P, Limet R. Cardiac
surgery in octogenarians. Peri-operative outcome and long-
term results. Eur Heart J 2001; 22: 1235—43.
98. Sundt TM, Bailey MS, Moon MR et al. Quality of life after
aortic valve replacement at the age of >80 years. Circulation
2000; 102 (Suppl III): 11170-74.
103. Pearlman AS. Medical treatment of aortic stenosis. Promis¬
ing, or wishful thinking? J Am Coll Cardiol 2002; 40:1731—4.
104. Mohler ER. Are atherosclerotic processes involved in aortic
valve calcification? Lancet 2000; 356: 524—5.
109. Bellamy MF, Pellikka PA, Klarich KW, TajikAJ, Enriquez-
Sarano M. Association of cholesterol levels, Hydroxymethyl-
glutaryl coenzyme-A reductase inhibitor treatment, a progression
of aortic stenosis in the community. J Am Coll Cardiol 2002;
40:1723-30.
Received 17 September 2003; accepted 8 April 2004
Page 7 of 7
The NEW ENGLAND JOURNAL ofMEDICINE
ORIGINAL ARTICLE
ARandomizedTrial oflntensive Lipid-Lowering
Therapy in Calcific Aortic Stenosis
S. Joanna Cowell, B.M., David E. Newby, M.D., RobinJ. Prescott, Ph.D.,
Peter Bloomfield, M.D., John Reici, M.B., Ch.B., David B. Northridge, M.D.,
and Nicholas A. Boon, M.D., for the Scottish Aortic Stenosis
and Lipid Lowering Trial, Impact on Regression (SALTIRE) Investigators
ABSTRACT
BACKGROUND
Calcific aortic stenosis has many characteristics in common with atherosclerosis, in¬
cluding hypercholesterolemia. We hypothesized that intensive lipid-lowering therapy
would halt the progression ofcalcific aortic stenosis or induce its regression.
METHODS
In this double-blind, placebo-controlled trial, patients with calcific aortic stenosis were
randomly assigned to receive either 80 mg ofatorvastatin daily or a matched placebo.
Aortic-valve stenosis and calcification were assessed with the use ofDoppler echocardi¬
ography and helical computed tomography, respectively. The primary end points were
change in aortic-jet velocity and aortic-valve calcium score.
RESULTS
Seventy-seven patients were assigned to atorvastatin and 78 to placebo, with a median
follow-up of 25 months (range, 7 to 36). Serum low-density lipoprotein cholesterol
concentrations remained at 130130 mg per deciliter in the placebo group and fell to
63123 mg per deciliter in the atorvastatin group (P<0.001). Increases in aortic-jet
velocity were 0.199+0.210 m per second per year in the atorvastatin group and
0.20310.208 m per second per year in the placebo group (P=0.95; adjusted mean dif¬
ference, 0.002; 95 percent confidence interval, -0.066 to 0.070 m per second per year).
Progression in valvular calcification was 22.3121.0 percent per year in the atorvastatin
group, and 21.7119.8 percent per year in the placebo group (P=0.93; ratio of post-
treatment aortic-valve calcium score, 0.998; 95 percent confidence interval, 0.947 to
1.050).
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CONCLUSIONS
Intensive lipid-lowering therapy does not halt the progression ofcalcific aortic steno¬
sis or induce its regression. This study cannot exclude a small reduction in the rate of
disease progression or a significant reduction in major clinical end points. Long-term,
large-scale, randomized, controlled trials are needed to establish the role ofstatin ther¬
apy in patients with calcific aortic stenosis.
N ENGL J MED 352;23 WWW.NEJM.ORG JUNE 9, 2005 2389
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■jr N THEWESTERN WORLD, CALCIFIC AORTIC
stenosis is the most common form ofvalvular
heart disease, and its incidence increaseswith
age such that 3 percentofadults over 75 years ofage
have aortic stenosis.1 It is a gradually progressive
disease, characterized by a long asymptomatic
phase, lasting several decades, followed by a shorter
symptomatic phase associated with severe narrow¬
ingofthe orifice ofthe aortic valve. Once symptoms
occur, the prognosis is poor and surgery is usually
mandated. Calcific aortic stenosis is now the lead¬
ing indication for valve replacement in North Amer¬
ica and Europe. However, there are currently no
effective disease-modifying treatments, and the
possibility of halting the disease process would
represent a therapeutic advance.
Calcific aortic stenosis is mediated by a chronic
inflammatory disease process that has many simi¬
larities with atherosclerosis and includes inflam¬
matory-cell infiltrates, lipoproteins, lipids, extra-
cellular-bone-matrix proteins, and bone mineral.2"5
Consistentwith these observations, clinical studies
have revealed a strong association with coronary
artery disease6,7 and manyofits risk factors, includ¬
ing hypercholesterolemia.1 Disease progression in
aortic stenosis is variable and influenced by several
factors, including the degree of stenosis,8 valvular
calcification,9"11 and hypercholesterolemia.12,13 In¬
deed, calcific aortic stenosis is a feature of severe
homozygous familial hypercholesterolemia,14 and
intensive lipid-lowering therapywith plasmaphere¬
sis can reverse valvular stenosis in patients with
this disease.15
The use of hydroxymethylglutaryl-coenzyme A
reductase inhibitors, or statins, is an established
treatment for the primary and secondary prevention
ofcoronary artery disease.16'17 Several studies have
shown that these drugs can halt the progression of
coronary artery disease18"20 and reduce coronary
calcification.21"23 Given the clinical associationwith
hypercholesterolemia and coronary artery disease,
and the histologic similarities with atheroma, it
has been suggested that statin therapy may halt the
progression, or even induce regression, of calcific
aortic stenosis. This hypothesis is supported by
numerous retrospective observational studies24"29
showing that concomitant statin therapywas asso¬
ciated with a delay in disease progression, demon¬
strated by a reduction of0.30 m per second per year
in the rate ofchange in aortic-jet velocity, and of30
percent per year in valvular calcification.
The aim ofthe Scottish Aortic Stenosis and Lipid
Lowering Trial, Impact on Regression (SALTIRE)
was to establish whether intensive lipid-lowering
therapywith 80 mgofatorvastatin dailywould halt
the progression or induce regression of the aortic-
jet velocity on Doppler echocardiography, and of
the aortic-valve calcium score on computed tomog¬
raphy (CT), in patients with calcific aortic stenosis.
METHODS
PATIENTS
Patients older than 18 years ofagewith calcific aor¬
tic stenosis, an aortic-jet velocity ofat least 2.5 m per
second, and aortic-valve calcification on echocar¬
diography11 were eligible for inclusion. Exclusion
criteria were child-bearing potential without con¬
traception, active or chronic liver disease, a history
ofalcohol or drug abuse, severe mitral-valve steno¬
sis (mitral-valve area, <lcm2), severe mitral or aor¬
tic regurgitation,30 leftventriculardysfunction (ejec¬
tion fraction, <35 percent), a planned aortic-valve
replacement, intolerance of statins, statin therapy
or a potential benefit from statin therapy (accord¬
ing to the treating physician), a baseline serum total
cholesterol concentration of less than 150 mg per
deciliter (4.0 mmol per liter), and presence of a
permanent pacemaker or cardiodefibrillator. Ofthe
patients screened, 455 were eligible for inclusion,
173 agreed to participate, and 155 ultimately under¬
went randomization.
STUDY PROTOCOL
Between March 2001 and April 2002, the blinded
study coordinator randomly assigned eligible pa¬
tients by the minimization technique31 with the use
of a dedicated, locked computer program (Edin¬
burgh University) incorporating the following eight
variables: age, sex, smoking habit, hypertension,
diabetes mellitus, serum cholesterol concentration,
aortic-jet velocity, and aortic-valve calcium score.
Patients were assigned to either 80 mg of atorva-
statin (Lipitor, Pfizer) or matched placebo as a sin¬
gle daily dose. Numbered containers were used.
Patients were assessed at baseline, two months,
and six months and every six months thereafter for
a minimum of two years. Clinical evaluation in¬
cluded assessmentoffunctional status and adverse
events, and the biochemical analysis of blood.
Echocardiography and CTwere performed at base¬
line, at each annual visit, and before withdrawal
from the study. Patients who underwent random¬
ization and whowere subsequently started on open-
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label statin therapy by their attending physician
were immediately scanned and withdrawn from the
study.
Drs. Cowell, Reid, Northridge, and Bloomfield
collected the data; Drs. Newby, Northridge, and
Boon designed the study and vouch for the data
and the analysis; Dr. Prescott analyzed the data; and
all investigators participated in writing the article.
The drug and the placebo were provided by Pfizer,
who had no other input into the study. The investi¬
gation conformed to the Declaration of Helsinki
and was approved by all regional ethics commit¬
tees. All patients gavewritten informed consent.
ECHOCARDIOGRAPHY
Assessment ofvalvular stenosis was determined by
a single dedicated research ultrasonographer. Pa¬
tients were studied with the use ofa 3-MHz trans¬
ducer for M-mode (single-dimensional) and pulsed
and continuous-wave Doppler scanning. All mea¬
surements were determined online, averaged from
three cardiac cycles (five cycles if the patient was in
atrial fibrillation), and recorded onto super-VHS
videotape and optical disk according to a standard
protocol.
Peak and mean aortic-valve pressure gradients
were calculated with the Bernoulli equation, and
aortic-valve area was calculated with the continuity
equation. The severity ofaortic stenosis was deter¬
minedwith echocardiography according to the fol¬
lowing standard guidelines: normal is defined by a
peak velocity of 1.0 to 2.0 m per second, peak and
mean gradients of 0 mm Hg, and a valve area of
greater than 2.0 cm2; mild by a peak velocity of
2.1 to 3.0 m per second, a peak gradient of 16 to
35 mm Hg, a mean gradient ofless than 15 mm Hg,
and a valve area of 2.0 to 1.3 cm2; moderate by a
peak velocity of 3.1 to 4.0 m per second, a peak
gradient of36 to 64 mm Hg, a mean gradient of15
to 50 mm Hg, and a valve area of1.2 to 0.8 cm2; and
severe by a peak velocity ofgreater than 4.0 m per
second, a peak gradient ofgreater than 64 mm Hg,
a mean gradient ofgreater than 50 mm Hg, and a
valve area ofless than 0.8 cm2.
COMPUTED TOMOGRAPHY
CT was performed by a single operatorwith the use
of a double-helix scanner (Twin II Flash, Philips
Medical Systems) calibrated against a standard
phantom. The region ofthe aortic valvewas scanned
with a spiral CT with the use of2.7-mm slices, a
pitch of 0.7, and an increment of 1.4 mm during
inspiratory breath-holding sessions. All images
were analyzed by a single operator with the use of
automated computerized software (Picker Cardiac
Scoring), involving a modified Agatston scoring
method32 with a threshold of90 Hounsfield units
to compensate for nongated imaging.
Reproducibility of echocardiography and CT
assessments was determined in two subsets of 20
patients, as described elsewhere.33 Coefficients of
reproducibility34 for aortic-jet velocity and aortic-
valve calcium score were 0.32 m per second and
0.07 log arbitrary units (AU), respectively.33
STATISTICAL ANALYSIS
The two primary end points were progression of
stenosis, determined according to changes in aortic-
jet velocity on Doppler echocardiography, and pro¬
gression of valvular calcification, as measured by
CT. Secondary end pointswere a composite ofclin¬
ical end points (death from cardiovascular causes,
aortic-valve replacement, or hospitalization attribut¬
able to severe aortic stenosis), aortic-valve replace¬
ment, death from any cause, hospitalization for
any cause, and hospitalization for cardiovascular
causes. On the basis of standard deviations of
0.32 m per second per year8,29'35 and 1100 AU per
year,32 we calculated that the planned sample size
of 75 patients per group would give the study a
powerof80 percent at a 5 percent significance level
to detect a difference in the primary end points of
0.15 m per second per year in aortic-jet velocity and
500 AU per year in aortic-valve calcium score. These
differences are equivalent to a reduction ofmore
than 30 percent in the rate ofprogression ofaortic
stenosis. This would exclude a clinically significant
effect in the majority of older patients with estab¬
lished disease, although a smaller effect may be
clinically relevant in younger patients with mild
aortic stenosis.
The data-monitoring committee conducted two
interim assessments ofsafety and an interim assess¬
ment of efficacy one year after enrollment began.
The trial was to be terminated early in the event of
a negative effect of treatment (i.e., P<0.05) or a
strong benefit of treatment (i.e., P<0.001). On the
recommendation of the data-monitoring commit¬
tee, the trial continued until the study was com¬
pleted.
Analyses were performed using SPSS software,
version 12.0, and SAS software, version 8e. Inten-
tion-to-treat analyses were used for all clinical
outcome variables. Disease progression was deter-
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Table 1. Baseline Characteristics ofthe Patients.*
Characteristic Atorvastatin (N=77) Placebo (N=78)
Age— yr 68±11 68±10
Male sex— % 68 72
Hypertension — no. 48 54
Hyperlipidemia — no. 8 5
Diabetes mellitus — no. 3 4
Current smoker— no. 21 22
Coronary heart disease— no. 18 21
Cerebrovascular disease— no. 9 11
Peripheral vascular disease— no. 5 13
Drug history— no.
Aspirin 43 40
ACE inhibitor 12 14
Beta-blocker 21 27
Warfarin 8 12
Height— cm 168±9 169±8
Weight— kg 79±15 80±15
Heart rate — bpm 68±11 66±12
Systolic blood pressure— mm Hg 144±18 144±21
Diastolic blood pressure— mm Hg 82±10 81±12
Biochemistry^
Total cholesterol — mg/dl 220±38 217±34
LDL cholesterol — rng/dl 137±34 133±30
CholesterokHDL ratio 4.1±1.1 4.1±1.4
Urea — mg/dl 38±13 43±13
Creatinine— mg/dl 1.07±0.25 1.08±0.26
Glucose— mg/dl 91±19 95±21
Sinus rhythm — % 94 92




Tricuspid aortic valve— % 96 97
Bicuspid aortic valve — % 4 3
Aortic-jet velocity— m/sec 3.39±0.62 3.45±0.67
Peak gradient— mm Hg 47.8±17.4 49.5±19.5
Aortic-valve area — cm2 1.03±0.4 1.02±0.41
Aortic-valve calcium score —
median AU (interquartile range)
5424 (2750-9689) 6221 (3037-9575)
Log aortic-valve calcium score—
log AU
3.7±0.5 3.7±0.6
* Plus-minus values are means ±SD. ACE denotes angiotensin-converting
enzyme, LDL low-density lipoprotein, HDL high-density lipoprotein, and AU
arbitrary units.
'j" To convert values for cholesterol to millimoles per liter, multiply by 0.02586. To
convert values for urea to millimoles per liter, multiply by 0.357. To convert val¬
ues for creatinine to micromoles per liter, multiply by 88.4. To convert values
for glucose to millimoles per liter, multiply by 0.05551.
mined primarily by dividing the change between
the baseline and final scans by the duration of fol¬
low-up. Treatment comparisons for the continuous
outcome variables were based on an analysis ofco-
variance, with the prerandomization level ofa vari¬
able used as a covariate. In a confirmatory analysis
ofthe primary end points, random-coefficientmod¬
els were fitted to incorporate all observations.35 In
the subgroup analyses, interaction terms between
treatment and subgroup have been added to a
model incorporating prerandomization level, treat¬
ment, and subgroup to identify factors that were
associated with a differential treatment effectwith¬
in subgroups. Categorical variables have been ana¬
lyzed using Fisher's exact test. Two-tailed tests were
used throughout. Two-sided P values of less than
0.05 were considered to indicate statistical signifi¬
cance.
RESULTS
Seventy-seven patients were assigned to atorva-
statin and 78 to placebo, with a median follow-up
of 25 months (range, 7 to 36). As a consequence
ofminimization, baseline characteristics were well
matched (Table 1). Mean aortic-jet velocity was
3.43±0.64 m per second (range, 2.5 to 5.0), and the
median aortic-valve calcium score was 5920 AU
(interquartile range, 2485 to 14,231). Of the 155
patients, 119 had mild-to-moderate aortic stenosis
(aortic-jetvelocity, 2.5 to 3.9 m per second), and 36
had severe stenosis (aortic-jetvelocity, £4.0 m per
second).
SERUM CHOLESTEROL CONCENTRATIONS
The mean serum low-density lipoprotein (LDL) cho¬
lesterol concentration remained at 130±30 mg per
deciliter (3.4±0.8 mmol per liter) in the placebo
group and decreased by 53 percent to 63±23 mg
per deciliter (1.7±0.6 mmol per liter) in the atorva-
statin group (P<0.001) (Fig. 1C). Serum total cho¬
lesterol was 209±35 mg per deciliter (5.5±0.9mmol
per liter) and 132±27 mg per deciliter (3.5±0.7
mmol per liter) in the placebo and atorvastatin
groups, respectively (P<0.001), and is in keeping
with 97 percent adherence to the study treatment in
both groups, which was confirmed by a pill count.
EFFECT OF ATORVASTATIN
ON DISEASE PROGRESSION
Intensive lipid-lowering therapywith 80 mgofator¬
vastatin daily had no effect on the rate ofchange in
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Figure 1. Progression in Aortic-Valve Stenosis and Serum
LDL Cholesterol Concentrations in Patients Treated
with Intensive Atorvastatin Therapy or Matched Placebo.
Patients received 80 mg of atorvastatin daily or matched
placebo. LDL denotes low-density lipoprotein, CT com¬
puted tomography, and AU arbitrary units. I bars indicate
SDs.
aortic-jet velocity or valvular calcification (Table 2).
Progression in valvular calcification was 22.3±21.0
percent per year in the atorvastatin group, and
21.7±19.8 percent per year in the placebo group
(P=0.93; ratio ofpost-treatment aortic-valve cal¬
cium score, 0.998; 95 percent confidence interval,
0.947 to 1.050). We also performed a longitudinal
analysis of the rate ofchange over time for the two
treatment groups with the use of a mixed-effects
linear model.36 This showed no difference in the
rate of disease progression, with point estimates
and 95 percent confidence intervals for the treat¬
ment difference that were similar to those shown
in Table 2 (mean difference in the rate ofchange of
aortic-jet velocity [the change in the atorvastatin
groupminus that in the placebo group], 0.008m per
second per year [-0.058 to 0.075]; mean difference
in rate ofchange ofaortic-valve calcium score, 71
AU per year [-524 to 666]). Serum LDL cholester¬
ol concentrations did not correlate with disease
progression demonstrated on echocardiography
(r=0.021, P=0.81) or CT (r=-0.109, P=0.21). The
proportion of patients reaching secondary clinical
end points seemed to be less in the atorvastatin
group, but none of the comparisons achieved sta¬
tistical significance (Table 3).
SUBGROUP ANALYSES
Prespecified subgroup analysis of the primary end-
point data was conducted in patients with mild-to-
moderate aortic stenosis (aortic-jetvelocity, <4.0 m
per second) and severe aortic stenosis (aortic-jet
velocity, £4.0 m per second) at baseline. As antic¬
ipated from earlier studies, patients with severe
stenosis at baseline progressed more rapidly
(P=0.04), but the study findings were consistent
regardless of the severity of stenosis at baseline
(Table 4).
Likewise, the length of follow-up did not influ¬
ence outcome. In those followed for more than 24
N ENGL J MED 3$2;23 WWW.NEJM.ORG JUNE 9i 2OO5
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Table 2. Progression from Baseline ofAortic-Valve Stenosis on Echocardiography and Computed Tomography.''
Variable All Patients Atorvastatin Placebo
Adjusted Difference;
Atorvastatin - Placebo
(95% CI) P Value
Echocardiography
No. of patients 134 65 69
Change in aortic-jet velocity (m/sec/yr) 0.201±0.208 0.199±0.210 0.203±0.208 0.002 (-0.066 to 0.070) 0.95
Increase in peak gradient (mm Hg/yr) 6.52±7.24 6.48±7.43 6.56±7.10 0.21 (-2.02 to 2.45) 0.85
Change in aortic-valve area (cm2/yr) -0.081±0.107 -0.079±0.107 -0.083±0.107 0.007 (-0.026 to 0.040) 0.68
Computed tomography
No. of patients 133 64 69
Absolute change in aortic-valve calcium score
(AU/yr)
1608±1865 1564±1956 1648±1790 85 (-554 to 723) 0.80
Change in log aortic-valve calcium score (per yr) 0.20±0.16 0.20±0.16 0.20±0.15 0.00 (-0.05 to 0.05) 0.93
* Plus-minus values are means ±SD. CI denotes confidence interval, and AU arbitrary units.
Table 3. Number of Patients Reaching Secondary End Points.
P Value
Atorvastatin Placebo (Fisher's
Secondary End Point (N = 77) (N = 78) Exact Test)
Composite'' 13 21 0.19
Death from cardiovascular causes 3 3 1.00
Aortic-valve replacement 11 19 0.17
Hospitalization for severe aortic stenosis 3 5 0.73
Death from any cause 3 5 0.73
Hospitalization for any cause 10 12 0.84
* The composite end point was death from cardiovascular causes, aortic-valve
replacement, or hospitalization for severe aortic stenosis.
months (median, 33), the increase in aortic-jet
velocitywas 0.21+0.20 m per second per year in the
atorvastatin group and 0.17+0.14 m per second per
year in the placebo group (Table 4). In those fol¬
lowed for 24 months or less (median, 23), the in¬
crease in aortic-jetvelocitywas 0.19±0.22m per sec¬
ond per year in the atorvastatin group and 0.23±0.25
m per second per year in the placebo group.
ADVERSE EVENTS
There were similar rates of adverse events in the
two treatment groups. Four patients (5 percent) in
the placebo group and seven patients (9 percent) in
the atorvastatin group discontinued the study drug
(P=0.52 by Fisher's exact test), predominantly as
a result of gastrointestinal symptoms. Three pa¬
tients in the atorvastatin group had an increase in
the creatine kinase level to more than five times the
upper limit of the normal range, without symp¬
toms ofmyositis; one of these patients was with¬
drawn at the request of the data-monitoring com¬
mittee. Therewere no cases ofrhabdomyolysis and
no serious adverse events.
DISCUSSION
In this randomized, double-blind, placebo-con¬
trolled, parallel-group trial oflipid-lowering ther¬
apy in patients with calcific aortic stenosis, a single
coordinating center used a consistent and repro¬
ducible approach to assess the severity of aortic
stenosis.33 We have clearly shown that high-dose
atorvastatin reduces serum LDL cholesterol con¬
centrations by more than a factor of two, as antici¬
pated,37 but it does not halt the progression or in¬
duce regression ofthe valvular disease process. This
was shown with the use oftwo distinctmeasures of
disease severity— aortic-jet velocity assessed with
Doppler echocardiography and valvular calcification
assessed with helical CT. Moreover, there was no
relationship between serum LDL cholesterol con¬
centrations and the progression ofaortic stenosis,
nor did high-dose atorvastatin have a demonstrable
effect on clinical end points. Thus, regardless of
the method ofassessing disease progression, we
have consistendy shown that aortic stenosis pro¬
gresses despite intensive reductions in serum cho¬
lesterol concentrations.
The minimization technique helped ensure that
there were no baseline inequalities between the
2394 N ENGL J MED 352;23 WWW.NEJM.ORG JUNE 9, 2005
Downloaded from www.nejm.org by DAVID NEWBY MD on March 31, 2007
Copyright © 2005 Massachusetts Medical Society. All rights reserved.
INTENSIVE LIP1D-LOWER1NG THERAPY IN CALCIFIC AORTIC STENOSIS
Table 4. Subgroup Analyses ofDisease Progression According to Aortic-Jet Velocity.*
Characteristic Atorvastatin Placebo
Baseline Rate Baseline Rate
No. Value No. ofChange No. Value No. of Change
m/sec m/sec/yr m/sec m/sec/yr
Baseline severity of stenosis")
Mild to moderate 58 3.12±0.43 49 0.17±0.21 61 3.18±0.44 55 0.19±0.20
Severe 19 4.24±0.21 16 0.27±0.21 17 4.45±0.26 14 0.27±0.23
Duration of follow-up
s24 Mo:) 30 3.49±0.69 30 0.19±0.22 37 3.64±0.67 37 0.23±0.25
>24 Mo§ 35 3.31±0.55 35 0.21±0.20 32 3.28±0.61 32 0.17±0.14
* Plus-minus values are means ±SD. P=0.57 for the interaction of treatment and the baseline severity of stenosis, and
P=0.41 for the interaction of treatment and the duration of follow-up.
t Patients with mild-to-moderate aortic stenosis had an aortic-jet velocity of less than 4.0 m per second, and those with
severe stenosis an aortic-jet velocity of at least 4.0 m per second.
The median follow-up was 23 months.
§ The median follow-up was 33 months.
treatment groups. Several factors may have influ¬
enced our ability to detect an effect ofstatin therapy
on the progression of aortic stenosis in this trial.
First, as a consequence ofour inclusion criteria, we
recruited some patients with severe disease and an
aortic-jet velocity ofat least 4 m per second, and it
could be argued that lipid-lowering therapy is un¬
likely to influence disease progression at such an
advanced stage. We therefore conducted a prespec-
ified subgroup analysis excluding patients with a
baseline aortic-jet velocity of 4 m per second or
more. Our findings were consistent regardless of
the severity of stenosis at baseline — atorvastatin
had no effect on disease progression, even in the
majority ofpatients with mild-to-moderate steno¬
sis. We excluded patients with an aordc-jet velocity
ofless than 2.5 m per second, andwe acknowledge
that intervening at this earlier stage of the disease
process may have been more beneficial. However,
such padents do not commonly present to roudne
clinical practice, and their identification would po¬
tentially require population screening.
Second, two years of treatment may not have
been sufficient to influence the natural history of
the disease. We assessed this possibility by deter¬
mining ifpatients with a longer follow-up showed
a treatment benefit. In patients who underwent
nearly three years of treatmentwith intensive statin
therapy, no trend toward a beneficial effect ofator¬
vastatin was apparent. Therefore, we do not believe
that the lack ofan effect was due to an inadequate
treatment period.
Finally, our study was designed to detect a sub¬
stantial delay in disease progression and was not
powered to assess meaningful effects on clinical
end points, such as valve replacement and cardio¬
vascular death. Although we can exclude a treat¬
ment benefit of the magnitude previously reported
in retrospective observational studies (a reduction
in the aortic-jet velocity of 0.30 m per second per
year29 and valvular calcification of 30 percent per
year24'26), the 95 percent confidence intervals indi¬
cate that we may have missed a modest treatment
benefit (a delay in disease progression of<0.07 m
per second per year for aortic-jet velocity and <5 per¬
cent per year for valvular calcification). Although
such modest reductions are unlikely to be meaning¬
ful in themajorityofolder patients, a small decrease
in disease progression may be clinically important
in younger patients with mild disease that may
progress over many years.
Given the strength of the data linking aortic ste¬
nosis with atherosclerosis and hypercholesterole¬
mia, why have we failed to halt the progression of
calcific aortic stenosis? One potential explanation
is that, although these features may drive the initia¬
tion ofaortic stenosis, disease progression may de¬
pend on other factors. The aortic valve is subject
to continuous dynamic mechanical stress, and the
plasticity and structure of the leaflets can have an
overriding influence, as is the case with a bicuspid
valve. Moreover, in contrast to atherosclerosis, aor¬
tic stenosis is associated with a virtual absence of
smooth-muscle-cell proliferation and lipid-laden
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macrophages2 and is dominated by earlier and
more extensive mineralization. Decreasing the lipid
pool and strengthening the fibrous cap may be less
relevant to the progression of aortic stenosis than
they are for the reduction in atherosclerotic-plaque
rupturewith statin therapy in patients with coronary
heart disease.
Because of the association between aortic ste¬
nosis and coronary artery disease, statin therapy in
patients with aortic stenosis may confer secondary
preventive benefits that are independentofits effects
on the valvular disease process. The current study
was not powered to assess the benefits of lipid-
lowering therapy on cardiovascular end points such
as nonfatal and fatal myocardial infarction. It re¬
mains a possibility that aortic stenosis and sclero¬
sis38 may be important markers of occult vascular
disease and may identify patients who would gain
from the preventive benefits ofstatin therapy.
We conclude that intensive lipid-lowering ther¬
apy with 80 mg ofatorvastatin daily does not halt
the progression ofcalcific aortic stenosis or induce
its regression. Nevertheless, this trial does not rule
out a small but potentially relevant reduction in the
rate ofdisease progression or a significant reduc¬
tion in major clinical end points. Our study reinforc¬
es the need for a long-term, large-scale, random¬
ized, controlled trial of intensive lipid-lowering
therapy in patients with calcific aortic stenosis,
particularly in thosewith early, mild disease. In the
meantime, we do not recommend statin therapy
for patients with calcific aortic stenosis in the ab¬
sence ofcoexisting vascular disease.
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Progressive coronary calcification despite intensive
lipid-lowering treatment: a randomised controlled trial
E S Houslay, S J Cowell, R J Prescott, J Reid, J Burton, D B Northridge, N A Boon,
D E Newby, on behalf of the Scottish Aortic Stenosis and Lipid Lowering Therapy, «f ST
Impact on Regression (SALTIRE) trial Investigators ,^line
Heart 2006;92:1207-1212. doi: 10.1136/hrt.2005.080929
Objectives: To evaluate the effect of intensive lipid-lowering treatment on coronary artery calcification in a
substudy of a trial recruiting patients with calcific aortic stenosis.
Methods: In a double blind randomised controlled trial, 102 patients with calcific aortic stenosis and
coronary artery calcification were randomly assigned by the minimisation technique to atorvastatin 80 mg
daily or matched placebo. Coronary artery calcification was assessed annually by helical computed
tomography.
Results: 48 patients were randomly assigned to atorvastatin and 54 to placebo with a median follow up of
24 months (interquartile range 24-30). Baseline characteristics and coronary artery calcium scores were
similar in both groups. Atorvastatin reduced serum low density lipoprotein cholesterol (—53%, p < 0.001)
and C reactive protein (—49%, p < 0.001) concentrations whereas there was no change with placebo
(—7% and 17%, p > 0.95 for both). The rate of change in coronary artery calcification was 26%/year
(0.234 (SE 0.037) log arbitrary units (AU)/year; n = 39) in the atorvastatin group and 18%/year (0.167
(SE 0.034) log AU/year; n = 49) in the placebo group, with a geometric mean difference of 7%/year
(95% confidence interval —3% to 1 8%, p = 0.18). Serum low density lipoprotein concentrations were not
correlated with the rate of progression of coronary calcification (r = 0.05, p = 0.62).
Conclusion: In contrast to previous observational studies, this randomised controlled trial has shown that,
despite reducing systemic inflammation and halving serum low density lipoprotein cholesterol
concentrations, statin treatment does not have a major effect on the rate of progression of coronary
artery calcification.
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Coronary artery calcification is an independent riskfactor for coronary heart disease, with even lowcoioiiaiy calcium scuils duubling the risk of coronary
events.' The relative risk associated with coronary calcifica
tion is greater than that associated with established factors
such as smoking, hypertension and diabetes mellitus.
Progression of coronary artery calcification is associated with
a higher incidence of coronary events even among people
who are asymptomatic at the time of initial scanning.' Thus,
not only is the presence of coronary artery calcification
indicative of atheromatous plaque disease but its progression
may correspond with cardiovascular event rates.
Statin treatment has a proven role in the primary'4 and
secondary prevention5"* of cardiovascular disease, with
incremental benefits seen with more intensive reductions in
serum cholesterol concentrations." Previous studies' have
reported that statins can halt the progression and may even
induce regression of coronary artery calcification. Indeed, the
rate of progression of coronary artery calcification correlates
with the average serum low density lipoprotein (LDL)
cholesterol concentration.' This has led to the use of
computed tomography to monitor disease progression and
response to treatment, particularly with statins. Two recent
trials, however, did not show a benefit of statin on the
progression of coronary artery calcification in asymptomatic
people." "
The SALTIRE (Scottish Aortic Stenosis Lipid lowering
Therapy, Impact on Regression) trial was a prospective
double blind, randomised controlled study of intensive
lipid-lowering treatment of patients with calcific aortic
stenosis." As part of this trial, aortic valve and coronary
artery calcium scores are measured by helical computed
tomography. The objective of this substudy was to assess the
effect of atorvnslatin 80 mg daily on the rale of progression of




Patients aged > 18 years with calcific aortic stenosis (grade
1-3 calcification on echocardiography14) and a peak post
valve velocity of & 2.5 m/s were recruited from eight hospital
centres across the southeast of Scotland. Exclusion criteria
were women of childbearing potential without contraception,
active or chronic liver disease, history of alcohol or drug
misuse, severe mitral stenosis (valve area < 1 cm2), severe
mitral or aortic regurgitation,15 major left ventricular dys¬
function (ejection fraction < 35%), planned aortic valve
replacement, intolerance to statins, patients who were taking
or would in the opinion of the treating physician benefit from
statins, baseline serum total cholesterol of < 4.0 mmol/1, and
permanent pacemaker or cardiodefibrillator. For the sub-
study, we also excluded patients who had no coronary artery
calcification on computed tomography. The study was
conducted with the approval of all the regional research
ethics committees and in accordance with the Declaration of
Abbreviations: AU, arbitrary units; BELLES, Beyond Endorsed Lipid
Lowering with EBT Scanning; CRP, C reactive protein; LDL, low density
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Helsinki. Written informed consent was obtained from each
participant.
Study protocol
Between March 2001 and April 2002, the blinded study
coordinator randomly assigned eligible patients by the
minimisation technique" with a dedicated locked computer
program (Edinburgh University), which incorporated eight
baseline variables: age, sex, smoking habit, hypertension,
diabetes mellitus, serum cholesterol concentration, peak
aortic jet velocity and aortic calcium score. Patients were
assigned either to atorvastatin 80 mg daily or matched
placebo (Pfizer, Tadworth, UK) as a single daily dose in
numbered containers.
Patients were assessed at baseline, two months, six months
and every six months thereafter for a minimum of two years.
Clinical evaluation included assessment of functional status,
adverse events and biochemical blood analysis. Serum high
sensitivity C reactive protein (CRP) concentrations were
determined by a highly sensitive immunonephelomelric
method (Dade Behring, Milton Keynes, UK) as previously
described." All patients underwent computed tomography
within the month before randomisation to study treatment
and at each annual visit. Randomly assigned patients who
were later treated with an open label statin by their attending
physician were immediately scanned and withdrawn from
further observation.
Computed tomography
A single blinded operator performed computed tomography
with a double helix scanner (Twin II Flash; Philips Medical
Systems (UK), Stevenage, UK) calibrated against a standard
phantom. Images were acquired in 2.7 mm slices (with a
0.75 s full 360° scan mode) through the region of the
coronary arteries with a pitch of 0.7 and an increment of
1.3 mm during held inspiration. Exposure factors were
120 kV at 270 mA and the scan angle was 360°. Images were
analysed off line with an automated, computerised software
program (Picker cardiac scoring). This uses an Agatston
scoring method," producing sensitivity and specificity com¬
parable with electron beam computed tomography." Scans
were scored by both the Agatston (130 HU threshold) and
the modified Agatston (90 HU threshold) methods." The
Agatston method has been shown to reduce interobserver
and interscan variation compared with the threshold of
90 HU."To assess the reproducibility of the method, repeated
baseline computed tomography scans were recorded within
four weeks of each other in an unselected random sample of
16 patients.
Data analysis and statistics
Coronary artery calcium scores are expressed in arbitrary
units (AU) based on the 130 HU threshold. The calcium
scores and high sensitivity CRP concentrations were not
normally distributed and data are presented as median





284 Declined to participate
Figure 1 Consolidated Standards of Reporting Trials (CONSORT) flow diagram of patients recruited into the trial and substudy. CT, computed
tomography; ITT, intention to treat.
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Table 1 Baseline characteristics of participants with
calcific aortic stenosis in the treatment groups
Atorvastatin Placebo
Characteristic (n = 39) (n = 49)
Age (years) 70(8) 70(9)
Men 74% 78%




Diabetes mellitus 0 2
Current smoker 5 10
Cardiovascular disease
Coronary heart disease 7 13
Cerebrovascular disease 5 7
Peripheral vascular disease 3 7
Drug history
Aspirin 17 26
ACE inhibitor 7 8
(1 blocker 11 15
Warfarin 4 8




Total cholesterol (mmol/l) 5.7 (0.9) 5.5 (0.9)
LDL cholesterol (mmol/l) 3.6 (0.8) 3.4 (0.7)
HDL cholesterol (mmol/l) 1.5 (0.4) 1.5 (0.4)
Total cholesterol:HDL 4.2(1.2) 4.0(1.0)
Triglycerides (mmol/l) 1.5 (0.8) 1.4 (0.7)
Coronary calcification score (AU)
Left anterior descending artery 112(40-285) 207 (76-461)
Circumflex artery 0(0-9) 0(0-4)
Right coronary artery 0 (0-29) 0(0-0)
Total coronary score 195 (57-448) 235 (83-526)
Log total coronary score (log AU) 2.16 (0.68) 2.30 (0.65)
Continuous variables stated as mean (SD) or median (interquartile
range).
ACE, angiotensin-converting enzyme; AU, arbitrary unit; HDL, high
density lipoprotein; LDL, low density lipoprotein.
(interquartile range) or mean (SD) after logarithmic trans¬
formation (log AU). The primary end point, the rate of
change of coronary calcium scores, was analysed with
random coefficient models'3" after logarithmic transforma¬
tion of the scores. In summarising the data, we calculated the
change in coronary artery calcium scores by dividing the
change between the baseline and final scores by the duration
of follow up. Rate of change in coronary calcium score is
expressed as percentage change per year or as absolute
change in the logarithm of the coronary artery calcium score.
Reproducibility was assessed by the method of Bland and
Altman.31 As well as tests of significance, 95% confidence
intervals are reported as appropriate. Significance was taken
as a two-sided p < 0.05.
RESULTS
Of 155 patients recruited into the SALTIRE trial, 102 had
coronary calcification at baseline (fig 1), of whom 88 had at
least two scans. Coronary calcification predominated in the
left anterior descending artery (100% of patients) although it
was also present in the circumflex (33%) and right (27%)
coronary arteries. Baseline characteristics and coronary artery
calcium scores were well matched in both treatment groups
(table 1) in the 88 evaluable participants.
Reproducibility
The reproducibility of the left anterior descending coronary
score and of the total coronary score was examined with the
approach of Bland and Altman." Without transformation,
the difference between replicate observations tended to
increase with the magnitude of the measurement. After





















Figure 2 Progression of (A) coronary artery calcification, (B) serum C
reactive protein (CRP) concentrations (p < 0.001, atorvastatin v
placebo) and (C) serum low density lipoprotein (LDL) cholesterol
concentrations (p < 0.001, atorvastatin v placebo) in patients treated
with atorvastatin 80 mg daily or matched placebo. AU, arbitrary units.
differences, but differences were higher at the lowest scores.
Overall, the differences on the log scale correspond to a
coefficient of variation of 28% for both variables, but when
the analysis was restricted to the 10 pairs with a geometric



















Figure 3 Absolute rate of change in coronary calcium score expressed
in arbitrary units (AU) per year for patients treated with atorvastatin 80
mg or matched placebo.
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Effect of atorvastatin treatment
Patients were followed up for a median of 24 months
(interquartile range 24-30). Atorvastatin 80 mg daily more
than halved serum LDL cholesterol concentrations (53 (SD
19)%, p < 0.001), whereas placebo had no effect (fig 2). This
reduction in serum LDL cholesterol concentrations was
associated with a major decrease in serum CRP concentra¬
tions from 1.95 (interquartile range 1.15-4.86) to 1.00 mg/1
(0.49-2.31) (Wilcoxon signed rank test p < 0.001) (fig 2).
Atorvaslalin was well tolerated: two patients in the placebo
group and five patients in the atorvastatin group discon¬
tinued the treatment, predominantly as a result of gastro¬
intestinal upset. One patient taking atorvastatin had an
increase in creatine kinase of > 5 times the upper limit of
normal without symptoms ofmyositis and was withdrawn at
the request of the Data Monitoring Committee. There were
no cases of rhabdomyolysis.
Coronary artery calcium score
Atorvastatin did not affect the rate of progression of the
coronary artery calcium score (fig 2). Similar results were
obtained when the 90 IIU threshold was used (42 (SD 73)%/
year in the atorvastatin group and 29 (SD 37)%/year in the
placebo group, p = 0.24). Serum LDL cholesterol concentra¬
tions did not correlate with the rate of progression of
coronary artery calcification (r = 0.05, p = 0.62).
The rates of change of coronary artery calcium scores were
primarily analysed on the logarithms of the scores by random
coefficients models." This showed no difference between the
average rates of change in the two treatment arms
(p = 0.18). The mean coronary calcium score increased by
0.234 (SE 0.037) log AU/year in the atorvastatin group and
0.167 (SE 0.034) log AU/year in the placebo group. These
figures correspond to a 26%/year increase in the atorvastatin
group and 18%/year in the placebo group. The geometric
mean (adjusted for baseline) is 7% higher at one year with
atorvastalin than with placebo, with 95% confidence limits
ranging from 3% lower to 18% higher. Figure 3 summarises
the observed annual changes in coiunaiy calcium scutes,
calculated from the first to the last visit.
As anticipated in such a modest clinical trial, all cause
mortality, cardiovascular mortality or cardiovascular hospi¬
talisation did not differ significantly between the two groups.
DISCUSSION
We have confirmed that, despite major reductions in serum
LDL cholesterol and CRP concentrations, atorvastatin 80 mg
daily did not halt the progression, or induce regression, of
coronary artery calcification in patients with calcific aortic
stenosis. Consistent with recent trials of asymptomatic
people," " our findings contrast notably with previous
observational studies and suggest that the potential bene¬
ficial effects on coronary artery calcification have been
overestimated.
Previous observational and non-randomised prospective
studies' 10 have suggested that reductions in serum LDL
cholesterol concentrations decrease the progression of cor¬
onary calcification. Not all observational studies, however,
have had consistent findings. In the largest observational
study of 182 patients, Hecht and colleagues" recently found
no difference in the progression of coronary calcium scores in
patients who were maintained on lipid-lowering treatment
and achieved significant reductions in serum LDL cholesterol
concentrations. Observational data may be misleading and
prospective randomised controlled trials are necessary to
confirm or to refute these interesting preliminary observa¬
tions. The recent BELLES (Beyond Endorsed Lipid Lowering
with EBT Scanning) trial" found no differential effect
between pravastatin (40 mg daily) and atorvastatin (80 mg
daily) on the progression of coronary artery calcification in
615 hyperlipidaemic postmenopausal women. Study follow
up was brief (one year), however, and there was no placebo
control group. The St Francis Heart Study" randomly
assigned 1005 asymptomatic middle-aged men and women
with high coronary artery calcium scores to combination
atorvastatin 20 mg, vitamin C 1 g, and vitamin E (a
tocopherol) 1000 U daily or to matching placebos. After 4.3
years of follow up, the rate of progression of coronary artery
calcification did not differ.
We have conducted a double blind randomised controlled
trial with helical computed tomography in patients with
aortic stenosis. Minimisation technique ensured good match¬
ing of the baseline characteristics of the patient population
and reproducibility studies confirmed the validity of our
repeated assessments. Although documenting very similar
rates of progression of coronary calcification to previous
studies,'10" we have not observed a reduction in coronary
calcification with intensive lipid-lowering treatment despite
more than halving serum LDL cholesterol concentrations.
Statins have been extremely successful in the primary and
secondary prevention of cardiovascular disease. Why then
have we and others not observed a beneficial effect of statin
on coronary artery calcification? Unstable atherosclerotic
plaques have a large lipid-rich core, a preponderance of
macrophages and foam cells, and a thin fibrous cap contain¬
ing few smooth muscle cells." It has been suggested that
calcified lesions may be relatively more stable," indicating a
possible protective role of calcification in coronary plaques.
Statins produce many of their beneficial effects through
plaque stabilisation. In both primate" and swine" models,
anlialherosclerotic interventions are associated with an
increase in vascular fibrous tissue and calcification. This
calcium deposition continues during the initial phase of
plaque regression due to the death of foam cells and an
increase in necrotic tissue. Thus, vascular calcification may
have a role in the initial stabilisation of atherosclerotic
plaques. This is consistent with our findings and would
account for the lack of effect on the progression of coronary
artery calcification despite a reduction in serum CRP
concentrations.
After the initial stabilisation of the atherosclerotic plaque,
subsequent progression of coronary calcification would be
anticipated to be inhibited. The present study was brief, and
follow up was only continued for a median of two years. It
would be important to extend our observations to five or
more years to assess properly the impact of statin on the
long-term progression of coronary artery calcification. It
should be acknowledged, however, that the clinical benefits
of statin are apparent within the first few years,'"" and in
some cases the first few months,2" of treatment. Moreover,
the St Francis Heart Study showed no beneficial effects
despite 4.3 years of follow up.'
On the basis of previous non-randomised studies," the
practice of performing serial computed tomography to
monitor disease progression and the response to treatment
has become widespread, especially in North America. Our
data, and those of the St Francis Heart Study" and the
BELLES study,12 indicate that repeated scanning to assess
response to statin is not justified. Indeed, the radiation dose
incurred for such serial scans poses potential health risks,
particularly when multideteclor computed tomography scan¬
ners are used.
Study limitations
Several factors should be taken into account when consider¬
ing the results of our study. This was a subsludy of the
SALTIRE trial" that recruited only patients with calcific aortic
stenosis. Our findings are consistent, however, with two
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recent randomised controlled trials in asymptomatic younger
people without valvular heart disease." 12 Our study therefore
suggests that failure of statins to restrict the progression of
coronary artery calcification can be extended to include
patients with valvular heart disease as well as older
populations. Moreover, our findings suggest that the lack of
benefit seen in the St Francis Heart Study is not attributable
to the modifying effects of antioxidant vitamins.
When compared with electron beam computed tomogra¬
phy, the accuracy of helical computed tomography in
detecting coronary artery calcification has been ques¬
tioned.18 29 Technological advances have also meant that
double helical scanners have now been overtaken by 64-slice
scanners. At trial inception, the double helix scanner was the
latest technology, and it would have been inappropriate to
replace the scanner during the conduct of the trial. Moreover,
our approach has been previously validated21 and we have
shown good reproducibility of coronary artery calcification
scores in patients with scores of > 100 AU. We do not believe
the absence of a major beneficial effect on coronary artery
calcification is attributable to our methods. We acknowledge
that our population size is modest; however, the 95%
confidence intervals can exclude a relative reduction in
progression of coronary artery calcification of > 3%/year. We
therefore suggest that if lipid-lowering treatment does reduce
the progression of coronary artery calcification then the effect
is rather small.
The method of quantification of coronary artery calcifica¬
tion is controversial. The Agatston method is traditionally
used but this may overestimate the coronary calcium score in
newer generation scanners with reduced slice thickness due
to partial voluming. More recent methods include the
volume30 and the coronary calcium mass31 scores, although
neither is superior to the Agatston score in terms of
reproducibility from consecutive scans in an individual
patient.32
Conclusion
We conclude that intensive lipid-lowering treatment does not
halt the progression, or induce regression, of coronary artery
calcification. Although coronary artery calcium scores corre¬
late well with the presence of atherosclerosis and predict
future coronary risk, our findings confirm that monitoring
progression of coronary artery calcification to assess the
response to lipid-lowering treatment has no role.
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IMAGES IN CARDIOLOGY
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Anomalous origin of right coronary artery from the mid left anterior descending coronary artery
A 59-year-old women underwentdiagnostic coronary angiographywith history of atypical chest
pain and an inconclusive treadmill
exercise tolerance test. Cine-angiogram
revealed an unusual origin of the right
coronary artery (RCA) arising from the
mid left anterior descending coronary
(LAD) artery and coursing to the right,
anterior to the right ventricular outflow
tract. Such an anomaly is unusual and
has not been listed in the classification
of such anomalies.
Coronary anomalies are seen in about
1% of cineangiograms. While some
anomalies have been associated with
adverse clinical outcomes, most are
benign. The RCA has been documented
to have an anomalous origin from
the left anterior coronary sinus and
pulmonary trunk, but the origin of the
RCA from the LAD has not been
reported before.
P Saravanan, P Mennim, J E Hancock
saravananpl@aol.com
Huge left atrial thrombus in a patient with mitral bioprosthesis
doi: 10.1136/hrt.2005.078394
Transoesophageal echocardiography revealing
a heavy thrombus burden in the posterior wall
of left atrium with the bioprosthesis in the mitral
position (M).
ablation were performed to reduce the
risk of future thromboembolism.
K-M Chiu, T-Y Lin, S-H Chu
kmchius@yahoo.com.tw
A 77-year-old woman had sufferedfrom atrial fibrillation and rheu¬matic mitral stenosis for more
than 20 years. She underwent mitral
valve replacement with bioproslhesis six
months before her admission.
Inadequate anticoagulation treatment
was noted during the follow-up period.
She presented with unsteady gait and
dizziness to our emergency room. Brain
magnetic resonance images confirmed
cerebellar infarction. Echocardiography
was arranged to search for the possible
embolus source, and revealed a huge left
atrial thrombus. Because of the thrombus
burden and recent stroke, redo cardiac
surgery was proposed three weeks after
the cerebrovascular event. The preopera¬
tive computed tomography (CT) for redo
surgery found a large left atrial mass (left
panel). During the less invasive cardiac
surgery via right small thoracotomy,
transoesophageal echocardiography
Computed tomography demonstrating a huge
mass in an enlarged left atrium. LA, left atrium;
LV, left ventricle; T, thrombus.
revealed the significant thrombus burden
again (right panel). The bioprosthesis
was found to be functioning well and
thrombus-free. Additional left atrial
appendage closure and endocardial
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HEART REVIEW
Emerging medical treatments for aortic stenosis: statins,
angiotensin converting enzyme inhibitors, or both?
D E Newby, S J Cowell, N A Boon
Aortic stenosis is the most common adult heart valve
condition seen in the Western world and its incidence
continues to rise. No established disease modifying
treatments retard progression of the stenotic process.
Recent insights into the pathogenesis of calcific aortic
stenosis suggest that the disease mimics atherosclerosis.
The natural history and progression of calcific aortic
stenosis are described with particular emphasis on new
and emerging medical treatments that may modify the
disease process. In particular, statins and angiotensin
converting enzyme inhibitors appear to hold promise but
definitive evidence from large clinical trials is awaited.
Aortic stenosis is the most common adultheart valve condition seen in the Westernworld. It is predominantly due to "degen¬
erative" calcific disease, although it can be a
consequence of congenital disease such as a
bicuspid aortic valve and rheumatic heart disease
or of a rare metabolic disease such as ochronosis.
Watchful waiting and the judicious use of aortic
valve replacement surgery remains the mainstay
of its management and treatment. We describe
here the aetiology and natural history of calcific
aortic stenosis and discuss the prospect of
developing medical treatments that can modify
the disease process.
NATURAL HISTORY OF CALCIFIC AORTIC
STENOSIS
Calcific aortic stenosis has been recognised for
over a century. Recently it has been suggested
that aortic sclerosis may be the earliest manifes¬
tation of this disease process: sclerosis arising
from the development of valvar calcific lesions
that progress slowly over many years before
ultimately causing aortic stenosis.1 The current
prominence of calcific aortic valve disease prob¬
ably results from increased human longevity
associated with the declining prevalence of
rheumatic fever.
Calcific aortic stenosis is a progressive condi¬
tion, characterised by a long asymptomatic phase
lasting several decades, followed by a shorter
symptomatic phase usually associated with
severe narrowing of the aortic valve orifice. The
outlook for patients with asymptomatic disease
is generally good but the prognosis changes
dramatically with the onset of symptoms in
association with severe outflow obstruction—a
two year survival rate of about 50%.*
See end of article for
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Despite the favourable outlook for patients
with mild asymptomatic disease, the risk of
cardiovascular events unrelated to the aortic
valve disease is increased. Otto et a I1 reported
that patients with aortic sclerosis have a 50%
increased risk of myocardial infarction and
cardiovascular death even in the absence of
significant outflow tract obstruction. The
Helsinki aging study also indicated that patients
with moderate to severe aortic stenosis were at
an increased risk of all cause and cardiovascular
death irrespective of associated symptoms.*
PATHOLOGY OF CALCIFIC AORTIC
STENOSIS
Historically, calcific aortic stenosis has been
attributed to prolonged "wear and tear" and
age associated valve degeneration. However,
recent evidence suggests that it may be the
result of an active inflammatory process invol¬
ving biochemical, humoral, and genetic factors.
Normal aortic valve leaflets appear smooth,
thin, and opalescent, with clearly defined tissue
layers and very few cells. Increasing age gives rise
to thickening of the tips of the valve leaflets,
with an increase in the number of adipose cells
and thinning of tissue layers." Calcific aortic
stenosis is characterised by leaflet thickening,
with irregular nodular masses on the aortic
aspect of the valve. Microscopic assessment of
both mild and severely affected valves shows
endothelial and basement membrane disruption,
with underlying subendothelial thickening. The
lesion itself contains disorganised collagen fibres,
chronic inflammatory cells, lipids, extracellular
bone matrix proteins, and bone mineral.4
The histological features described closely
resemble those seen in atherosclerosis and are
strongly suggestive of chronic inflammation
(fig 1). The factors initiating the inflammatory
process have not been identified but mechanical
injury to the endothelium is thought to pave the
way for subsequent inflammation. Indeed, the
disease tends to affect the aortic surface of
the leaflets and the non-coronary cusp that
correspond to areas of low shear and high tensile
stress. Congenitally bicuspid aortic valves are less
efficient than tricuspid valves at distributing
mechanical stress leading to the more rapid
development of stenosis.
Abbreviations: ACE, angiotensin converting enzyme;
ASTRONOMER, aortic stenosis progression observation:
measuring effect of rosuvastatin; LDL, low density
lipoprotein; SALTIRE, Scottish aortic stenosis and lipid
lowering therapy, impact on regression; SEAS,
simvastatin and ezetimibe in aortic stenosis
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Figure 1 Common and specific pathogenetic features of aortic stenosis and atherosclerosis.
Lipids
Endothelial injury or disruption may allow lipids to penetrate
the valvar interstitial tissue and accumulate in areas of
inflammation.''' The lipoproteins implicated in atherogen-
esis, including low density lipoprotein (LDL) and Lp(a)
lipoprotein, are present in early aortic valve lesions and
undergo oxidative modification.'6 These oxidised lipopro¬
teins are highly cytotoxic and capable of stimulating
inflammatory activity and mineralisation.7
Inflammation and calcification
Both macrophages and activated T lymphocytes are present
in the early and advanced lesions of congenitally bicuspid
and tricuspid aortic valves." Migration of these effector
inflammatory cells appears to be mediated through increased
endothelial expression of cellular adhesion molecules such as
E selectin, intercellular adhesion molecule 1, and vascular cell
adhesion molecule 1. Once recruited into the subendolhe-
lium, the inflammatory cells release enzymes, such as matrix
metalloproteinases, that degrade collagen, elastin, and
proteoglycans within the aortic valve cusps.
Mineralisation is a characteristic of both atherosclerotic
and aortic valve lesions and arises close to areas of
inflammation. It is a prominent feature in calcific aortic
stenosis and has been observed in early as well as advanced
lesions.1" Surgically excised valves have even shown areas of
mature lamellar bone, haemopoietic marrow, and bone
remodelling." Some features suggest the presence of an active
highly regulated process closely resembling developmental
bone formation.'
The initiation of mineralisation (nucleation) may be
stimulated by the presence of cellular degradation
products following apoptosis or by the presence of oxidised
lipids.1'" In vitro studies of cultured explanls of stenotic
valves have identified cells with osteoblastic characteristics
capable of phenotypic differentiation and spontaneous
calcification. Their origin is unknown but they may be
derived from a pool of circulating immature pluripolent
mesenchymal cells. These osteogenic cells or "calcifying
valvar cells" express and produce a variety of regulatory
bone matrix proteins including osleopontin and bone
morphogenetic protein."
CALCIFIC AORTIC STENOSIS AND
ATHEROSCLEROSIS
Although the similarities with atherosclerosis were recog¬
nised as long ago as 1917, they were largely disregarded until
recently. Histological studies have highlighted the common
features but also confirmed differences in the cellular and
mineral components of the two lesions.
Smooth muscle proliferation and lipid laden macrophages
(or foam cells) are prominent features of vascular atheroma
but are virtually absent from stenotic aortic valves (fig 1).
Furthermore, mineralisation occurs earlier and is a more
extensive feature of aortic valve lesions than in athero¬
sclerosis." These differences may, in part, explain why only
40% of patients with severe aortic stenosis have significant
coronary artery disease and why the majority of patients with
coronary artery disease do not have aortic stenosis.1" As the
underlying pathological processes of the two conditions
appear to be similar, other unknown factors are likely to
influence the development of valvar as opposed to vascular
lesions."
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Figure 2 Clinical assessment by
(A) Doppler echocardiography;
(B) two dimensional echocardiography
(parasternal short axis view}; and
(C) three dimensional computed
tomography of the severity (lower
panel) of aortic stenosis.
Aortic valve Normal Mild Moderate Severe
Peak velocity (m/s) 1-2 2-3 3-4 >4
Peak gradient (mm Hg) 0 16-36 36-64 >64
Mean gradient (mm Hg) 0 <15 15-50 >50
Valve area (cm2) >2.0 2.0-1.2 0.8-1.2 <0.8
PREDICTORS OF DISEASE PROGRESSION AND
CLINICAL OUTCOME
Patients with calcific aortic stenosis should be monitored
regularly in the clinic for the development of symptoms:
chest pain, breathlessness, and syncope. Progression of the
valvar stenosis is principally monitored with Doppler
echocardiography, although complementary clinical informa¬
tion can also be obtained from the ECG (left ventricular
hypertrophy, heart block), two dimensional echocardiogra¬
phy, and computed tomography. This permits grading of the
severity of the aortic stenosis (fig 2).
The natural history of aortic stenosis is for the valve
gradient to rise inexorably with time. Disease progression and
clinical outcome have been linked to many of the risk factors
for calcific aortic stenosis (table 1). However, much of the
evidence is conflicting and limited by the retrospective nature
of the studies. The most consistent and strongest predictors
of disease progression are severity of stenosis at baseline and
degree of valvar calcification: the more severe the stenosis
and the more heavily calcified the valve, the faster the rate of
progression." " Clinical outcome is also influenced by the
degree of valvar calcification, with nearly 80% of patients
with moderate to severe calcification progressing rapidly
(> 0.3 m/s/year) either to death or to aortic valve replace¬
ment within two years."















'Low density lipoprotein, Lp(a) lipoprotein.
NOVEL TREATMENTS FOR CALCIFIC AORTIC
STENOSIS
Current management of patients with aortic stenosis
comprises monitoring disease progression and ensuring
patient awareness of the need for antibiotic prophylaxis
against the relatively low risk of infective endocarditis. For
those patients with severe symptomatic disease, aortic valve
replacement is a priority with conventional medical treat¬
ment reserved for symptom control in inoperable cases.
However, the majority of patients with aortic stenosis do not
have symptoms or an indication for surgery. Are there any
interventions that can halt or slow the progression of the
disease process? Theoretically, anti-inflammatory and anti¬
proliferative agents would be anticipated to alter the natural
history of aortic stenosis. Statins and angiotensin convening
enzyme (ACE) inhibitors are two commonly used treatments
that have proven secondary preventative benefits in cardio¬
vascular disease and exhibit some of these desirable anti¬
inflammatory and antiproliferative properties.
Statins
Hydroxymethylglutaryl coenzyme A reductase inhibitors, or
statins, are now well established in the primary and
secondary prevention of coronary artery disease. Several
studies have suggested that these drugs can cause regression
of coronary artery disease and reduce the calcific volume of
coronary plaques.''1 Given the clinical association of calcific
aortic stenosis with hyperlipidaemia and coronary artery
disease, and the striking histological similarities with
atheroma, the hypothesis that statins may have the potential
to influence disease progression in aortic stenosis is
intriguing."
Recent retrospective studies have suggested that statins
may delay disease progression in aortic stenosis (table 2"'"J
through their lipid lowering and anti-inflammatory
actions."-" These observational data should be interpreted
with caution, since none of these studies were prospective
randomised trials, serum LDL cholesterol concentrations did
not correlate with disease progression, and the statin doses
were small. There also appears to be some publication bias
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et a/21 Cowell et aP2
Design RO RO RO RO RO RO Prospective RCT
Patients 180 174 156 211 112 242 134
Patients taking statin 62 57 38 50 55 121 65
Mean age (years) 82 68 77 70 73 68 68
Mean follow up (months) 33 21 44 24 NA 54 25
Total cholesterol (mmol/l) NA 5.5 5.8 5.8 NA NA 5.7
Correlation of progression with NA Yes/no No No Yes NA No
LDL cholesterol
Reduced progression with statin Yes Yes Yes Yes No No No
LDL, low density lipoprotein; NA, not available; RCT, randomised controlled trial; RO, retrospective observational study.
Results of the SALTIRE (Scottish aortic stenosis and lipid
lowering therapy, impact on regression) trial were recently
reported. It was the first double blind randomised controlled
trial of lipid lowering treatment in patients with calcific aortic
stenosis." This trial of 155 patients showed that, although
atorvastatin 80 mg daily more than halved serum LDL
cholesterol concentrations, it did not halt the progression or
induce regression of the valve disease process as measured by
Doppler echocardiography or helical computed tomography
(fig 3). This occurred despite the association of atorvastatin
with major reductions in serum C reactive protein concentra¬
tions (unpublished observations).
Given the data linking aortic stenosis with atherosclerosis
and hypercholesterolaemia, why did intensive lipid lowering
treatment not halt the progression of calcific aortic stenosis?
One potential explanation is that, while these features may
drive the initiation of aortic stenosis, disease progression may
depend on other factors. The aortic valve is subjected to
continuous dynamic mechanical stress, and leaflet plasticity
and structure can have an overriding influence, such as with
a bicuspid valve. Moreover, in contrast to atherosclerosis,
aortic stenosis is associated with a virtual absence of smooth
muscle cell proliferation and lipid laden macrophages, and is
dominated by earlier and more extensive mineralisation.
Decreasing the lipid pool and increasing the fibrous cap may
be less relevant to the progression of aortic stenosis than it is
for the reduction of atherosclerotic plaque rupture with
statins in patients with coronary heart disease.
It may be argued that lipid lowering treatment is unlikely
to influence disease progression in the presence of significant
aortic stenosis. Patients with aortic velocities below 2.5 m/s
were excluded from the SALTIRE trial, and intervening at
this earlier stage of the disease process may have been more
beneficial. However, such patients do not commonly present
to routine clinical practice and their identification would
potentially require population screening. Moreover, the
SALTIRE trial was unable to exclude a modest treatment
benefit (a delay in disease progression of < 0.07 m/s/year or
< 5% aortic valve calcification/year). Although such modest
reductions are unlikely to be meaningful in the majority of
older patients, a small decrease in disease progression may be
clinically important in younger patients with mild disease
who may progress over many years. Indeed, a small
preliminary observational study suggests that statins may
reduce disease progression in patients with aortic sclerosis.21
Statin treatment of patients with aortic stenosis may
confer secondary preventative benefits that are independent
of its effects on the valve disease process because of the
association between aortic stenosis and coronary artery
disease. The SALTIRE trial was not powered to assess the
benefits of lipid lowering treatment on cardiovascular end
points, such as non-fatal and fatal myocardial infarction, but
there was a trend in favour of reduced clinical events. Aortic
stenosis and sclerosis may be important markers of occult
vascular disease and thereby identify patients who would
gain from the preventative benefits of statins. Larger clinical
end point trials, such as the SEAS (simvastatin and ezelimibe
in aortic stenosis) and ASTRONOMER (aortic stenosis
progression observation: measuring effect of rosuvastatin)
trials, will be able to address this issue.
Lastly, for many patients with aortic stenosis, the first
symptom to develop is chest pain, and this precipitates the
decision to replace the aortic valve. However, this may be
driven by concomitant coronary artery disease rather than
progression of valvar stenosis. Previous secondary prevention
trials in coronary heart disease have reported a reduction in
coronary artery bypass graft surgery rales.2' Thus, the larger
clinical end point trials of statins in aortic stenosis may
suggest a reduction in the rate of valve surgery, but this may
be driven by patients with aortic stenosis who undergo
combined aortic valve and bypass surgery for symptoms of
angina pectoris. If statins truly reduce disease progression
then a reduction in isolated aortic valve replacement would
be anticipated.
ACE inhibition
There are several reasons to believe that ACE inhibitors may
have a role in the management of patients with aortic
stenosis. Firstly, in contrast to normal valves, sclerotic aortic
valve tissues demonstrably express angiotensin II and ACE,
which may contribute to valve inflammation, calcification,
and disease progression.24 25 Secondly, the pressure overload
induced by aortic stenosis has several effects on the
myocardium including left ventricular hypertrophy, apopto-
sis, and fibrosis. This may accelerate the left ventricular
systolic and diastolic dysfunction associated with aortic
stenosis. Lastly, blood pressure lowering indirectly reduces
the pressure overload of the left ventricle and potentially
reduces the mechanical stress and strain on the aortic valve.
Two preliminary observational studies with ACE inhibitors
have produced conflicting results. In a retrospective analysis
of 211 patients, Rosenhek et al" found that progression of
aortic stenosis was not delayed in patients maintained on
ACE inhibitors. Furthermore, the presence of hypertension
did not appear to influence the outcome. In contrast, O'Brien
el al" found that ACE inhibitor treatment was associated with
a 71% reduction in the progression of aortic valve calcifica¬
tion in 123 patients with aortic stenosis undergoing electron
beam computed tomography. However, such retrospective
observational data are difficult to interpret and the study
findings have wide confidence intervals.
Historically, ACE inhibition was said to be contraindicated
in patients with aortic stenosis. This has primarily been due
to the concern of invoking profound peripheral vasodilatation
that would result in haemodynamic compromise, collapse,
and potentially death. However, patients with aortic stenosis
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Figure 3 Effect of atorvastatin (80 mg daily) on the progression of
aortic stenosis and serum low density lipoprotein (LDL) concentrations.2'
AU, arbitrary units; CT, computed tomography. Copyright 2005
Massachusetts Medical Society. All rights reserved. Reproduced with
permission of the publisher.
tolerate ACE inhibitors very well on initiation26 27 and many
patients (about 30%) with aortic stenosis are unknowingly
established on such treatment without compromise. Indeed,
the use of ACE inhibitors appears to confer long term survival
benefit on patients considered to have a contraindication
including those with aortic stenosis.28 The potential beneficial
haemodynamic and cardiac effects of ACE inhibition are
increasingly being recognised and warrant further study in
patients with aortic stenosis.29
CONCLUSIONS
The need for an alternative to aortic valve surgery is
highlighted by the increasing longevity of the population
and rising prevalence of aortic stenosis. New therapeutic
strategies to limit disease progression are needed to delay,
and potentially avoid, the need for valve surgery.
Statins and ACE inhibitors are two potential and promising
treatments that may have beneficial effects in patients with
aortic stenosis. Statins are likely to reduce cardiovascular
events rather than disease progression per se but may
potentially be a valuable preventative treatment in these
patients. However, we must await the results of ongoing large
randomised controlled trials to define the role of statins.
The prejudice against the use of ACE inhibitors by patients
with aortic stenosis is changing.2*-26 We would argue that
there is sufficient theoretical evidence to support the conduct
of a randomised controlled trial to explore further its
potential benefits. In the meantime, the cautious use of
ACE inhibition by patients with concomitant hypertension,
coronary heart disease, or heart failure seems appropriate.
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A common cause of secondary hypertension: coarctation of the aorta
A 16 year old male was referred lo ourdepartment with hypertension refrac¬tory to medical treatment. He had
recurrent episodes of headache. On physical
examination, his blood pressures in right
and left arms were 190/120 and 180/
120 mm Hg, respectively. Also a systolic
ejection murmur of grade 2/6 was present
al the left upper sternal border radiating to
the interscapular region. Femoral pulsations
were diminished. The ECG revealed left
ventricular hypertrophy. The chest x ray
showed no pathology, but echocardiography
revealed a bicuspid aortic valve, left ventri¬
cular hypertrophy, normal ascending aortic
size, and an ejection fraction of 67% with
normal systolic and diastolic dimensions. By
using continuous wave Doppler, a 50 mm Hg
pressure gradient was assessed 3-4 cm from
the left subclavian artery with the supra¬
sternal notch view. Computed tomographic
angiography (CTA) of the thoracic aorta was
performed. CTA showed a significant coarc¬
tation of the thoracic aorta distal to the
origin of the left subclavian artery (panel). It
was decided to undertake surgical interven¬
tion to correct the problem.
Hypertension in teenagers and young
adults is uncommon. As secondary causes
are more commonly found in this age group
than in older adults, aortic coarctation
should be considered. Thus, palpation of
femoral pulses and measurement of blood
pressure in the limbs should be performed in
every hypertensive young patient. Early
diagnosis and treatment are essential for
Computed tomographic angiography of the thoracic aorta showing a significant coarctation
beyond the origin of the left subclavian artery (arrows).
the prevention of morbidity and mortality from premature cardiovascular complications.
Surgical or percutaneous techniques should be performed together with medical treatment to
prevent end organ damage.
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